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 Laminitis is a crippling disease of horses that can result in chronic lameness and 
debilitation, and sometimes warrants euthanasia.  It is a complication of inflammatory conditions 
such as gastrointestinal disease, and also occurs in obese, insulin-resistant horses with Equine 
Metabolic Syndrome (EMS).  Inflammation and insulin resistance are risk factors for laminitis, 
and these mechanisms might converge to induce laminitis in susceptible animals. 
 Systemic inflammation is often attributed to endotoxemia, although circulating endotoxin 
concentrations are not commonly measured in the clinical setting.  Although a theoretic basis 
exists for endotoxemia in the pathogenesis of laminitis, administration of endotoxin alone does 
not induce the condition.  This could be related to differences between experimental models and 
naturally occurring disease. 
 Studies presented in this dissertation address the overall hypothesis that systemic 
inflammation causes laminitis and new experimental models can be developed to better represent 
clinical disease.  Associations between systemic inflammation and laminitis were first 
established by measuring blood inflammatory cytokine expression during a laminitis induction 
model.  A clinically relevant endotoxin model that induced laminitis was then sought, but 
endotoxin administration alone was insufficient to cause laminitis and endotoxin tolerance 
developed.  Endotoxemia was therefore evaluated in conjunction with predisposing factors such 
as obesity.  In horses with EMS, endotoxin infusion caused exaggerated inflammatory responses, 
and derangements in glucose homeostasis were more pronounced.  Laminitis, however, did not 
develop.  Repeated inflammatory events are implicated in the pathogenesis of sepsis-associated 
vii 
 
organ failure, so a final study was performed to test whether preexisting endotoxemia increased 
the risk of laminitis during subsequent carbohydrate overload-induced systemic inflammation.  
This did not occur, however systemic inflammation was more pronounced in horses that 
developed laminitis compared to non-responders, and tissues rather than circulating leukocytes 
appeared to be the major source of inflammatory mediators. 
 Our results do not support a role for endotoxin as the causal agent of laminitis, even when 
combined with predisposing factors.  Tissues appear to be an important source of inflammatory 
mediators, therefore their role in laminitis should be further characterized.  Additionally, future 
investigations should determine whether exaggerated inflammatory responses and loss of 
glycemic control increase the risk of laminitis in horses with EMS. 
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 Laminitis is a crippling disease of horses that affects 2% of the U.S. horse population, or 
180,000 animals, each year.
1,2
  This condition can result in chronic lameness and debilitation, 
and sometimes warrants euthanasia for humane reasons.  Laminitis is a complication of 
inflammatory conditions such as gastrointestinal (GI) disease,
3
 and occurs in conjunction with 
obesity, insulin resistance (IR), and endocrine disorders such as Equine Metabolic Syndrome 
(EMS) and pituitary pars intermedia dysfunction (PPID).
4,5
  This review will examine 
inflammation and IR as risk factors for laminitis, and will explore how these mechanisms might 
converge to induce laminitis in susceptible animals. 
 
1.1  Inflammation 
 
1.1.1  Role of Inflammation in Host Defense Against Pathogens 
 
 The inflammatory response is present to protect the body from invasion by pathogens.  
Inflammation is a major component of innate immunity and can be thought of as a rapid-
response system that protects the organism from infection until a more specific adaptive immune 
response is orchestrated.
6-8
  Invading pathogens must first breach defenses such as an intact 
epithelium, antimicrobial peptides on body surfaces, commensal flora that inhibit pathogen 
survival, and secreted antibodies such as immunoglobulin A.
8
  If successful, the pathogen will 
2 
 
next encounter a rapid generalized inflammatory response.  For simplicity, consider a bacterium.  
Once it, or portions of it such as cell wall, gain access to the host, they encounter sentinel cells of 
the immune system, including reticuloendothelial cells, mast cells, and neutrophils.
9
  Other cell 
types, such as endothelial cells, are also capable of recognizing and responding to pathogens.
10
  
These cells possess pattern recognition receptors (PRRs), which include toll-like receptors 
(TLRs), nucleotide-binding and oligomerization domain-like receptors, and others.
11
  Pattern 
recognition receptors are highly conserved phylogenetically, and recognize molecules called 
pathogen associated molecular patterns (PAMPs) that are not found in the host, but are common 
to pathogens.
12,13
  For example, glycolipids such as lipopolysaccharide (LPS) and lipoteichoic 
acid are not found in mammals, but are common in bacteria.
14
  Double stranded ribonucleic acid 
(RNA) is also absent in mammals, but found in viruses.
15
  Pattern recognition receptors may be 
at the cell surface or intracellular, depending on the optimal location to recognize their particular 
ligand.
8,11
  Some PRRs also recognize alarmins, which are molecules such as high mobility 
group box 1 protein that are produced by distressed host cells.
16,17
  Pattern recognition receptors 
then trigger inflammatory signaling cascades leading to transcription of genes involved in killing 
the invading pathogen.
11
  For example, many of the cytokines produced by nuclear factor κB 
(NFκB) activation, including tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, IL-6, and IL-
8, are essential for the innate immune response.
18,19
  Most cytokines have pleotropic and 
redundant functions, and usually work in combinations to elicit responses from target cells.
20
  
Responses elicited by pro-inflammatory mediators include 1) leukocyte attachment, rolling, and 
extravasation from the vasculature into tissues through expression of leukocyte and endothelial 
cell surface adhesion molecules, 2) enhancement of neutrophil and macrophage respiratory burst 
and phagocytic activity, 3) enhancement of macrophage and dendritic cell antigen presentation, 
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4) acute-phase protein production, 5) activation of coagulation that helps to sequester the 
infection, and 6) activation of complement components that neutralize invaders through 
agglutination, opsonization by phagocytic cells, and lysis via membrane attack complexes.
8
   
 The specific PRRs stimulated by a pathogen dictate the cytokine expression profile 
induced in an antigen-presenting cell, causing activated cells such as macrophages to begin 
secreting cytokines accordingly to the type of pathogen encountered.
6,7
  The specific cytokine 
profile then determines the adaptive immune response by directing lymphocyte development.
6,7
  
The initial innate immune response is activated very rapidly and is therefore invaluable to 
clearing pathogens.
8
  Its major limitation is that the response is the same regardless of the 
inciting source.  This lack of specificity towards the antigen or microbe can ultimately become 
detrimental, as with sepsis and organ failure, because a massive inflammatory response can 
damages organs to the point that death occurs.
21,22
  Innate immune responses are designed to 
clear pathogens rapidly, or at least to hold them at bay until the adaptive immune response can 
develop.   
 The adaptive immune response is centered around lymphocytes.
23
  Macrophages and 
other host cells that have encountered an antigen or pathogen present it on their surfaces in 
association with major histocompatibility molecules (MHCs).
23
 Class I MHC is present on all 
nucleated cells, whereas class II is only present on antigen presenting cells.  Interaction of a 
lymphocyte with MHC-associated antigen on an antigen presenting cell, in conjunction with co-
stimulatory signals received in the form of secreted cytokines, influences lymphocyte 
development and clonal expansion.  Both B-lymphocyte and T-lymphocyte lineages have the 
capacity to develop into either effector or memory cells.
23
  In the case of B-lymphocytes, effector 
cells secrete antibodies with specificity towards the target antigen.  T-lymphocytes also become 
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either memory cells or effector cells, and include cluster of differentiation (CD) 8+ cytotoxic T-
cells and CD4+ T-helper cells.  These T-cells also have specificity towards the target antigen.  
Cytotoxic T-cells are responsible for directly killing cells such as infected host cells, while T-
helper cells secrete cytokines that enhance either B-cell or cytotoxic T-cell function.   
 Overall, this later adaptive immune response is characterized by activation of the optimal 
cells to combat a particular pathogen.
6,7
  T-helper cells also secrete cytokines involved in down-
regulation of the initial inflammatory response.
24
  In the case of severe sepsis, this mechanism of 
checks and balances does not occur.
19,25
  There are two key areas of dysregulation.  First, the 
initial inflammatory response may be overwhelming, resulting in massive damage to host 
tissues.
26-28
  Second, secretion of anti-inflammatory mediators such as IL-10 and glucocorticoids, 
as well as macrophage and neutrophil tolerance during the later phases of sepsis, results in 




1.1.2  Deleterious Effects of Inflammation 
 
 On a whole-organism level, activation of the inflammatory cascade leads to the 
production of mediators that can damage the endothelium.
33-35
  A number of clotting factors and 
mediators such as plasminogen activator inhibitor-1, which inhibits fibrinolysis and promotes 
coagulation, are acute-phase proteins.
36
  A smooth, undamaged endothelium is largely 
responsible for preventing thrombosis under normal conditions.
36,37
  When activated or damaged, 
the endothelium fails to secrete antithrombotic mediators such as antithrombin, Proteins S and C, 
and tissue factor pathway inhibitor.
35-37
  It also expresses abundant tissue factor and adhesion 
molecules,
35,38,39
 leading to a prothrombotic condition in which thrombosis, or disseminated 
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intravascular coagulation in severe cases, results in tissue hypoxia.
22,25,40-43
  Maintenance of 
smooth laminar blood flow is important to reduce coagulation in normal vessels.
44,45
  
Inflammation upregulates the activity of enzymes such as phospholipase A2, cyclooxygenase-2 
(COX-2), and lipoxygenase.
22
  Vasoactive lipid derivatives generated by these enzymes include 
prostaglandins and thromboxanes that both regulate vascular tone and promote platelet 
activation.
8,43
  Prostaglandins that are upregulated by inflammation alter vascular tone, which 
creates turbulent blood flow and promotes coagulation.
33,34
  Activated neutrophils also contribute 
to platelet activation by secreting factors such as cathepsin G.
46-48
 
 Vasoactive mediators such as nitric oxide (NO), which is generated by inducible nitric 
oxide synthase (iNOS), are responsible for the widespread vasodilation seen in sepsis.
43,49
  
Peripheral vasoconstriction occurs in an attempt to maintain blood pressure, resulting in regional 
hypoperfusion and tissue hypoxia.
50
  Endothelin-mediated vasoconstriction initially helps 
maintain blood pressure as well, however excessive endothelin-1 (ET-1) production eventually 
induces profound vasoconstriction and contributes to hypoperfusion of tissues.
51,52
  Also, direct 
myocardial suppression occurs during sepsis and further exacerbates microcirculatory perfusion 
abnormalities in tissues.
53
  All of these events can lead to hypoxic damage, which increases cell 
stress, promotes mitochondrial dysfunction, and further intensifies inflammation.
54
  
Reestablishment of blood flow can also lead to reperfusion injury, which is characterized by the 
generation of reactive oxygen species (ROS), mitochondrial stress, and subsequent cell 
apoptosis.
55-57
  In addition, complement activation and endothelial cell stimulation increases 
vascular permeability and leads to edema.
35,58,59
    
 Tissue damage also results from cytokine secretion and subsequent activation of 





  Endothelial cells and neutrophils express adhesion molecules, 
including intercellular adhesion molecules, vascular cell adhesion molecules, and integrins.
22
  
Adhesion molecules on both the endothelial cells and neutrophils bind to their integrin ligand 
counterparts, causing neutrophils to roll, slow down, and eventually adhere tightly to the vascular 
wall.
21
  Once a tight attachment has formed, neutrophils squeeze through the vessel wall and 
enter the tissue.  Neutrophils secrete proteases that digest the extracellular matrix and facilitate 
movement into tissues.
21
  They then follow chemotactic factors such as IL-8, complement 
component C5a, and bacterial chemoattractants along concentration gradients into tissues.
19,60
  
Once at the site of infection or inflammation, neutrophils begin to phagocytize pathogens and 
debris, and generate reactive oxygen and nitrogen species in a process known as the respiratory 
burst.
8
  They also secrete proteolytic enzymes to kill microbial invaders.  Unfortunately, these 
enzymes are not specific to pathogens, and also kill surrounding host cells.  Depending on the 
duration of inflammation, macrophages follow a slower progression into tissues, where they 
phagocytize necrotic cells and dead neutrophils in an effort to minimize damage to the host.
8
  
Extensive damage to the tissues can result in organ failure.   
 
1.1.3  Structure of Endotoxin 
 
 Lipopolysaccharide, or endotoxin, is a major component of the outer cell membrane of 
Gram-negative bacteria, and influences permeability properties that are essential to cell 
survival.
61
  Lipopolysaccharide is a complex glycolipid composed of a hydrophobic lipid A 
moiety that anchors the molecule to the outer membrane, a core oligosaccharide chain, and an O-
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antigen polysaccharide chain.  The core oligosaccharide and the O-antigen chain are variable, 
while the lipid A moiety is more highly conserved among bacterial species.
62
   
 The O-antigen polysaccharide is composed of linear or branched homopolymeric or 
heteropolymeric glycosyl residues, with a highly variable structural across different bacterial 
species and strains.
9,62
  The O-antigen is not required for bacterial growth in culture, but prevents 
phagocytosis and complement-mediated lysis in vivo.
9
  The core oligosaccharide is more highly 
conserved than the O-antigen and is composed of an outer core connected to the O-antigen 
region and an inner core that connects to lipid A.  Within the core region, the inner core is less 
variable, and consists of 3-deoxy-D-manno-octulosonic acid and L-glycero-D-manno-heptose, 
while the outer core contains oligosaccharides of 3-deoxy-D-manno-octulosonic acid, L-glycero-
D-manno-heptose, D-glucose, and D-galactose.
9,62
     
 Lipid A is a unique phosphoglycolipid that is synthesized from UDP-N-
acetylglucosamine.
9,63
  Its structure is highly conserved among Gram-negative species, but 
modifications exist that allow bacteria to evade recognition by host innate immune receptors and 
resist host-derived antimicrobial peptides and exogenous antibiotics.
62
  The basic structure is a 
phosphorylated (β1-6) homo- or heterodimer of 2,3-diamino-2,3-dideoxy-D-glucose that is 
linked to a variable number of 12- to 14-carbon fatty acid chains.  However, the degree of 
phosphorylation, type of hexosamine incorporated into the disaccharide backbone, and number, 
position, and chain length of the fatty acid groups may vary considerably among bacterial 
species.
9
  The most biologically active lipid A configuration consists of two D-gluco-configured 
hexosamine residues, two phosphoryl groups, and 6 fatty acid residues.
9,64
  Lipopolysaccharides 
derived from some bacterial species are poorly recognized by the immune system,
62
 so LPS from 
different bacterial strains stimulates different inflammatory mediator profiles.
65
  Lipid A derived 
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1.1.4  Endotoxin Recognition and Intracellular Signaling 
 
 Endotoxin is liberated from the outer cell membrane of Gram-negative bacteria as they 
proliferate or die and undergo lysis.
9
  Host innate immune defenses recognize PAMPs such as 
the lipid A moiety of LPS that are not found in the host, but are conserved among pathogenic 
organisms.
12,13
   A wide array of host cells recognize LPS, including cells of the immune system 
such as monocytes, macrophages, dendritic cells, and granulocytes, as well as endothelial cells 
and smooth muscle cells.
9
  Lipid A represents the toxic component of LPS, and stimulates the 
host’s innate immune response (Figure 1.1).
67
  Lipopolysaccharide from most bacterial species 
is recognized by TLR4 in conjunction with cluster of differentiation antigen 14 (CD14) and the 
adaptor protein myeloid differentiation factor-2 (MD-2).
67-70
  Circulating lipopolysaccharide 
binding protein (LBP) recognizes the lipid A moiety, forms a high-affinity complex, and 
transports LPS to cells that express TLR4, including sentinel cells of the immune system.
67,71
  
Intracellular signaling occurs through a variety of adaptor proteins and culminates with 
activation of transcription factors including NFκB, activator protein-1 (AP-1), and interferon 




 Binding of LPS to the TLR4/CD14/MD-2 complex causes the intracytoplasmic toll/IL-1 
receptor (TIR) domain of TLR4 to associate with either the adaptor protein myeloid 





Figure 1.1  Lipopolysaccharide from most bacterial species is recognized by the TLR4 complex.  
Toll-like receptor 4 signaling through the MyD88-dependent and MyD88-independent/TRIF 
pathways activates transcription factors and leads to the production of pro-inflammatory 
cytokines.  Negative feedback mechanisms, including production of the anti-inflammatory 
cytokine IL-10 and the regulatory molecules SOCS3 and BCL3, are also activated.  Signaling 
cascade components are shaded in light grey, transcription factors are shaded in dark grey, and 
negative regulators are shaded in blue.  From Biswas SK, Lopez-Collazo E. Endotoxin tolerance: 






  These diverging pathways are referred to as either 
MyD88-dependent or MyD88-independent, and both are capable of capable of upregulating 
transcription factors including NFκB because cross-talk occurs between them.  However, the 
MyD88-dependent arm is responsible for most of the early increase in pro-inflammatory gene 
transcription, while the MyD88-independent pathway is concerned with the production of 
interferon-β (IFN-β) and late-phase upregulation of cytokines such as TNF-α,
12,73,74
 as well as 
the induction of endotoxin tolerance.
70,74-76
  The MyD88-independent pathway promotes 
endotoxin tolerance by upregulating expression of IL-10 and enhancing production of regulatory 
proteins of the MyD88-dependent pathway, including IL-1 receptor-associated kinase (IRAK)-
M, inhibitor of κB (IκB), B-cell CLL/lymphoma 3 (BCL3), and suppressor of cytokine signaling 
(SOCS) proteins.  
 The MyD88-dependent pathway proceeds from MyD88 through IRAK-4, a serine kinase 
which then phosphorylates IRAK-1.
12,70,72,73
  Interleukin-1 receptor-associated kinase-4 
associates with, and activates, TNF receptor-associated factor 6 (TRAF6), which then activates a 
complex called transforming growth factor-β activated kinase-1.  This leads to activation of 1) 
mitogen activated protein kinases (MAPKs) such as c-jun N-terminal kinase (JNK), 
extracellular signal-regulated kinase (ERK), or p38 MAPK that ultimately activate the 
transcription factor AP-1, or 2) activation of the inhibitor of κB kinase (IKK), which then 
phosphorylates IκB.
12,70,72,73,77,78
  Inhibitor of κB is bound to the transcription factor NFκB, and 
when phosphorylated, releases NFκB before being ubiquinated and destroyed.  Nuclear factor κB 
then dimerizes to form either the active p50/p65 heterodimer or inactive dimers such as the 
p50/p50 homodimer, and then translocates to the nucleus where it promotes the expression of 
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over 150 genes, many of them inflammatory mediators such as cytokines, iNOS, or inducible 
COX-2.   
 Activation of NFκB induces expression of pro-inflammatory cytokines.
79
  Receptors for 
several of these mediators, including IL-1β and TNF-α, utilize signal transduction cascades very 
similar to that of TLR4, and therefore the inflammatory cycle is further perpetuated.
8,80-82
  Type 
1 cytokine receptors, such as the IL-10 receptor, employ Janus Kinase - Signal Transducer and 
Activator of Transcription (JAK-STAT) signaling, which also relies on tyrosine phosphorylation 
of pathway intermediates.
8,83
  This pathway ultimately leads to the formation of Signal 
Transducer and Activator of Transcription (STAT) dimers that function as nuclear transcription 
factors.  Communication exists between JAK-STAT and MyD88-dependent pathways.  For 
example, IFN-β and IL-10 signal through JAK-STAT pathways, upregulating the expression of 
interferon-inducible genes, SOCS, and BCL3.  While some of the genes induced are pro-





1.1.5  Inflammation and Insulin Resistance 
 
 Cross-talk between the insulin signaling cascade and inflammatory signaling cascades 
occurs on many levels.  Insulin resistance results from inappropriate serine phosphorylation of 
insulin receptor substrates (IRSs) or the insulin receptor itself.
84
  Signaling by the insulin 
receptor, as well as TLR4 and cytokine receptors, relies on phosphorylation of 
intermediates.
67,70,85,86
  The residue on which the intermediate is phosphorylated determines 
whether the signal is propagated or terminated.  With regard to the insulin signaling pathway, the 
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insulin receptor is a tyrosine kinase that autophosphorylates itself as well as IRSs, while later 
members of the pathway, such as protein kinase B (PKB/Akt) are serine kinases.
87
   
 Many of the kinases activated by cytokine receptors and TLRs during inflammation are 
serine kinases, the most important to IR being IKK, JNK, and protein kinase C (PKC).
82,88-92
  
Serine kinases phosphorylate insulin signaling pathway components such as IRSs on serine 
residues rather than on tyrosine, resulting in inhibition of insulin signaling.  Isoforms of PKC are 
activated by TRAF6 in inflammatory signaling pathways, diacylglycerol (DAG)-dependent 
signaling pathways that are initiated by epinephrine, and during insulin signaling.
82,90,93,94
  In 
addition to direct serine phosphorylation of insulin signaling pathway intermediates, certain PKC 
isoforms also activate NFκB and JNK, further promoting inflammation and exacerbating 
IR.
88,95,96
  In addition, SOCS molecules induce IR through one of two mechanisms.  Classically, 
SOCS proteins bind to IRSs and cause them to be ubiquinated and destroyed,
97
 but they can also 
bind to IRSs and directly inhibit their association with the insulin receptor.
98
  The inflammatory 
cytokine IL-1β exerts additional effects by down-regulating IRS gene and protein expression.
99
  
Glucocorticoids are released as part of the counterregulatory response to inflammation and 
sepsis, and induce IR by down-regulating the expression of proteins involved in the 
phosphoinositide 3-kinase (PI3-kinase) signaling cascade
100,101
 and also by interfering with the 
function of the PI3-kinase p85 regulatory subunit.
102
  Glucocorticoids reduce cellular IRS-1 and 
PKB/Akt concentrations in adipocytes
100,101
 and inhibition of glucose transporter (GLUT) 4 
translocation to the plasma membrane has been demonstrated.
103
   
 Obesity, which is frequently associated with IR, can be regarded as an inflammatory 




 tissues of 
obese individuals.  Abnormalities of the GI flora and reduced hepatic Kupffer cell function in 
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obese individuals might also result in higher LPS concentrations in the systemic circulation, 
further promoting inflammation.
110-112
  Also, glucotoxicity
91
 and higher pro-inflammatory 
cytokine concentrations
113
 promote ROS formation and mitochondrial stress, which further 
exacerbate inflammation and activate serine kinases such as IKK and JNK.
88-90,114
  Mitochondrial 
dysfunction in obese individuals may also inhibit oxidation of fatty acids, leading to 




1.1.6  Hypothalamic-pituitary axis activation 
  
 Activation of hypothalamic-pituitary axis (HPA) occurs as part of the inflammatory 
response.  Neurons of the paraventricular nuclei of the hypothalamus secrete corticotrophin-
releasing hormone, which stimulates the release of adrenocorticotropic hormone (ACTH) from 
corticotrophs of the pars distalis.
115
 Adrenocorticotropic hormone exerts its greatest effect on the 
zona fasciculata of the adrenal gland, where it increases the production and release of 
glucocorticoids.
116
  Normally, 67-87% of cortisol is inactive and bound to corticosteroid-binding 
globulin, 7-19% is bound to proteins such as albumin, and the remaining 6-14% unbound 
hormone is active.
117
  Neutrophil elastase also liberates biologically active free cortisol from 
corticosteroid-binding globulin locally to increase tissue concentrations at sites of 
inflammation.
118,119
  Glucocorticoids affect physiologic processes in most tissues, and the 
importance of an appropriate increase in glucocorticoid concentrations during sepsis is illustrated 
by the fact that relative adrenal insufficiency has been associated with nonsurvival in several 
species, including the horse.
120-123
  One major role of these hormones is to provide the body with 





Glucocorticoids increase peripheral blood glucose concentrations, increase tissue protein 
catabolism, and mobilize fatty acids from adipose depots. 
 Another major role of glucocorticoids is to down-regulate the inflammatory response and 
prevent rampant production of pro-inflammatory mediators during sepsis.
31,125
  Accordingly, 
exaggerated HPA activation is implicated in the immunosuppressive phase of sepsis.
27,29,30
  To 
exert physiologic effects, glucocorticoids must diffuse across plasma membranes and bind to the 
carboxyterminal end of a 777-amino acid cytosolic receptor.
126
  The glucocorticoid-receptor 
complex translocates to the nucleus, where it either binds to specific regulatory sequences of 
glucocorticoid-responsive genes or interferes with binding of other transcription factions to 
promoter sites, thereby modulating gene transcription.
126,127
  In cells such as monocytes and 
lymphocytes, glucocorticoids increase the expression of IκBα, preventing NFκB activation and 
down-regulating the production of inflammatory mediators.
128,129
  Direct inhibitory interaction 
between the glucocorticoid-receptor complex and NFκB has also been demonstrated in 
endothelial cells.
130
  Glucocorticoids exert post-transcriptional effects by altering the stability of 
messenger RNA (mRNA) and the rate of protein synthesis and release from the cell.
126
  Most 
immune cells exhibit altered function when exposed to glucocorticoids.
126
  Macrophage and 
neutrophil cytokine production and bactericidal activity decrease, neutrophil adhesion and 
extravasation are reduced, and lymphocyte proliferation and activity, particularly in the T-







 and dampen the inflammatory response.
134
 
 Arginine vasopressin (AVP), which is also called antidiuretic hormone, is produced by 
neurons of the supraoptic and paraventricular nuclei of the hypothalamus and is a major regulator 
of systemic blood pressure and osmolarity.
135,136
  Circulating AVP increases during shock and 
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helps maintain perfusion to vital organs by inducing profound vasoconstriction in certain 
vascular beds.
137
  Higher AVP concentrations are detected in septic and critically ill equine 
neonates.
120
  Increased release of AVP and oxytocin from the hypothalamus has been 
demonstrated in adult horses following administration of a single intravenous LPS bolus.
138
  The 
mechanisms underlying this increase in AVP are likely to involve histamine, prostaglandins, and 
cytokines such as IL-1β and IL-6.
138
  
 Many complex interactions exist among hormones and inflammatory mediators.  For 
example, AVP functions as an ACTH secretagogue in addition to its role in maintaining blood 
pressure
139,140
  Also, direct neuronal connections exist between hypothalamic neurons that 
produce corticotrophin-releasing hormone and those that produce norepinephrine, so each of 
these hormones can induce the secretion of the other.
134
  As a result, increased catecholamine 
concentrations during stress or illness promote glucocorticoid release.  Inflammatory mediators 
and PAMPs communicate with the central nervous system and exert effects on the HPA via the 
circumventricular organs where the blood-brain barrier is incomplete, or through upregulation of 
inflammatory mediator production in brain endothelial cells and perivascular microglia.
125
  
Interleukin-1β, IL-6, and TNF-α are the most important cytokines involved in upregulating the 
HPA during sepsis.
134
  In addition, IL-6 can stimulate ACTH and cortisol release through 
receptors located directly on pituitary corticotrophs and the adrenal cortex.
118,141
  Activation of 
lemniscal tract nociceptive pathways by inflammatory cytokines and mediators relays pain 
signals to the thalamus and somatosensory cortex, ultimately leading to HPA activation.
127
  
Interleukin-6 and glucocorticoids also act synergistically to stimulate the production of acute-
phase proteins.
134
  Other cytokines and mediators such as prostanoids, platelet activating factor, 
and neuropeptides may also regulate the HPA axis.
134
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1.1.7  Metabolic alterations and development of insulin resistance  
 
 Metabolic alterations occur as a result of mediators that are released during the systemic 
inflammatory response.  A number of the inflammatory mediators upregulated by NFκB 
signaling, as well as the counterregulatory hormones cortisol, epinephrine, glucagon, and growth 
hormone, induce IR.
91,142,143
  The overall goal of these counterregulatory mechanisms is to 
ensure the provision of adequate energy in the form of carbohydrates, proteins, and lipids to meet 
the body’s requirements while fighting infection.
124
  Inducing a state of peripheral and hepatic IR 
tips the balance in favor of glucose liberation from tissue stores and glucose synthesis via 
gluconeogenesis in the liver.
144
  Energy requirements during critical illness may not be as high as 
once believed, however,
145
 and IR can be detrimental because it can lead to endothelial 
dysfunction and organ failure.
91,143
 
 Glucocorticoids are important regulators of metabolism during inflammation and sepsis, 
and alter metabolic functions directly and by potentiating the effects of other hormones such as 
insulin, glucagon, catecholamines, and growth hormone.
146,147
  Glucocorticoids promote hepatic 
glucose output by increasing the rate of gluconeogenesis and glycogenolysis.
148
  
Gluconeogenesis is enhanced by stimulation of the rate-limiting enzymes phosphoenolpyruvate 
carboxykinase (PEPCK) and glucose-6-phosphatase (G6P).
148
  Glycogen phosphorylase activity 
is also stimulated.
149
  Skeletal muscle catabolism occurs through the activation of intracellular 
proteases.
150
  Liberated amino acids are then utilized by the liver for gluconeogenesis.  Adipose 
tissue amino acid uptake is also inhibited.
148
  Glucocorticoids stimulate lipolysis by increasing 
cyclic adenosine monophosphate production and activating protein kinase A, as well as through 





  Cytokines such as TNF-α and IL-6, catecholamines, and growth hormone 
also down-regulate the function of lipoprotein lipase (LPL) and upregulate hormone sensitive 
lipase (HSL), thereby increasing lipolysis.
152-154
  This results in a net efflux of free fatty acids 
from adipose depots.
151,155
  Increased lipolysis also leads to a buildup of lipid metabolism 
intermediates such as DAG in tissues, and these intermediates can activate PKC and induce 
IR.
82,156,157
  Increased lipid oxidation may also decrease glucose phosphorylation, glucose 
oxidation, and glycogen synthesis through inhibition of enzymes including  phosphofructokinase, 
pyruvate dehydrogenase, and hexokinase that are involved in these pathways.
156
  Very-low 
density lipoprotein synthesis by the liver increases, while high density lipoprotein production is 
reduced.
155
  Decreased insulin-independent glucose uptake occurs in adipocytes, and has been 
attributed to decreased GLUT1 expression in response to glucocorticoids.
103
  Reduced glucose 
uptake and glycogen synthesis by skeletal muscle has also been demonstrated following 
glucocorticoid exposure.
158
  Reduced insulin-mediated phosphorylation of PKB/Akt prevents 
phosphorylation and deactivation of glycogen synthase kinase-3, resulting in decreased glycogen 
synthase activity.  Glucocorticoids also inhibit glucose-stimulated pancreatic β-cell insulin 
secretion.
159
   
 
1.2  Carbohydrate Metabolism 
 
1.2.1  Dietary Carbohydrate 
 
 Carbohydrates represent the major source of calories in the equine diet.
160
  Horses 
evolved to utilize forage as the primary source of carbohydrate, however concentrated feeds may 
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contribute significantly to the diet of animals under intensive management conditions.
160
  Grass 
and legume nonstructural carbohydrate (NSC) content is subject to both diurnal and seasonal 
variation, with forage NSC content highest in the spring, intermediate during the fall, and lowest 
during the midwinter and midsummer.
161,162
  Nonstructural carbohydrate content is highest in the 
late afternoon, and also increases in response to environmental factors that affect plant 
photosynthesis rates, including amount of sunlight, rainfall, soil fertility, and stressors such as 
drought or overgrazing.
161,162
  Pasture grass NSC content can exceed 400 g/kg of dry 
matter.
161,162
  Depending on the individual animal and pasture conditions, a 500 kg horse may 
consume approximately 0.75 to 10 kg of water soluble carbohydrate (WSC) per day, which 
corresponds to 0.56 to 7.3 kg of ingested fructan.
161
  Administration of 2.5 kg of oligofructose 
(OF), a type of fructan, to a 500 kg horse as a single bolus is sufficient to cause mild 
laminitis,
163,164
 while administration of 6.25 kg results in severe disease.
165
  The specific fructan 
structure also varies among plant species; those with lower molecular weights may be more 
rapidly fermentable in the equine GI tract, and may therefore be more likely to cause laminitis.
162
   
 Photosynthetic plants convert atmospheric carbon dioxide into simple sugars and store 
sugars that are produced in excess of the plant’s metabolic needs as the complex storage 
carbohydrates starch and fructan.  Temperate (C3) grasses accumulate fructans in 
nonreproductive tissues such as the stem, and accumulate starch in the seeds.
161
  Starch also 
accumulates in both the seeds and nonreproductive tissues of legumes and warm season (C4) 
grasses.
161
  Starch production and storage in leaf chloroplasts is a saturable process, whereas 
fructan production can continue unrestrained.
161
  Therefore legumes and C4 grasses tend to 
accumulate less NSC than C3 grasses.
161
  Stems and seeds of C3 grasses are highest in 
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carbohydrate, while the highest carbohydrate concentrations are found in the leaves and seeds of 
C4 grasses and legumes.
161
   
 The term NSC refers to the sum of simple sugar, starch, and fructan content (equation 1), 
while WSC refers to the sum of simple sugars and fructans only (equation 2).
160-162
  Ethanol 
soluble carbohydrate includes only simple sugars, although some short-chain OFs may partition 
into the ethanol-soluble fraction.
160,162
  “Nonstructural carbohydrate” has also been used to refer 
to the sum of all simple sugars, starches, fructans, gums, mucilages, and pectins (equation 3), and 
a similar method of calculating nonfiber carbohydrate (NFC) is sometimes used (equation 
4).
161,162
     
 
Eq. 1:  NSC = simple sugar % + fructan % + starch %  
Eq. 2:  WSC = simple sugar % + fructan %  
Eq. 3:  NSC = 100 – (water % + crude protein % + fat % + ash % + neutral detergent fiber %) 
Eq. 4:  NFC = 100 – [crude protein % + (neutral detergent fiber % - neutral detergent insoluble 
crude protein %) + fat % + ash %] 
 
The ethanol soluble carbohydrate and starch content of the feed provide information about the 
glycemic response, as well as the potential for rapid fermentation if fed in large quantities that 
exceed small intestinal hydrolysis capacity.
160
  Mammals lack the digestive enzymes necessary 
to hydrolyze fructans,
166
 although some acid hydrolysis or fermentation occurs in the equine 
stomach.
161
  Most fructans, however, pass undigested through the stomach and small intestine 
and are rapidly fermented in the hindgut.
161,165
 Fructan content therefore also provides 
information about fermentability.  Because simple sugars, starches, and fructans all have the 
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potential to cause excessive hindgut fermentation and subsequent alterations in hindgut pH, all 
have potential relevance to the development of pasture-associated laminitis.   
 
1.2.2  Insulin Action in the Post-Prandial State 
 
 Blood glucose is tightly regulated, even after the intake of a large meal.
167,168
  The major 
organ systems involved in macronutrient (glucose, amino acid, and fat) regulation following a 
meal are the liver, skeletal muscle, and adipose tissue.
94
  The major hormones involved in 
nutrient regulation are insulin, glucagon, glucocorticoids, epinephrine, and growth hormone.
94
  In 
general, insulin’s actions oppose those of the counterregulatory hormones, except for some 
overlap with growth hormone actions on amino acid and protein metabolism.
169
  Insulin secretion 
increases following a meal, and insulin plays the dominant role in regulating glucose metabolism 
in the fed state.  Secretion of the other counterregulatory hormones decreases, so their role in 
post-prandial nutrient metabolism has mostly to do with release of inhibition on metabolic 
pathways.  As such, the role of insulin will be focused upon.  Rising blood glucose concentration 
is detected by pancreatic β-cells, and this stimulates β-cell insulin secretion.  Secretion of 
glucagon from pancreatic α-cells also declines as blood glucose concentration rises.   
 Following a meal, macronutrients are transported out of the gut via the portal circulation 
(sugars, amino acids, and a few lipids) or the lymphatics (chylomicrons and intestinal very low 
density lipoprotein (VLDL) that contain triglycerides, phospholipids, and cholesterol).
94
  
Glucose and amino acids circulate first to the liver, while chylomicrons and intestinal VLDL 
enter the circulation via the thoracic duct.  Most lipids therefore circulate to the periphery, where 
LPL on the capillary endothelium of adipose and muscle tissues hydrolyzes triglyceride and 
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liberates free fatty acids.
170
  The majority of the lipid is stored in adipose tissue depots, although 
some is stored within myocytes to provide energy during fasting.  Lipoproteins become 
progressively less dense as they lose triglyceride, and eventually circulate back to the liver, 
where they are taken up by hepatocytes to be either oxidized, stored, or repackaged as VLDL and 
recirculated to the periphery.  Amino acids and glucose reach the liver before the periphery.  
Amino acids are either partially catabolized in the liver or exit the liver and enter the peripheral 
circulation.  There is no storage form for amino acids, so they are either used immediately for 
protein synthesis and turnover, or carbon skeletons generated from their partial catabolism are 
used by the liver to synthesize glucose via gluconeogenesis.  The glucose produced may then be 
either oxidized or stored as glycogen.  In the initial 2-3 hours following a meal, most tissues that 
utilize glucose will do so.  Therefore, in tissues such as the liver, and even in muscle, which 
preferentially oxidizes fatty acids except when glucose is highly abundant, glycolysis and 
glycogen synthesis are activated in parallel.
94,169
  In this way, the majority of glucose in a meal is 
either oxidized for energy immediately or stored as glycogen in liver and muscle to provide 
energy during fasting.  In contrast, the gluconeogenesis and glycogenolysis pathways that lead to 
glucose output from the liver are suppressed, as well as glycogenolysis in muscle.  In addition, 
pathways that promote amino acid catabolism are suppressed in muscle and lipolysis is 
suppressed in adipose tissue.  Diets high in carbohydrate and low in lipid promote de novo 
lipogenesis in the liver, facilitating the conversion of excess dietary carbohydrates to lipids, 
which are then exported from the liver via VLDL to peripheral adipose storage depots.
171
 
 Metabolic pathways of synthesis and catabolism for a given macronutrient are generally 
regulated in tandem.
94
  This is often accomplished through phosphorylation or changes in gene 
expression of key pathway enzymes.  The same hormone can promote activity in one pathway 
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(for example, synthesis), while inhibiting the opposing pathway (for example, catabolism).  This 
is seen in insulin’s control of macronutrient metabolism.  In the liver, for example, insulin 
promotes glycogen synthesis by increasing glycogen synthase activity, while inhibiting 
glycogenolysis by decreasing activity of glycogen phosphorylase and G6P.
172,173
  Insulin also 
promotes the activity of hexokinases, including glucokinase, thereby increasing glycolysis while 
glucose is abundant.  Insulin promotes fatty acid synthesis in the liver via the transcription factor 
sterol regulatory element binding protein 1c, which enhances expression of genes involved in the 
fatty acid synthesis pathway.
174
  Insulin restrains gluconeogenesis in the liver by inhibiting key 
enzymes such as the rate-limiting enzyme PEPCK.
173,175
  Insulin down-regulates gene expression 
of PEPCK and decreases activity of G6P, which therefore inhibits the final step of 
gluconeogenesis.
173,175
  Insulin promotes GLUT4-mediated glucose uptake into adipose and 
skeletal muscle tissues.
176
  Glucose is then either oxidized or converted into glycogen in muscle.  
In adipose tissue, glucose is either oxidized for energy or partially oxidized to obtain a 3-carbon 
glycerol backbone on which to esterify fatty acids and form triglycerides. 
 In general, insulin promotes the storage of fat.  Accordingly, insulin increases the activity 
of LPL so that fats are taken into storage depots, while decreasing the activity HSL and 
inhibiting lipolysis.
170,177,178
  These effects occur primarily in adipose tissue, but also in muscle 
since myocytes can store intramyocellular triglyceride.   
 Insulin has milder effects on amino acid metabolism.  Insulin, in conjunction with growth 
hormone (acting through insulin-like growth factor-1), promotes protein synthesis while 
inhibiting protein catabolism.
94,169
  Inhibition of protein catabolism is the main mechanism 
through which insulin promotes growth.  Insulin may also enhance the uptake of some amino 
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acids by increasing the activity of amino acid transporters, although this is only a minor function 
of the hormone. 
 
1.2.3  Metabolic Derangements in Insulin-Resistant and Diabetic States 
 
 Type 2 diabetes mellitus (T2DM) is characterized by a lack of insulin sensitivity in the 
tissues that maintain glucose and nutrient homeostasis in the body.
179-181
  The initiating 
pathology is loss of responsiveness to insulin in adipose, muscle, and liver tissues.  Initially, 
pancreatic β-cells become more responsive to glucose, and therefore compensate for the 
decreased peripheral insulin action by increasing insulin secretion in response to elevated blood 
glucose concentrations.
4,182,183
  Eventually, β-cells may decompensate and fail to secrete insulin, 
whereupon glycemic control is lost.  Decompensation and true T2DM are infrequently 
encountered in the horse, however the condition has been reported.
184-188
  Once decompensation 
occurs, the body can no longer utilize glucose effectively and enters a state resembling 
starvation.  In this state, the majority of energy is provided by fat and amino acid catabolism.  
Only obligate glycolytic tissues that obtain glucose through insulin-independent uptake, 
including the brain, structures in the eye, and erythrocytes, utilize glucose for fuel.
94
   
 Hyperglycemia contributes to much of the pathology seen in diabetes.   Glucotoxicity 
caused by elevations in ROS and consequent mitochondrial dysfunction, as well as glycation 
reactions, lead to vascular disease, retinopathy, renal disease, and neurologic disease.
189,190
  
Hyperglycemia that exceeds the renal threshold results in osmotic diuresis and causes 
dehydration and electrolyte abnormalities.
191,192
  Since glucose is unable to reach its target 
tissues, the body attempts to raise blood glucose concentrations by increasing gluconeogenesis, 
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glycogenolysis, lipolysis, and protein catabolism.
94
  Atherosclerotic cardiovascular disease in 
humans and other species can result from increased cholesterol synthesis and mobilization from 
the liver, which is a consequence of increased lipolysis and loss of insulin inhibition of lipid 
metabolism.
193
  In advanced disease, many tissues, including parts of the brain, switch to using 
ketones for energy.
194




 A functional insulin signaling cascade is required for insulin to elicit its biological 
actions, which include suppression of hepatic gluconeogenesis and glycogenolysis, suppression 
of lipolysis and increased triglyceride storage, and inhibition of protein catabolism.
94
  Insulin 
performs these functions through regulation of key enzymes in these processes.  Enzymes 
regulated by insulin include HSL and LPL in lipid metabolism, PEPCK and G6P in 
gluconeogenesis, G6P and glycogen phosphorylase in glycogenolysis, hexokinase, and enzymes 
of protein catabolism.
94
  Regulation occurs through both phosphorylation of enzymes as well as 
upregulation or down-regulation of gene expression. 
 
1.2.4  Intracellular Insulin Signaling Pathways 
 
 Intracellular signaling pathways diverge distal to the insulin receptor (Figure 1.2).
85,196
  
Pathways lead to activation of PI3-kinase signaling, MAPK signaling, or activation of the 
guanosine triphosphate-binding protein TC10.  The PI3-kinase pathway is most important to the 
metabolic actions of insulin, including phosphorylation of metabolic enzymes, phosphorylation 
of endothelial nitric oxide synthase (eNOS), regulation of metabolic gene expression, and 
GLUT4 translocation to the cell surface.
85,197-199





Figure 1.2  Insulin signaling pathways diverge distal to the insulin receptor and lead to various 
biological responses.  Activation of the PI3-kinase pathways is required to stimulate the 
metabolic actions of insulin, while MAPK signaling is critical for mitogenic functions.  Cross-
talk also occurs among signaling pathways.  From Kanzaki M, Pessin JE. Signal integration and 




GLUT4 translocation (Figure 1.3).
200-204
  Insulin’s effects on cell growth and differentiation, 
apoptosis, and gene expression are controlled through MAPK pathways involving ERK.
85
   
 The insulin receptor is a dimer composed of 2 α- and 2 β-subunits.  The α-subunits are on 
the extracellular face of the cell membrane, while β-subunits span the membrane and have 
cytosolic portions that possess tyrosine kinase activity.
85
  Insulin binds to the α-subunits, 
inducing a conformational change in the β-subunits and subsequent autophosphorylation of the 
β-subunits on 3 tyrosine residues.
94
  The β-subunits then acquire tyrosine kinase activity and 
phosphorylate downstream adaptor proteins including IRSs that lead to PI3-kinase activation, 
casitas b-lineage lymphoma (Cbl) protein and Cbl-associated protein (CAP) that lead to 
activation of the TC10 pathway, and the adaptor protein Shc and growth factor receptor binding 
protein (Grb) that lead to MAPK activation.
85
   
 The PI3-kinase pathway is the most important with respect to glucose metabolism 
because it is required for GLUT4 translocation to the cell membrane as well as regulation of 
metabolic enzymes.  Insulin receptor substrate-1, located primarily in muscle and adipose 
tissues, and IRS-2, located in the liver, are the most important IRS proteins.
94
  Phosphorylation 
of IRSs on a specific tyrosine residue exposes a binding region for proteins that contain a highly 
conserved, approximately 100 amino acid sequence known as the Src homology 2 (SH2) 
domain.  The lipid kinase PI3-kinase contains an SH2 domain in the p85 regulatory subunit.  The 
SH2 domain binds to tyrosine-phosphorylated IRSs, causing allosteric activation of the catalytic 
p110 subunit.  Phosphoinositide 3-kinase then phosphorylates a plasma membrane phospholipid 
called phosphatidylinositol 4,5-bisphosphate (PIP2), generating phosphatidylinositol 3,4,5-
triphosphate (PIP3).
94
  Phosphatidylinositol 3,4,5-triphosphate serves as a binding domain for 





Figure 1.3  Insulin signaling pathways leading to cellular glucose uptake.  Concurrent activation 
of the PI3-kinase and TC10 pathways is required to stimulate GLUT4 vesicle translocation to the 
cell surface.  From Saltiel AR, Pessin JE. Insulin signaling pathways in time and space. Trends 




substrates PKB/Akt and the atypical protein kinase C (aPKC) isoforms PKCδ and PKCλ.  
Protein kinase B and aPKC are phosphorylated on serine and threonine residues by PDK-1 in 
conjunction with the serine/threonine kinase mammalian target of rapamycin.
205-207
  Protein 
kinase B, itself a serine/threonine kinase, functions through downstream targets to phosphorylate 
and regulate several metabolic enzymes and eNOS, and is partially responsible for GLUT4 
translocation from its intracellular storage vesicles to the cell surface following ingestion of 
glucose.
85,198,199,208
   
 The PI3-kinase pathway alone is not sufficient for GLUT4 translocation because a second 
signal is required from TC10.
200-204
   The TC10 pathway also originates from the insulin 
receptor.  The receptor phosphorylates the adaptor protein Cbl, which is associated with 
CAP.
85,209,210
  Since CAP associates with fillotin in the lipid bilayer caveolae, this pathway is 
spatially segregated to lipid raft domains.
201,211
  Many stimuli can activate PKB/Akt signaling, so 
the TC10 pathway ensures that only insulin mobilizes GLUT4 to the cell surface.  Intermediates 
downstream of PKB/Akt and TC10 that facilitate GLUT4 translocation have not been clearly 
identified.
208
  Possible targets include PKB/Akt substrates such as Akt substrate of 160 kDa 
(AS160) and phosphoinositide kinase for five position containing a Fyve finger.
204,208,212
  
Impaired phosphorylation of AS160 has been associated with diabetes
213
 and increased TNF-α 
concentrations.
214
  Results are inconsistent, however, and unchanged or increased muscle AS160 





  A recent study of AS160 in horses did not detect any differences in protein 
content or phosphorylation state in the muscles of insulin-resistant and insulin sensitive horses 
despite differences in cell surface GLUT4 protein expression, suggesting that AS160 is not 





 In the unstimulated state, GLUT4 is largely sequestered in intracellular vesicles, with 
only about 2-10% cycling to the cell surface at any given time.
204,212,218
  The mechanism of 
GLUT4 vesicle fusion is similar to that of neural synaptic vesicles and involves PKB/Akt 
substrates known as soluble NSF attachment protein receptors (SNARES).
204,212
  On the GLUT4 
vesicle, SNARES such as vesicle-associated membrane protein (VAMP)2 and VAMP3 interact 
with syntaxin4 and synaptosomal-associated protein 23 on the cell membrane to facilitate vesicle 
fusion and GLUT4 expression on the cell surface.
204,212
 A small protein call synip appears to be 
associated with syntaxin4, and is also a PKB/Akt substrate.
204,208,212,219
  This molecule is 
phosphorylated and dissociates from syntaxin4 upon insulin stimulation, allowing vesicle fusion 
to occur.  In addition, TC10 and PI3-kinase signaling may be involved in depolymerization of 
actin cytoskeleton tethers that anchor the GLUT4 vesicle to its intracellular location in the basal 
state.
200,201,212
  It can therefore be appreciated that abnormalities in postreceptor signaling 
pathways will reduce insulin’s ability to mobilize GLUT4 to the cell surface, as well as reduce 
its ability to phosphorylate and regulate metabolic genes.  Although the exact mechanism of IR 
in EMS remains to be fully elucidated, altered GLUT4 protein trafficking has recently been 




1.2.5  Assessment of Insulin Sensitivity 
 
 Insulin sensitivity can be assessed in a number of ways.  The simplest of these is to 
measure resting glucose and insulin concentrations in the blood.
221,222
  While easy to perform, 
these tests are at best a screening tool because resting glucose and insulin concentrations 
represent the endpoint of complex metabolic pathways that are subject to extensive regulation, 
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diurnal and seasonal variation, and are affected by conditions such as stress and illness.
167,182
  
Resting hyperglycemia and elevated hemoglobin A1c values, commonly measured in humans,
223
 
suggest loss of glycemic control due to peripheral IR or from decreased pancreatic β-cell insulin 
secretion, but factors such as stress, pain, and diet can also cause hyperglycemia.
167
  
Hyperglycemia is uncommon in insulin-resistant horses and indicates progression to 
uncompensated IR or diabetes mellitus.
4
   
 Resting insulin concentration is frequently used as a screening tool in horses and 
hyperinsulinemia is suggestive of IR.
4
  However, insulin concentrations vary  throughout the 
day, so resting insulin concentration can fall within the normal range at the time of sampling in a 
horses with IR.
224
  As with blood glucose, insulin concentration is also affected by factors such 
as stress, pain, and diet,
167
 so a result is more likely to represent a true positive the further it falls 
outside the reference range.  Additionally, the test is only valid in animals with compensated IR, 
and false negative results may be obtained if pancreatic β-cell exhaustion and decompensation 
have resulted in declining insulin secretion.
221,222
     
 Ratios of resting glucose (in mg/dL) and insulin (in µU/mL or mU/L) concentrations can 
also be calculated.  Glucose-to-insulin ratios correlate positively with peripheral insulin 
sensitivity and describe the effectiveness of insulin on lowering blood glucose, while insulin-to-
glucose ratios describe pancreatic release of insulin in response to increasing blood glucose 
concentration.
221,222
  Glucose-to-insulin ratios less than 10 indicate IR, while ratios less than 4.5 
indicate severe IR or decompensation.  As with resting glucose and insulin concentrations, ratios 
are affected by factors such as stress that can confound the results.  
 In both humans and horses, proxies calculated from resting insulin and glucose 





  The modified insulin-to-glucose ratio (MIRG) and 
reciprocal of the square root of insulin (RISQI) are calculated as follows: 
 
MIRG = [800 – 0.3 × (basal insulin concentration – 50)
2
] / (basal glucose concentration – 30) 
RISQI = 1 / [√ (basal insulin concentration)] 
 
The MIRG proxy was designed to estimate the acute insulin response to glucose (AIRg) 
parameter from minimal model analysis of insulin-modified frequently samples intravenous 
tolerance test (FSIGTT) data, while the RISQI proxy was designed to estimate the insulin 
sensitivity index (SI).  Acute insulin response to glucose and insulin sensitivity can be calculated 
from proxy values using the following formulas: 
 
AIRg = 70.1 × (MIRG) – 13.8 
Insulin sensitivity = 7.93 × (RISQI) – 1.03 
 
 Dynamic testing can unmask abnormalities in glucose and insulin homeostasis that are 
not evident when resting samples are assessed, and additional metabolic function parameters can 
be obtained.  Tests are performed by administering a challenge dose of insulin or glucose and 
monitoring physiologic responses.  A number of techniques are available to assess whole-body 
insulin sensitivity, each with its own benefits and limitations.
221,222,227,228
  Commonly used 
procedures include oral glucose tolerance tests, intravenous glucose tolerance test (IVGTTs), 
intravenous insulin tolerance tests, the combined glucose-insulin tolerance test (CGIT), 
hyperinsulinemic-euglycemic clamp (HEC) procedures, hyperglycemic clamps, and the FSIGTT 
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with minimal model analysis.  These tests are interpreted by comparing parameters such as area 
under the curve values for glucose or insulin, peak and trough glucose and insulin responses, and 
the return of insulin and glucose concentrations to baseline.  As an example, a glucose challenge 
that elicits an abnormally high insulin peak, delayed return of insulin concentrations to baseline, 
or an increased area under the insulin curve value could indicate increased β-cell responsiveness 
to glucose or decreased insulin clearance.  During the same test, delayed return of glucose 
concentrations to baseline and an increased area under the glucose curve value could indicate 
peripheral IR, since glucose is not cleared as rapidly as expected.   
 While dynamic tests offer several advantages, limitations of each test must be recognized.  
Oral glucose tolerance tests are affected by gastric emptying time, small intestinal absorption 
rates, hepatic glucose uptake, and pancreatic β-cell responsiveness.
222
  The IVGTT assesses 
insulin sensitivity by providing information on the functional turnover rate of glucose, however 
exaggerated peak glucose concentration or delayed return to baseline may be due to either 
impaired insulin secretion or decreased insulin sensitivity.
221,222
  Insulin tolerance tests assess the 
glycemic response to exogenous insulin, and may be confounded by endogenous insulin 
secretion.
221,222
  It is therefore important to consider potential confounders when performing any 
of these procedures. 
 The CGIT is useful for evaluating insulin sensitivity because it provides more 
information than either the IVGTT or intravenous insulin tolerance test alone, and is easily 
performed.
227
  During this test, an intravenous bolus of glucose is administered concurrently with 
an intravenous bolus of insulin and blood glucose and insulin concentrations are monitored.  
Failure of glucose concentrations to return to baseline by 45 minutes following intravenous 
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glucose and insulin administration or an insulin concentration exceeding 100 µU/mL at 45 
minutes are indicative of IR in the horse.
4
  
 The HEC is widely regarded as the gold standard test of insulin sensitivity in 
humans,
229,230
 and has been adapted for use in the horse.
231
  This test utilizes an intravenous 
insulin infusion to maintain supraphysiologic plasma insulin concentrations, thereby suppressing 
hepatic glucose output.  A concurrent intravenous glucose infusion is titrated to maintain 
euglycemia.  The rate of the glucose infusion therefore equals the rate of whole-body glucose 
disposal.  Glucose disposal rate is a measure of peripheral insulin sensitivity, and is represented 
by a parameter called the M/I ratio.   
 The FSIGTT and minimal model analysis can also be used to assess insulin sensitivity.  
The test involves administration of an intravenous glucose bolus followed 20 minutes later by an 
intravenous insulin bolus.
232
  The minimal model is a compartmental representation of glucose 
and insulin regulatory systems that partitions glucose disposal into glucose-dependent and 
insulin-dependent components.
182,221,233
  The SI parameter describes the change in the rate of 
glucose clearance by tissues in response to a known dose of exogenous insulin.  Glucose 
effectiveness is a parameter that describes the ability of glucose to stimulate its own disposal 
through mass effect.
234,235
  Glucose effectiveness is determined by subtracting the rate of insulin-
dependent glucose clearance from total glucose clearance to obtain the insulin-independent 
component.  The AIRg quantifies endogenous insulin secretion by pancreatic β-cells in response 
to glucose.  Disposition index is calculated by multiplying AIRg × SI.  Comparison of pancreatic 
insulin secretion with tissue insulin sensitivity provides information about whether β-cell 
responses to exogenous glucose administration are appropriate, and detects exaggerated β-cell 
responses that occur during compensated IR.   
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 In horses, the HEC was found to be more repeatable than the FSIGTT,
236
 however there 
are also shortcomings.
228
  The test is less physiologic than the FSIGTT, more technically 
challenging to perform, and fewer parameters of glucose and insulin dynamics can be assessed 
than when minimal model analysis is performed on FSIGTT data.  In addition, difficulty 
attaining steady state blood glucose concentrations may occur, and it can be challenging to 
adequately restrain animals during the procedure without causing stress and confounding the 
results.  For these reasons, use of the FSIGTT is sometimes preferable. 
 
1.3  Obesity 
 
1.3.1  Equine Metabolic Syndrome 
 
 In a recent consensus statement,
4
 the American College of Veterinary Internal Medicine 
has defined EMS as a syndrome with 3 key components: 
1) Obesity or regional adiposity, particularly of the subcutaneous adipose tissues 
surrounding the nuchal ligament, tail head, behind the shoulders, or in the prepuce or 
mammary gland region 
2) Insulin resistance 
3) A predisposition towards the development of laminitis, where laminitis develops in the 
absence of identifiable causes such as colic, colitis, grain overload, or retained placenta 
Additional components of the syndrome include hyperleptinemia, dyslipidemia, arterial 
hypertension, altered reproductive cyclicity in mares, and increased systemic inflammatory 





 Environmental conditions that favor increased NSC storage in plants also appear to be 
associated with the development of pasture-associated laminitis.
226,237,238
  Pasture NSC content 
correlates positively with circulating insulin concentrations in healthy horses, and IR and 
compensatory hyperinsulinemia are exacerbated in laminitis-prone ponies that graze on pastures 
high in NSC.
162,226
  Only a small subset of animals develop laminitis when allowed to graze 
under such conditions, suggesting that some horses may be inherently more susceptible to the 
disease than others.  Ponies are more prone to developing EMS and laminitis than horses.
239-242
 
Among horses, Morgan, Spanish Mustang, Arabian, American Saddlebred, Haflinger, 
Norwegian Fjord, Paso Fino, and warmblood horses are predisposed to developing EMS, 
whereas Thoroughbreds and Standardbreds are less susceptible.
4,243
  Interactions between 
environmental factors and genetic predisposition lower the threshold for developing T2DM in 
humans,
244,245
 and a similar situation may occur with horses and laminitis.
246
  Although genes 
that predispose an individual to IR may have conferred an evolutionary advantage on both horses 
and humans during times of famine, it is likely that this genotype has become obsolete and is 
now detrimental under modern conditions where food is abundant.
226,247
  
 As with the metabolic syndrome in humans,
248
 a set of risk factors has been identified to 
predict the development of laminitis in apparently healthy ponies.
226
  Initial criteria were defined 
using an inbred herd of Welsh and Dartmoor ponies.  Fifty-four of 160 animals had previously 
experienced laminitis, and pedigree analysis suggested a dominant pattern of inheritance partially 
suppressed in males.  Use of two proxies, RISQI and MIRG, to evaluate insulin sensitivity and 
the insulin response to glucose, respectively, indicated that ponies predisposed to laminitis had 
decreased insulin sensitivity and an exaggerated compensatory pancreatic response to glucose.  
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Proxy measurements were validated using minimal model analysis in a subset of the ponies.   A 
prelaminitic metabolic syndrome (PLMS) was defined as meeting 3 of the following 4 criteria:   
1) Insulin resistance (RISQI < 0.32 [mU/L]) 
2) Compensatory β-cell response to glucose (MIRG > 5.6 mUinsulin
2
/[10•L•mgglucose]) 
3) Hypertriglyceridemia (triglyceride concentration > 57.0 mg/dL) 
4) Obesity (body condition score > 6.0 on a scale of 1 to 9,249 and regional adiposity of the 
neck and tailhead) 
The presence of PLMS predicted the development of laminitis with an overall power of 78%, 
sensitivity of 74%, and specificity of 79%, and development of laminitis coincided with an 
increase in pasture starch content.  The odds of developing laminitis were 10 times higher in 
ponies with PLMS than in healthy ponies.   
 Using the same group of ponies, individual variables were subsequently identified that 
accurately predicted the development of laminitis when at-risk animals were exposed to nutrient-
dense pastures.
250
  Predictive variables and cut-off values included plasma insulin concentration 
greater than 32 mU/L, plasma leptin concentration greater than 7.3 ng/mL, neck circumference to 
height ratio greater than 0.71, body condition score of 7/9 or above, and cresty neck score of 4/5 
or above.  Diagnostic accuracy of the individual variables was found to be comparable to the 
combinations originally used to define PLMS.  A standardized scoring system called the cresty 
neck score was developed as part of this work to assess regional adiposity of the nuchal crest,
251
 
since this adipose depot is thought to be the most metabolically active in the horse and may 
therefore secrete adipokines that contribute to the development of IR and laminitis.
226,252,253
  
Increased overall adiposity as well as local adiposity of the neck were found to be associated 
with elevations in blood variables such as insulin.
251
  In another study, obesity and IR were also 
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associated with increased resting glucose, insulin, and leptin concentrations, and increased neck 
circumference was positively correlated with area under the insulin curve measured during the 
CGIT.
254
  Increased plasma concentrations of nonesterified fatty acid, very low-density 
lipoprotein, and high-density lipoprotein-cholesterol were detected, indicating that obese, 
insulin-resistant horses suffer from dyslipidemia.  Increased inflammatory cytokine production 
has been detected in obese horses
104
 and in ponies that are prone to developing laminitis,
255
 and 
may represent the underlying link between obesity, IR, and the development of laminitis in these 
animals.   
 Underlying predispositions may not lead to the development of laminitis or to expression 
of the EMS phenotype until an animal is exposed to certain environmental factors.  For example, 
PLMS criteria were not evident in a population of ponies while grazing on winter pasture, 
however, blood insulin, triglyceride, and uric acid concentrations increased, insulin sensitivity 
decreased, and mean blood pressure increased in laminitis-prone animals after exposure to 
summer pasture.
256
  In another study, feeding inulin, a type of fructan, to laminitis-prone ponies 
resulted in an exaggerated insulin response when compared to normal animals.
257
  Insulin 





1.3.2  Abnormal Adipose Tissue in Obesity 
 
 Besides its function in energy storage, adipose tissue is an important endocrine 
organ.
105,106,258,259
  The adipose tissue of an obese individual is abnormal.
260
  Adipocytes tend to 
be larger than normal, and a number of pathologies stem from the fact that these adipocytes have 
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reached their maximal storage capacity.
260
   Adipocytes become stressed for a variety of reasons.  
Hypoxia may be a major factor in adipocyte stress during obesity.
260,261
  Typically, oxygen 
diffuses about 100 µm from capillary beds, and the diameter of large adipocytes may exceed this.  
In addition, the endothelium of vessels within the adipose tissue may become unresponsive to 
NO-induced vasodilation, and this may further contribute to hypoxia.
260,262
  Hypoxia affects cells 
in a number of ways, including reducing mitochondrial function and stimulating hypoxia-
induced genes that promote inflammation.  Stressed adipocytes therefore secrete pro-
inflammatory mediators including cytokines and acute-phase proteins that promote inflammation 
and coagulation.  Stressed adipocytes, and those that have become necrotic as a result of 
hypoxia, also release cytokines such as macrophage chemoattractant proteins that recruit 
macrophages to adipose tissues.
260,263-265
  Resident tissue macrophages within adipose tissue tend 
to be of an anti-inflammatory phenotype, while those recruited by stressed adipocytes exhibit a 
more pro-inflammatory profile.
260
  Resident macrophages may also convert to a pro-
inflammatory profile under these conditions.
266,267
  Inflammatory mediators secreted from 
adipose tissue act locally to promote inflammation, and also evoke inflammation at distant 
locations.  This becomes important with respect to laminitis in horses because the vascular 
endothelium is a target of many of these mediators.
198,199
   
 Increased fat mass may also predispose individuals to more severe inflammatory 
reactions when exposed to stimuli such as LPS, because adipocytes express PRRs such as TLR2 
and TLR4.
110
  Some studies have suggested that adipose tissues from obese and diabetic humans 
and rodents express more TLR2 and TLR4 than tissues of lean individuals, but this has not been 
a consistent finding.
110,268
  Higher mRNA expression of both receptors has been detected, but 
TLR4 protein abundance is not consistently increased.  However, TLR4 reactivity may be 
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enhanced in obesity and diabetes, and responsiveness of adipocytes to the TLR4 ligand LPS has 
been demonstrated in the horse.
269
  
 Adipocytes that are laden with triglycerides also lose their ability to buffer lipid fluxes 
within the body.
260,270
  In the adipocyte, this can cause inflammation due to a buildup of lipid 
metabolism intermediates such as DAG, long-chain fatty acyl coenzyme A, and ceramide, which 
further stresses the adipocyte.
82,89,114
  Lipid buffering capacity is lost, so lipids can also 
accumulate in other tissues, including the liver, muscle, and pancreas, and this may result in 
pathology in these organs.
90,270-272
  Reduced sensitivity of the capillary endothelium to NO-
dependent vasodilation may also impede post-prandial capillary recruitment in adipose tissue, 





1.3.3  Hepatic Manifestations of Obesity 
 
 Hepatic lipidosis is a frequent manifestation of obesity in humans,
273-275
 and has been 
detected in some horses that suffer from EMS.
276
  Enhanced peripheral lipolysis secondary to IR 
represents the major cause of lipid accumulation in the steatotic liver, with a smaller contribution 
by de novo lipid synthesis within hepatocytes.
277
  Lipid negatively affects hepatic macrophage 
(Kupffer cell) function.  Intermediates of fatty acid metabolism are agonists for Kupffer cell 
PRRs and therefore trigger an inflammatory cascade.
90,278
  Lipid-laden hepatocytes also 
compress liver sinusoids and this promotes Kupffer cell activation.  Compression decreases 
blood flow velocity and prolongs exposure of Kupffer cells to leukocytes and antigens present in 
the sinusoids.
279
  Activated Kupffer cells secrete pro-inflammatory mediators which damage 
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surrounding hepatocytes and cause them, in turn, to secrete more pro-inflammatory mediators.
280-
282
  Lipid accumulation within hepatocytes may also cause dysfunction of mitochondria and the 
endoplasmic reticulum, further stressing cells and exacerbating inflammatory mediator 
production.
282-285
  Hepatocytes with mitochondrial dysfunction may also have difficulty 
oxidizing lipids, resulting in a build-up of toxic lipid metabolism intermediates that promote 
inflammation.
55,278,282
  It has also been shown that chronic hyperinsulinemia depresses Kupffer 
cell phagocytosis in rats,
286
   so the liver may be less effective at clearing toxins such as LPS 
from the portal blood and may allow these antigens to pass into the systemic circulation where 
they incite an inflammatory reaction.  
 The liver,
107-109
 along with adipose tissue,
104-106
 contributes to the low-grade 
inflammatory state that characterizes obesity.
106-109
  A key cytokine produced by the liver (and 
adipose) during obesity is IL-6.
109,283
  A major function of IL-6 is to stimulate hepatic production 
of acute-phase proteins.  One of these acute-phase proteins is LBP, and LBP is elevated in obese 
humans.
287
  Increased circulating LBP suggests a role for LPS-induced inflammation in obesity.   
 Obesity-related liver dysfunction might also contribute to sepsis-associated 
hyperglycemia, which has been documented in the horse and is associated with a poorer clinical 
outcome in affected animals.
288-291
  Glucotoxicity and increased free radical production can incite 
tissue damage, heighten inflammation, and negatively impact immune function.
91
  The major 
source of glucose during sepsis is from increased hepatic gluconeogenesis.
91,144,292
  In an obese 
liver that is already insulin-resistant, sepsis-associated hepatic IR may be more pronounced, and 
a predisposition towards hyperglycemia may exist.  
 Gastrointestinal flora differs between obese and lean individuals of many species, 
including rodents and humans,
293,294
  and this may have implications for the obese horse.  
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Differences in GI flora may be particularly important if hepatic steatosis causes the liver to be 
less effective in clearing bacterial toxins that arrive from the gut via the portal circulation.  One 
study examining fecal pH following inulin administration failed to detect a difference between 
normal and laminitis-prone ponies, suggesting that differences in gut microflora may not feature 




1.3.4  Insulin Resistance and the Vasculature 
 
 In obese and insulin-resistant humans, the underlying defect that links obesity with 
cardiovascular disease is endothelial dysfunction.
296,297
  In this paradigm, the PI3-kinase insulin 
signaling pathway is inhibited during IR, while the MAPK pathway remains functional.
198,199
  
Although there is significant cross-talk between these pathways, some functions appear to be 
initiated almost exclusively by one or the other signaling cascade.  With regard to endothelial 
dysfunction, an important point is that the PI3-kinase pathway is responsible for the production 
of endothelial-derived NO, while the MAPK pathway is responsible for the production of ET-
1.
198,199
  These endothelial-derived vasoactive compounds are primarily responsible for 
regulating vascular tone in capillary beds.
198,199
  Under normal conditions, the opposing actions 
of NO (vasodilation) and ET-1 (vasoconstriction) are in balance because both arms of the insulin 
signaling cascade are active.  When PI3-kinase signaling is inhibited, however, NO production is 
reduced, and only the vasoconstrictive force of ET-1 remains.  Vasoconstriction may be further 
exacerbated when compensatory hyperinsulinemia occurs secondarily to IR,
162,199,298
  however, 
the relative importance of MAPK pathway overstimulation by hyperinsulinemia remains 
controversial.
299-301
  In addition, constitutively produced NO is consumed when ROS are 
42 
 
scavenged, making less NO available to promote vasodilation.  In individuals with endothelial 
dysfunction, this can also lead to paradoxical vasoconstriction in response to stimuli such as 
inflammation that normally cause vasodilation.
39,302
  Vascular dysfunction associated with IR is 




 Endothelial dysfunction in obese individuals might also result from effects of 
inflammatory cytokines produced by adipose
104-106
 and liver tissues, 
107-109
 and antigens such as 
endotoxin that have escaped clearance by Kupffer cells.
286,304
  Similar to endothelial dysfunction 
during sepsis, these stimuli cause the endothelium to produce pro-inflammatory cytokines and 
express adhesion molecules,
262,305,306
 with the following ramifications.  First, the activated 
endothelium promotes coagulation.
305
  Second, an individual with underlying endothelial 
dysfunction that experiences inflammation is more susceptible to endothelial damage from 
leukocyte adherence and free radical production.
307
  Third, the activated endothelium 
experiences stress, which can lead to mitochondrial dysfunction.
198,199,308
  Obesity-related 
endothelial dysfunction may therefore lower the “threshold” for activation during sepsis and 
predispose the animal to laminar damage caused by neutrophil migration into laminar 
tissues.
162,298,309
   
 In addition to activation by cytokines or endotoxin, adipokines such as leptin and 
adiponectin have direct effects on the vascular endothelium, as well as indirect vascular effects 
exerted through modulation of insulin sensitivity and inflammation.
310-312
  Adiponectin has anti-
inflammatory actions and can therefore counteract the effects of cytokines such as TNF-α on the 
endothelium.
313-317
  Leptin is generally pro-inflammatory, and exacerbates endothelial activation 
and the generation of free radicals that damage the endothelium.
318,319
  In obese individuals, 
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secretion of adiponectin by adipose tissue decreases,
259
 while leptin secretion increases.
315
  
Adipose-derived cytokines are also affected by systemic inflammation.  Adiponectin decreases 
and leptin increases following experimental administration of endotoxin as well as during 
clinical sepsis.
320-323
   It has been suggested that obese individuals with adiponectin deficiency 
may have a higher risk of mortality during sepsis because they lose the immunomodulatory 
effects of adiponectin and its protective actions on the endothelium.
313
      
 
1.3.5  Obesity, Sepsis, and the Immunomodulatory Properties of Adipokines 
 
 In many species, metabolic and nutritional status has been shown to affect immune 
function.  Both obesity and starvation can negatively impact immune function.
88,154,324
  Obese 
patients in human critical care units experience increased mortality rates,
325,326
   and it has been 
suggested that inflammation further exacerbates IR in obese individuals, which results in more 
extensive organ damage.  Insulin resistance also causes loss of glycemic control.  Sepsis-
associated hyperglycemia has been documented in horses,
288-291
  and experimental administration 
of LPS to horses induces IR.
327
  Hyperglycemia increases activation of NFκB signaling and 
production of pro-inflammatory mediators.
91,328,329
  In addition, hyperglycemia can cause 
glucotoxic endotheliopathy and promote organ damage.
328,330
  A well-known series of studies by 
van den Berghe and colleagues
331-333
 demonstrated that tight glycemic control (maintenance of 
circulating glucose concentrations between 80-110 mg/dL) significantly reduced morbidity and 
mortality in critically ill humans.  
 Comorbid conditions commonly seen with obesity, such as hepatic steatosis, can also 
increase inflammatory responses and organ damage.
286,304
    Kupffer cells and hepatocytes are 
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adversely affected by hepatic lipid accumulation, and this could impair the clearance of 
pathogens and toxins from blood.  In the case of a septic, hypotensive individual already 
predisposed to GI ischemia and bacterial translocation, inflammatory stimuli such as LPS may 
reach the systemic circulation more easily.   
 Inflammatory responses in the obese individual may be exaggerated simply due to 
increased fat mass.  Adipocytes express PRRs including TLR2 and TLR4
110
  and both adipocytes 
and preadipocytes secrete inflammatory cytokines in response to stimulation by LPS.
110,269,334
  
Adipose tissues may therefore contribute more to the inflammatory milieu in the obese 
individual.    
 Leptin is an adipocyte-derived hormone that is almost exclusively produced by white 
adipose tissue.
335
 Leptin concentrations increase in direct proportion to increasing adipose depot 
size.
336,337
  This hormone acts as an adiposity signal to keep other systems in the body apprised 
of the adipose depot size.
315,338
  Interaction of leptin with its long-form receptor in the 
hypothalamus is involved in satiety signaling.
338
  Leptin signals the size of adipose depots to the 
hypothalamus, affecting the way in which short-term satiety signals are processed.
338
  
Hypothalamic leptin signaling also regulates functions such as reproduction that rely on an 
adequately sized adipose depot.
339,340
  The immune system utilizes approximately 15% of the 
body’s energy,
154
  so it has been proposed that this system has evolved to recognize leptin and 
tailor its responses accordingly. 
 Leptin and its receptors share structural similarities with other pro-inflammatory 
cytokines, and its actions on the immune system are pro-inflammatory.
105,315,341
  Leptin 
concentrations increase during sepsis
323
 and following exposure to LPS.
322
  Leptin secretion can 
also be induced by cytokines such as TNF-α and IL-6.
218
  In humans, elevated leptin 
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concentrations and the associated pro-inflammatory actions have been proposed to be one reason 
why obese individuals have a poorer prognosis during sepsis.  However, results of one study 
examining leptin concentrations in diabetic and non-diabetic critically ill patients provided only 
equivocal results.
342
  Leptin stimulates innate immunity and promotes the activation of NFκB 
signaling, and therefore the production of cytokines such as TNF-α.
258,343
  It also influences 
lymphocyte proliferation and differentiation.
105
  Lymphocyte differentiation is polarized towards 
a T-helper 1 (cytotoxic) rather than T-helper 2 (humoral) response.  Leptin also activates 
endothelial cells directly, causing expression of adhesion molecules and generation of ROS that 
can lead to cellular stress and mitochondrial dysfunction.
318
  Endothelial activation is necessary 
for leukocyte emigration and also plays a major role in the pathogenesis of organ failure during 
sepsis.
35,344,345
  Increased leptin may therefore lead to detrimental outcomes, especially in the 
obese individual.  
 Obesity is associated with lower adiponectin concentrations.
315
  Adiponectin is secreted 
by adipocytes,
315
 and decreases in response to inflammation and sepsis.
320,321
  Adiponectin 
improves insulin sensitivity in tissues such as skeletal muscle, and counteracts IR caused by 
cytokines such as TNF-α.
346
  In obese patients that have preexisting adiponectin deficiency, a 
further reduction in adiponectin secretion might exacerbate IR following an inflammatory event, 
and could magnify the negative effects of IR on the vasculature and immune system.
313,347
  
Adiponectin also exerts direct anti-inflammatory actions on cells of the immune system, so lower 
concentrations might result in an exaggerated inflammatory response that leads to organ 
failure.
315,317,348
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 Resistin is a hormone produced by adipocytes and macrophages,  and it promotes 
IR.
259,315
  Resistin has similar immune effects as leptin, and also increases in response to 
inflammation.
349-351
   
 In conclusion, inflammation may predispose obese individuals to endothelial dysfunction 
and subsequent organ damage during sepsis, and could exacerbate IR as a result of altered 
adipokine secretion. 
 Some drugs used to treat IR have proven efficacious in mitigating the detrimental effects 
of inflammation and sepsis.  For example, administration of exogenous thyroid hormone 
increases insulin sensitivity in horses,
352,353
 and has been shown to ameliorate IR following LPS 
administration.
354
  The peroxisome proliferator-activated receptor-γ agonists known as 
thiazolidinediones, which include rosiglitazone, improve insulin sensitivity and may have 
beneficial effects during endotoxemia and sepsis.
355-357
  Also, blockade of the renin-angiotensin-
aldosterone system with agents such as the angiotensin-II receptor antagonist losartan improves 
insulin sensitivity because angiotensin-II inhibits activation of the PI3-kinase pathway.
358,359
  The 
finding that these drugs reduce inflammation and sepsis-related mortality underscores the 
potential importance of IR in the pathogenesis of these disorders.   
 
1.4  Laminitis 
 
1.4.1  Overview of Laminitis Pathophysiology  
 
 There are several ways in which to group the inciting causes of laminitis, and a great deal 
of overlap exists among individual causes.
360
  At the organism level, laminitis can be broadly 
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thought of as occurring secondary to endocrine and metabolic derangements, inflammation, 
derangements in digital blood flow, or mechanical overload.
237
  Within the laminar tissue, the 
three main mechanisms that have been proposed are vascular disorders leading to hypoxia and 
ischemia/reperfusion injury, metabolic and enzymatic derangements, and mechanical trauma.
303
  
In reality, these mechanisms overlap, since diseases have multiple effects on the hoof.  At its 
most fundamental level, laminitis results in structural failure of the tissues that connect the load-
bearing hoof capsule to the underlying bony column.
361
  Any weakening or disruption of these 
tissues causes mechanical forces to pull the bony column, specifically the distal phalanx, into an 
abnormal position and results in pain.
362-366
  Nociceptive, inflammatory, and neuropathic pain 
states feature prominently in this disease.
365
  Regardless of the underlying cause, once laminar 
failure occurs, the clinical signs look very much alike. 
 Mechanical, or “support limb,” laminitis appears to be the most dissimilar 
mechanistically.
303,367
  This form of laminitis occurs during prolonged unilateral weight-bearing 
or excessive concussion on a hard surface, and the cause appears to be traumatic injury to 
laminar tissues and compromise of the vasculature.
367
  Tissue trauma may incite inflammation, 
which is also a feature of other forms of laminitis.
368
  Vascular damage and resultant tissue 
hypoxia can be due either to mechanical trauma, or in the case of prolonged unilateral weight-
bearing, from decreased venous return.
367
  Inflammatory or mechanical damage to the 
vasculature results in edema, which can be particularly dangerous in a closed compartment such 
as the hoof.
369,370
  In a manifestation of compartmental syndrome, extravascular pressure may 
exceed the capillary wall strength, causing collapse of capillaries and further reduction in tissue 
perfusion.  Structural failure of the lamina may then occur as load-bearing continues.  The 
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importance of edema to tissue injury and the development of neuropathic pain in laminitis is an 
unresolved question.
303,365,371
   
 The next broad category to consider includes diseases involving systemic inflammation.  
Examples include GI diseases such as colic and colitis, metritis, pleuritis, and exposure to black 
walnut heartwood extract.
360,368
  Also in this category is carbohydrate-overload laminitis, and this 
may illustrate the link between inflammation and laminitis that occurs with metabolic and 
endocrine disease.
165,372
  In these processes, inflammatory stimuli gain access to the circulation 
and incite a systemic inflammatory response.  In the case of infection, PAMPs are recognized by 
the host immune system.
368
  For example, when GI disease develops, the integrity of the mucosal 
barrier is compromised and this allows translocation of whole bacteria, bacterial toxins, cells 
wall components, and vasoactive amines into the portal circulation.
238
  Inflammation appears to 
cause laminar damage in much the same way as it induces failure of other organs during 
sepsis.
373
  Host recognition of PAMPs activates signaling cascades that result in the production 
of pro-inflammatory cytokines, acute phase proteins, vasoactive eicosanoids, and NO.  
Inflammation also results in a pro-thrombotic state,
374
 as well as activation of the complement 
cascade.
8
  As a result, the vascular endothelium is activated, abnormal vasodilation and 
vasoconstriction occur (depending on the stage of the disease), systemic hypotension may 
develop, and leukocytes emigrate from the vasculature into tissues.  Effects on the laminae 
include tissue hypoxia and ischemia/reperfusion injury, as well as direct tissue damage caused by 
neutrophil-derived ROS and proteolytic enzymes.
368,373
  Release of vasoactive amines from the 
hindgut might also potentiate abnormal vascular contractility.
375
  It should be noted that the 
mucosal barrier can be compromised in any septic patient with poor perfusion,
376
 as well as in 
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cases of primary GI disease.  An important point to consider is that, since inflammation results in 
IR, this may be the link to metabolic and endocrine disease. 
 The final broad category is metabolic and endocrine disease.  The two diseases of 
importance to laminitis are EMS and PPID.
377
  Potential overlap exists between the two diseases, 
as well as between metabolic dysregulation and inflammation in general.  In the case of PPID, 
laminitis may be related either to glucocorticoid excess or to IR.
5,378,379
  Insulin resistance may be 
the most important risk factor for laminitis in affected horses, and it is possible that IR is a pre-
existing condition in some horses with PPID.
380,381
  Glucocorticoids may also exert effects 
directly on laminar tissues and weaken their structure.
5,378,379
  The mechanism proposed is that of 
protein catabolism, and is similar to cutaneous manifestations of Cushing’s disease in other 
species.
382,383
   
 In the case of EMS, both inflammation and IR may be involved in the pathogenesis of 
laminitis because of obesity-related changes in the vascular endothelium.
4,276
  Obesity is a pro-
inflammatory condition, and endothelial activation might increase susceptibility to inflammatory 
insults.  Pasture-associated laminitis is thought to involve inflammation.
162,298
  In this situation, a 
horse ingests large amounts of dietary carbohydrates, which leads to carbohydrate overload and 
subsequent GI mucosal compromise.
161,162,298
  The laminar tissue of animals with EMS may be 
more susceptible to damage from inflammatory events that occur secondary to minor GI 
disturbances.
162,298
   
 In addition, hyperinsulinemia itself might induce laminitis.
384,385
  Maintaining insulin at 
supraphysiologic concentrations in excess of 1000 µU/mL for approximately two days induces 
laminitis in normal horses and ponies.
384,385
  Hyperinsulinemia could induce laminitis through 
changes in digital perfusion, increased ET-1 concentrations within the laminar capillary beds, or 
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localized glucotoxicity to laminar tissues.
296,299
  Glucotoxicity would occur through increased 
passive uptake of glucose via GLUT1, since laminar keratinocytes do not appear to express the 
insulin-responsive GLUT4 transporter.
386
  Mitogenic stimulation by insulin and abnormal 
laminar tissue proliferation has also been suggested.
387,388
   It should be noted however, that the 
direct role of insulin in the development of laminitis is poorly understood.  Although 
administration of supraphysiologic doses of insulin to normal horses in the absence of systemic 
inflammation results in clinical laminitis, the histopathologic lesions seen in this model are not 
the same as those seen in inflammatory models such as carbohydrate overload or black walnut 
heartwood extract administration.
388
     
 Regardless of the inciting cause, all pathways, with the possible exception of the 
hyperinsulinemia model, converge on a common pathway that incites laminar damage.
303,389-391
  
Although the events leading to laminar separation must still be fully characterized, laminar 
separation results from destruction of the laminar basement membrane (BM).
361
  Loss of 
attachments between the lamina densa of the BM and hemidesmosomes of basal keratinocytes in 
the secondary epidermal laminae causes separation at the dermo-epidermal junction, and this 
process is mediated by matrix metalloproteinases (MMPs).
392-395
  These enzymes are involved in 
normal tissue extracellular matrix remodeling and also are induced by inflammation.
396
  Both 
endogenous MMPs, such as MMP-2,
397
 and those released by neutrophils, such as MMP-9, are 
important in the development of laminitis.
398
  Although MMPs can be inappropriately activated 




 and bacterial enzymes,
399
 the 
cause of activation in laminitis is still uncertain.  It has recently been proposed that a 
metalloproteinase enzyme called a disintegrin and metalloproteinase with thrombospondin type 1 
motifs-4 may be responsible for destruction of the BM early in the disease process prior to 
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immigration of neutrophils into tissues or stimulation of other MMPs.
390,400
  According to this 
theory, neutrophil infiltration would be a response to existing laminar inflammation, perhaps 
differentiating laminitis pathophysiology from other manifestations of septic organ failure.  
Calprotectin staining of laminae during the developmental phase of laminitis has demonstrated 
that neutrophil emigration precedes inflammation of the basal keratinocytes, therefore systemic 
inflammatory processes likely contribute to the pathogenesis of the disease.
372
  With regard to 
the insulin-resistant horse, studies in other species have shown that both insulin and glucose can 





1.4.2  Role of Inflammation and Endotoxemia  
 
 Laminitis appears to be associated with endotoxemia, although the exact role that 
endotoxin plays in laminitis remains elusive.  The odds of developing laminitis are 5 times 
higher in hospitalized horses that exhibit clinical signs consistent with endotoxemia or systemic 
inflammation.
3
  Endotoxin administration to horses impairs endothelium-dependent vasodilation 
in digital vessels.
303,403-406
  Endotoxin also reduces digital perfusion coincident with increases in 
blood concentrations of platelet-derived thromboxane A2 and 5-hydroxytryptamine,
407
 
suggesting that endotoxin primarily affects platelets rather than the digital vasculature itself.
407-
409
  Despite these findings, administration of LPS to horses has uniformly failed to induce 
laminitis.
327,410-415
   
 One criticism of LPS administration as a means of inducing laminitis is that it only 
stimulates a short-lived inflammatory response when compared with the complex 
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pathophysiology of clinical sepsis.
416
  Inflammation is of longer duration in the carbohydrate 
overload models that are used to study laminitis.
165,417,418
  In these models, horses are given 
carbohydrates such as starch or OF via nasogastric tube.  Excess carbohydrate reaches the 
hindgut where it is rapidly fermented by lactic acid producing bacteria.
419
  The subsequent 
decline in colon pH kills resident colon bacteria and denudes the colon epithelium,
420
 thereby 
allowing bacterial products such as LPS or lipoteichoic acid, as well as vasoactive protein 
metabolites,
421
 to enter the portal circulation.
422
  Some of these contaminants are cleared by 
hepatic Kupffer cells, however, the liver is unable to clear all of them, and some reach the 
systemic circulation.  Endotoxin has been detected in the peripheral blood of horses following 
carbohydrate overload.
409,423
  In addition, carbohydrate overload results in systemic inflammation 
and an associated decrease in insulin sensitivity.
164,165,409
   
 The pathological changes seen in the laminitic hoof resemble those seen in sepsis-
associated organ failure.
373,424-428
  Elevated concentrations of pro-inflammatory mediators 
including IL-1β, the potent neutrophil chemokine IL-8, free radicals, COX-2, and COX-2 
products such as prostaglandins have been detected in hoof tissues following laminitis 
induction.
429-435
  A significant influx of neutrophils into the laminar tissue also occurs following 
carbohydrate overload.
368,436
  Inflammatory cytokine gene expression also increases in hepatic 
and lung tissues following laminitis induction.
427
  Hoof tissues share many similarities with 
organs damaged in sepsis, so laminitis is a manifestation of multi-organ failure.      
 A recent study demonstrated that administration of LPS via an 8-hour long intravenous 
infusion prior to administration of OF resulted in a greater incidence and severity of laminitis 
than administration of OF alone.
164
  There are two likely possibilities to explain these findings.  
The first is that the initial inflammatory stimulus (LPS) primed cells of the immune system to 
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respond more strongly to a second inflammatory stimulus (either LPS or other bacterial-derived 
toxins) from the hindgut following OF challenge.  This theory is supported by the “two-hit 
hypothesis” of organ damage during sepsis.
21,437-439
    The second explanation is that insulin 
sensitivity decreased with LPS pretreatment since IR has been demonstrated for at least 24 hours 
following a single LPS bolus.
327
  Insulin resistance would therefore have still been present when 
the gut-derived toxic insult affected the laminar tissues. Endothelial activation caused by IR 
might have led to more severe laminar endothelial damage when a second inflammatory stimulus 
was superimposed.   
 
1.4.3  The “Two-Hit” Hypothesis of Organ Dysfunction 
 
 Humans with sepsis experience an initial pro-inflammatory period which subsides, and 
some subsequently develop acute lung injury, a manifestation of organ failure, in response to a 
seemingly innocuous second stimulus.
440,441
  Animal studies have also demonstrated that 
sequential exposure to combinations of inflammatory stimuli such as LPS, fecal peritonitis, 
burns, or hypovolemia and hypoxia results in more severe hemodynamic changes, aggravated 
inflammation, and increased mortality.
440
  The two-hit hypothesis of sepsis-associated organ 
failure holds that an initial systemic inflammatory response primes the immune system and 
causes an exaggerated response to the second stimulus.
21,437-439
   
 Animals exposed to multiple inflammatory stimuli have increased neutrophilic 
infiltration into tissues and this corresponds to increased concentrations of inflammatory 
cytokines.
442,443
  Fecal peritonitis alone does not induce hemodynamic changes indicative of 
severe sepsis or acute lung injury in pigs despite the development of systemic bacteremia, but 
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combining fecal peritonitis with gut ischemia/reperfusion injury induces marked hemodynamic 
alterations, acute lung injury, and greater elevations in serum and lung inflammatory cytokine 
production.
444
  Rats that experience hemorrhagic shock followed by LPS exposure demonstrate 
earlier and more pronounced expression of cytokine-induced neutrophil chemoattractant (the rat 
ortholog of IL-8) in alveolar macrophages, enhanced TNF-α expression,
445
 and a greater degree 
of alveolar neutrophil sequestration than animals that receive either treatment alone.
443
  Use of a 
mouse model of burn injury followed by LPS administration has shown a marked increase in 
death associated with neutrophil and mononuclear cell infiltration of the lungs and liver in 
animals exposed to both insults.
442
  Plasma concentrations of IL-6, IL-10, and TNF-α were 
greatly increased, but IL-1β remained unchanged.  Cytokine expression within the lungs and 
livers of these animals was similar to plasma, with the notable exceptions that IL-1β was 
elevated in all organs examined, and TNF-α expression was unaffected in the liver.  Although 
cell-surface TLR4 and MD-2 expression did not change, results suggested an increase in TLR4 
reactivity to the second LPS stimulus.  Finally, a study in humans demonstrated enhanced in 
vitro superoxide anion release from stimulated neutrophils harvested from trauma patients 
compared to healthy donors.
446
     
 Similar mechanisms may contribute to the pathophysiology of laminar injury.  Diseases 
such as colic and sepsis are usually present for several days prior to the development of 
laminitis.
447
  Frequently, animals appear to experience recurrent “toxic showers,” or episodes 
during which inflammation appears to be exacerbated.  These events presumably occur as waves 
of inflammatory stimuli enter the circulation from sources such as an infection site or the gut, 
and could represent multiple insults to the laminar tissues.  Additionally, since IR and loss of 
glycemic control are associated with inflammation, local glucose concentrations in the hoof may 
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increase during each inflammatory episode, leading to glucotoxic effects.  This has been 
suggested to occur even if peripheral blood glucose concentrations remain within reference 
range.
299
     
 
1.4.4  Endotoxin Tolerance and its Relevance to Laminitis  
 
 Endotoxin tolerance refers to a decrease in the ability of LPS to elicit certain clinical and 
biochemical responses following repeated exposures.
76,448
  Early-phase endotoxin tolerance 
occurs within hours to days, while late-phase tolerance takes days to weeks to develop.
449
  Early-
phase endotoxin tolerance is an adaptation that limits the deleterious effects of excessive 
inflammation on the host.
70,450
  However, this process has also been implicated in the later 
immunosuppressive phase of sepsis and may contribute to the increased risk of secondary 
infections seen in septic patients.
451-454
  This refractory condition has been documented in vitro 
and also in vivo in numerous studies of septic humans and rodents,
455-459
 as well as the 
horse.
460,461
  Lipopolysaccharide stimulation of whole blood from septic human patients results 
in decreased release of TNF-α, IL-1β, and IL-6 from peripheral blood mononuclear cells when 
compared to non-septic patients, and decreased responsiveness can persist for 10 days or 
more.
455
  Isolated monocytes from patients with both Gram-negative and Gram-positive sepsis 
produce less TNF-α and IL-1β in response to stimulation by multiple ligands including LPS and 
staphylococcal enterotoxin B, indicating that cross-tolerance develops between Gram-negative 
and Gram-positive bacterial components.
462
   
 Late-phase endotoxin tolerance is antibody-mediated, and may be directed either towards 
the highly variable O-antigen or towards the conserved core antigens if tolerance is induced 
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using mutant bacterial strains that lack O-antigen.
449
  Although antibodies directed against the O-
antigen are protective, clinical applicability is questionable given the variability of this region 
among bacterial species.
9,463
  Although all portions of the LPS molecule are theoretically 
antigenic, antibodies produced against other portions of the molecule confer less protection than 
those directed against the O-antigen.
449,464,465
  Failure of monoclonal antibodies generated against 
lipid A to cross-react with LPS suggests that the lipid A portion is not exposed to the host 
immune system in the native configuration of the molecule.
9
  Various monoclonal antibodies 
directed against the conserved inner core region have shown mixed results in protecting animals 
from endotoxemia.
9
   
 Although prolonged or repeated exposure of macrophages, neutrophils, and endothelial 
cells to LPS may induce a refractory state,
466-468
 endotoxin tolerance does not result in global 
down-regulation of the inflammatory response.
76,468
  Rather, intracellular signaling cascades are 
altered to favor the down-regulation of pro-inflammatory mediator secretion and upregulation of 
anti-inflammatory mediator secretion through complex alterations within the TLR4 signaling 
pathway.
76,448,469
  Interaction of TLR4 with MyD88 decreases,
470
  and decreased association of 
MyD88 with IRAK-4 has also been demonstrated.
471
  Upregulation of IRAK-M, which is a 
negative regulator of TLR4 signaling,
472
 has been demonstrated in endotoxin-tolerant Kupffer 
cells collected from mice.
473
  Increased turnover of IκB appears to be instrumental in preventing 
NFκB activation in the endotoxin-tolerant state.
474
  Endotoxin tolerance also results in an 
increase in the transcriptionally inactive p50/p50 homodimer of NFκB, which competes with the 
active p50/p65 heterodimer for binding sites on gene promoter regions.
475,476
  The MyD88-
independent pathway has been implicated in the development of endotoxin tolerance.
70,74-76
  
Myeloid differentiation factor 88-independent signaling upregulates negative feedback inhibitors 
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of the inflammatory cascade, while it also stimulates late-phase pro-inflammatory gene 
expression.  This leads to low-grade prolonged exposure of cells to cytokines, which promotes 
tolerance.  Endotoxin tolerance enhances certain cellular functions including macrophage 
phagocytic activity.
76
  Tolerant neutrophils also continue to secrete IL-8,
477
 a chemokine with 




1.4.5   Role of Insulin Resistance 
 
 Although IR has been identified as a risk factor for the development of laminitis,
226
 the 
underlying mechanisms must still be elucidated.  Initial efforts to explain the association focused 
on insulin-mediated glucose metabolism in laminar keratinocytes.  Insulin resistance decreases 
GLUT4-mediated glucose uptake in insulin-sensitive tissues.
478-480
  Laminar tissue consumes 
large amounts of glucose,
481
 and glucose deprivation caused separation between basal 
keratinocytes and the BM in laminar explants.
392,482
  In addition, one study demonstrated 
decreased GLUT4 immunostaining in the laminar tissues of horses with laminitis, leading to the 
assumption that glucose uptake in laminar tissue is insulin-dependent.
483
  Although this theory 
offered a plausible explanation for why IR predisposes horses to laminitis, it was later called into 
question when further studies revealed that glucose uptake in the hoof is not affected by insulin, 
and GLUT4 mRNA and protein are not expressed in laminar keratinocytes.
386,484
  Rather, 
laminar tissue appears to rely on the constitutive GLUT1 transporter.  However, the insulin 
receptor is expressed by the digital endothelium and vascular smooth muscle, so it is more likely 
that IR is related to laminitis through vascular effects in the same way that obesity-related 
endothelial dysfunction predisposes to cardiovascular disease.
198,199
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 Low-grade endothelial activation associated with IR may render the laminar vasculature 
more susceptible to injury when a second insult such as systemic inflammation is 
superimposed.
307
  Horses may experience transient inflammation when grazing on pasture if 
carbohydrate overload occurs, and this may be sufficient to trigger a laminitis episode in 
predisposed animals.  Overproduction of ET-1 is a feature of IR-associated endothelial 
dysfunction in other species,
198,199
 and ET-1 has also been demonstrated to increase during 
laminitis in the horse.
485,486
  If NO production is impaired in insulin-resistant horses, endothelial 
cells may be unable to counteract the vasoconstrictive actions of ET-1, leading to laminar 
hypoperfusion and stress.  The role of NO in laminitis pathology is unclear, however, because 
impaired NO production has not been demonstrated in laminitis models.  Topical NO donors 
have been reported to cause clinical improvement in ponies with lamintis
487
and in horses 
following the administration of black walnut heartwood extract,
488
 but results are 
inconsistent.
489,490
   
 The hyperinsulinemic model of laminitis achieves blood insulin concentrations greatly in 
excess of those commonly found in insulin-resistant animals with compensatory 
hyperinsulinemia,
384,385
 so its relevance to clinical disease is not clear.  However, prolonged 
exposure to moderately elevated insulin concentrations in horses with IR may also be detrimental 
to laminar tissues. 
 
1.5  Conclusions 
 
 Inflammation and IR are important risk factors for laminitis, and often develop 
concurrently in animals with systemic illness.  These conditions might have synergistic effects 
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on tissues and vessels in the hoof, increasing their susceptibility to damage.  Chronic 
inflammation and IR that accompany obesity are also likely to lower the threshold for laminitis 
to develop if a triggering event occurs. 
 In order to identify therapeutic targets, the role of systemic inflammation in laminitis 
must first be clarified.  Although systemic inflammation is associated with laminitis, the specific 
mediators involved are not well characterized.  In systemically ill horses, inflammation is often 
attributed to endotoxemia despite the fact that plasma endotoxin concentrations are not 
commonly measured in clinical cases.  A theoretical role exists for endotoxin in the pathogenesis 
of laminitis because endotoxin is known to affect the digital vascular and activate platelets. 
Endotoxin has also been detected during experimental laminitis induction, and laminitis is a 
complication of diseases in which endotoxemia has been demonstrated.  However, experimental 
endotoxin administration does not induce laminitis, and this could be related to differences 
between experimental models and naturally occurring disease. 
 The studies presented in this dissertation were performed to address the overall 
hypothesis that systemic inflammation causes laminitis and new experimental models can be 
developed to better represent clinical disease.  First, a study examining blood cytokine 
expression during the induction of carbohydrate overload laminitis was undertaken to establish 
the association between systemic inflammation and laminitis, and to more fully characterize 
inflammatory mediators involved in the process.  To further clarify the role of endotoxin in the 
pathogenesis of laminitis, a second study was performed to determine whether an endotoxin 
model that induced laminitis could be developed.  The remaining studies explored whether 
predisposing conditions such as EMS or existing endotoxemia increased susceptibility to 
laminitis during systemic inflammation.  Inflammatory cytokine responses and alterations in 
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glucose and insulin homeostasis were assessed in horses with EMS following intravenous 
endotoxin administration.  The incidence and severity of carbohydrate overload laminitis were 
also evaluated in horses with preexisting endotoxemia to assess whether repeated inflammatory 





Inflammatory cytokine blood messenger RNA expression during the development of 
oligofructose-induced laminitis in horses 
 
 
2.1  Introduction 
 
 Inflammation is hypothesized to play a key role in the pathogenesis of equine laminitis, 
with leukocyte infiltration
436,491,492





 and leukocyte adhesion molecules
430,491
 increasing in the hoof 
tissues as laminitis develops.  These changes resemble the pathological events of sepsis-
associated organ failure,
373,424
 so it is hypothesized that systemic inflammation precedes the 
onset of lameness in experimental models and incites laminar damage. Pyrexia and tachycardia 
precede the development of laminitis in carbohydrate overload models
165,409
 and results of a 
retrospective study showed that horses with clinical signs consistent with systemic inflammation 
had 5-fold higher odds of developing laminitis.
3
  Peripheral leukocyte activation,
425
 increased 
hepatic and pulmonary cytokine expression,
427
 and increased plasma tumor necrosis factor-α 
(TNF-α) protein concentrations
409
 have all been detected  during the developmental phase of 
carbohydrate and black walnut extract laminitis models, indicating that these events cause or 
accompany the development of laminitis.  Inflammation also causes peripheral insulin 
resistance,
164
 which is an independent risk factor for laminitis.
182
 
 In carbohydrate overload models, starch
418
 or  oligofructose (OF)
165
 is administered to 
horses via nasogastric intubation.  Fructans are non-structural storage carbohydrates that differ 
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among plant species with regard to chain length, linkage of fructose residues, and degree of 
branching and polymerization.
496
  Oligofructose is an inulin-derived short-chain polymer of β(2-
1)-linked fructose residues that is commercially extracted from the root of the chicory plant 
(Cichorium intybus) and used as a sweetener.
497,498
  Horses, like most mammals, lack the small 
intestinal digestive enzymes necessary to hydrolyze dietary fructans, although some acid 
hydrolysis may occur in the stomach.
499
  Oligofructose passes into the hindgut, where it is 
rapidly fermented to lactic acid by Gram-positive streptococcal species.
500-502
  Cecal pH 
decreases precipitously from approximately 7 to 4 in experimental models,
165,503
 causing damage 
to the epithelium
420
 and increased permeability of the mucosal barrier.
165,422,504
  Death of Gram-
negative bacteria ensues and endotoxin concentrations increase in cecal fluid.
505
  
Lipopolysaccharide has been detected in the blood of horses that receive carbohydrate
409,423
 and 
it is assumed that translocation of endotoxin and other bacterial products into circulation incites 
systemic inflammation. 
 Inflammatory gene expression in blood can be measured in whole blood samples or the 
leukocyte fraction.  The commercially available PAXgene
®
 whole blood RNA collection system
a
 
has successfully been used to quantify inflammatory responses in horses.
269,506
  Advantages of 
this system include the ease of sample collection, time efficient processing, and minimal RNA 
degradation and alterations in the gene expression profile during collection and storage.
507
 
 The current study was undertaken to assess the systemic inflammatory response during 
the development of OF-induced laminitis using the PAXgene
®
 whole blood RNA collection 
system in horses.  We hypothesized that systemic inflammation could be quantified by 
measuring whole blood inflammatory cytokine gene expression and horses would develop 
systemic inflammation during the OF laminitis induction model.  We further hypothesized that 
                                                 
a
 Qiagen/PreAnalytiX, Valencia, CA 
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the time to onset and severity of laminitis would correlate with the magnitude of inflammatory 
gene expression. 
 
2.2  Materials and methods 
 
Animals – Fourteen healthy adult geldings (10) and mares (4) received OF in a study conducted 
at East Tennessee Clinical Research, Inc.
b
  Horses ranged in age from 2 to 5 years old and 
weighed between 358 and 556 kg (mean, 455 kg; median, 458 kg).  Breeds included Quarter 
Horse (5), Standardbred (3), Tennessee Walking Horse (2), mixed breed (2), Thoroughbred (1), 
and Standardbred cross (1).  The study protocol was approved by the East Tennessee Clinical 
Research, Inc. Institutional Animal Care and Use Committee. 
 
 Study Design – Blood samples were obtained from horses undergoing laminitis induction as part 
of a study in which animals were randomly assigned to receive either the placebo control 
treatment (4 horses) or one of 3 drugs; the identities of which were not disclosed.  Horses 
received 1 g/kg OF
c
 added to the basal ration for 3 days to adapt the hindgut flora to this 
carbohydrate.  Laminitis was induced in all animals on the fourth day by administering 10 g/kg 
OF dissolved in 4 L of warm water via nasogastric tube as previously described.
165
  Whole blood 
was collected at 0, 8, 12, 16, 20, and 24 hours for evaluation of inflammatory cytokine gene 
expression.  Lameness evaluations were performed every 4 hours, and laminitis was graded 
accordingly to the Obel grading scale.
508
  Horses were euthanized at the onset of Obel grade 3 
                                                 
b




 P95, formerly marketed as Beneo
®
 95, BENEO-Orafti S.A., Pemuco, Chile 
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laminitis or at 48 hours if Obel grade 3 laminitis did not occur.  All other physical examination 
data were withheld from the investigators.  
 
Whole blood inflammatory cytokine gene expression – Blood samples for quantitation of 
Interleukin (IL)-1β, IL-6, IL-8, IL-10, TNF-α, and β-glucuronidase gene expression were 
collected into PAXgene
®
 blood RNA tubes
d
 and allowed to incubate at room temperature for 4 
hours.  Samples were then transferred to a –20ºC freezer for 24 hours, and were subsequently 
stored at – 80 °C until analysed.   
 Total RNA was extracted from thawed whole blood samples using the corresponding 
PAXgene
®
 blood RNA extraction kit
d
 accordingly to the manufacturer’s protocol.  Concentration 
and purity of RNA in each sample was measured via spectrophotometry.
e
  Reverse transcription 
was performed using 1 μg of RNA diluted in 41.5 μL nuclease-free water and added to 38.5 μL 
of master mix that contained 0.5 μL avian myeloblastosis virus reverse transcriptase
f
 (AMV RT; 
22 U/μL), 1 μL oligo dT primer
f
 (0.5 μg/μL), 1 μL RNAsin
f
 (40 U/μL), 4 μL dNTP mix
f
 (10 
mM), 16 μL magnesium chloride
f
 (25 mM), and 16 μL AMV RT 5X buffer
f
 per reaction.  
Reactions were incubated in a thermal cycler
g
 at 42ºC for 15 minutes followed by 95ºC for 5 
minutes.   
 Real-time polymerase chain reaction (PCR) was performed using validated equine 
specific intron-spanning primers and probes.
104,269
  Primers and probes were designed to be 
intron spanning based on comparisons of the equine mRNA sequences to homologous splice 
sites reported for other species.  Predicted junctional sequences were then blasted against the 
                                                 
d
 Qiagen/PreAnalytiX, Valencia, CA 
e
 NanoDrop ND-1000, Thermo Fisher Scientific, Wilmington, DE 
f
 Promega Corp., Madison, WI 
g
 TaKaRa PCR Thermal Cycler Dice,™ TaKaRa Bio Inc., Otsu, Shiga, Japan 
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equine genome to confirm target gene specificity.  Assays using known positive and negative 
control samples, genomic DNA, and non-reverse transcribed RNA were employed to ensure that 
each primer/probe combination performed appropriately and did not amplify genomic DNA. 
 For each PCR reaction, cDNA was diluted 1:1 with 80 μL of nuclease-free water.  The 
PCR reaction mixture contained 4.5 μL of diluted cDNA, 5 μL of master mix,
h
 and 0.5 μL of 
20X primer/probe assay mix.
i
   Samples were loaded onto plates
j
 using an automated system
k
 and 
analyzed in duplicate using a real-time PCR thermal cycler.
l
  Thermal cycling parameters were 
95ºC for 10 minutes followed by 40 cycles of 95ºC for 15 seconds and 60ºC for 60 seconds.  
Amplification efficiencies of individual PCR reactions were verified to be between 80 and 120% 
using computer software.
m
  The comparative CT (ΔΔCT) method was used to determine fold 
changes in inflammatory cytokine gene expression.
509
  For each sample, cytokine threshold cycle 
(Ct) values were first normalized to the housekeeping gene β-glucuronidase.  Baseline 
measurements were not available for 4 of 14 horses, therefore a pooled calibrator was generated 
for each cytokine by averaging all baseline ΔCt values for that gene.  The pooled calibrator was 
used to calculate fold changes in gene expression. 
 
Statistical Analysis – Mixed model analysis of variance (ANOVA) for repeated measures was 
performed using computer software
n
 to determine the effect of time on whole blood 
inflammatory cytokine gene expression.  Data were blocked on horse.  The autoregressive 
                                                 
h
 TaqMan® Gene Expression Master Mix, Applied Biosystems, Foster City, CA 
i
 TaqMan® Custom Gene Expression Assays, Applied Biosystems, Foster City, CA; primer sequences provided 
courtesy of Dr. David Horohov 
j
 MicroAmp® Optical 384-Well Reaction Plate with Barcode, Applied Biosystems, Foster City, CA 
k
 epMotion 5070, Eppendorf, Hamburg, Germany 
l
 7900HT Fast Real-Time PCR System, Applied Biosystems, Foster City, CA
 
m
 LinRegPCR, http:// LinRegPCR.HFRC.nl 
n
 PROC MIXED, SAS, version 9.2, SAS Institute, Inc., Cary, NC 
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correlation parameter was excluded from the model for analysis of IL-6, IL-10, and TNF-α gene 
expression.  Data for IL-1β, IL-6, IL-8, and IL-10 required logarithmic transformation to fit 
ANOVA normal distribution assumptions and are reported as geometric means with 95% CI.  
Data for TNF-α were normally distributed and are reported as least squares means ± SEM.  Mean 
separation was performed using Fisher’s protected least significant difference.  The trapezoidal 
method was employed to calculate AUC for inflammatory cytokine expression using computer 
software.
o
  Peak inflammatory cytokine expression and AUC were correlated with time to onset 
of Obel grade 1 and 3 laminitis and maximum recorded Obel score at the level of the individual 
animal using Pearson correlation coefficients.  
 
To eliminate any potential treatment effects, all 
data analyses were repeated using only the 4 control group horses and results were compared to 
the 10 treated animals.  Significance was set at P < 0.05 for all comparisons. 
 
2.3  Results 
 
Development of laminitis – All horses developed clinically detectable laminitis during the 24-
hour blood sampling period.  The onset of Obel grade 1 laminitis occurred between 12 and 24 
hours (Table 2.1).  Two horses progressed to Obel grade 3 laminitis at 20 hours and were 
euthanized before the final blood sample was collected.  Four animals were euthanized at 48  
hours without having reached Obel grade 3.  The 4 horses in the control group developed 
laminitis at 12 hours (1) and 16 hours (3).  Two control animals progressed to Obel grade 3 at 24 
hours (1) and 28 hours (1).  Other physical examination parameters were not made available for 
the purposes of this study.  
                                                 
o
 SAS, version 9.2, SAS Institute, Inc., Cary, NC 
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Table 2.1  Time to onset of Obel grade 1 and Obel grade 3 laminitis in horses following 
administration of a 10 g/kg dose of OF.  All 14 horses developed Obel grade 1 disease, and 10 
horses progressed to Obel grade 3.  Numbers indicate how many animals developed either Obel 
grade 1 or 3 laminitis at the specified time points.     
 
 
Time to onset of laminitis 
12h 16h 20h 24h 28h 32h 36h 40h 
Obel grade 1 
14 horses 
2 8 3 1 - - - - 
Obel grade 3 
10 horses 





Inflammatory cytokine gene expression – Interleukin-1β (P < 0.001; Figure 2.1A), IL-6 (P = 
0.005; Figure 2.1B), IL-8 (P < 0.001; Figure 2.1C), and IL-10 (P < 0.001; Figure 2.1D) 
expression increased following OF administration.  Interleukin-6 and IL-10 expression peaked at 
16 hours, followed by IL-1β and IL-8 at 20 hours.  A lower IL-8 peak was also detected at 8 
hours.  Tumor necrosis factor-α expression did not change over time (Figure 2.1E).  No 
significant correlations were identified between peak gene expression values or AUC and time to 
onset or severity of laminitis.  When only control group animals were considered, IL-1β (P = 
0.002), IL-8 (P = 0.017), and IL-10 (P = 0.013) expression increased significantly, and gene 
expression curves retained the same shapes as in the full analysis.  Interleukin-6 did not increase 
significantly over time in the control group, resulting in a significant treatment effect (P = 0.040) 
when control and treatment groups were compared.  Although time effects were not significant 
for TNF-α, a treatment × time effect was detected (P = 0.048) because expression differed 
between control (2.2 ± 0.5 fold increase relative to baseline) and treatment (1.2 ± 0.2 fold 
increase) groups at 24 hours.    
 
2.4  Discussion  
 
 Inflammatory responses were successfully quantified using the PAXgene
®
 whole blood 
RNA collection system and systemic inflammation was detected during the OF carbohydrate 
overload model, so our hypothesis was supported.  The magnitude of systemic inflammation was 
not associated with either time to onset or severity of laminitis.   
 The pro-inflammatory cytokines IL-1β, IL-6, IL-8 and TNF-α measured in this study are 
major regulators of the innate immune response,
18,19
 while IL-10 is an anti-inflammatory   
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Figure 2.1  Change in whole blood gene expression of IL-1β, IL-6, IL-8, IL-10, and TNF-α in 
horses following administration of a 10 g/kg dose of OF.  Geometric means and 95% CI for IL-
1β, IL-6, IL-8, and IL-10, and mean ± SEM for TNF-α are displayed on a logarithmic scale.  
Letters refer to significant time effects on all graphs.  *Treatment × time effects indicate 
significant differences between control and treatment groups.  For IL-6 and TNF-α, values for 
the treated groups, collectively, and the control group are displayed separately.  Pooled data from 
all 14 horses are presented for all other variables.  A) Time (P < 0.001) effects were detected for 
IL-1β.  B) Time (P = 0.005) and treatment (P = 0.040) effects were detected for IL-6.  C) Time 
(P < 0.001) effects were detected for IL-8.  D) Time (P < 0.001) effects were detected for IL-10.  
E) Time (P = 0.369) effects were not significant for TNF-α, however treatment × time (P = 


























Figure 2.1, continued.  
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mediator that plays an important role in sepsis.
32
  Changes in cytokine expression were 
consistent with the systemic inflammatory response reported in other studies using the OF 
model.
165,409
  Expression of IL-1β, IL-8, and IL-10 increased above baseline beginning at 8 
hours, and IL-6 began to increase at 16 hours.  Although endotoxin concentrations were not 
measured in our study, this time frame coincides with previously reported increases in plasma 
endotoxin concentrations between 8 and 12 hours following OF administration.
409
  In the same 
report, increased plasma TNF-α protein concentrations were detected between 12 and 24 
hours.
409
   
 Endotoxin and other bacterial products activate circulating leukocytes through pattern 
recognition receptors such as Toll-like receptor 4.
13
  Activated leukocytes then secrete 
inflammatory mediators that orchestrate the innate and adaptive immune responses.
7,11
  The time 
course of gene expression in sepsis is variable among studies,
510
 and species-specific data are 
scarce in the horse.  Tumor necrosis factor-α and IL-1β generally increase first and stimulate the 
release of more distal mediators such as IL-6, IL-8, and IL-10.
511
  Plasma cytokine levels are 
often detectable within minutes to hours and may persist for several days.
18,19
  Because gene 
expression was first analysed at 8 hours in our study, temporal relationships among cytokines 
should be interpreted with caution.  Overall, cytokine expression in our study coincided with 
previously reported increases in plasma endotoxin and TNF-α protein concentrations, as well as 
fever, tachycardia, and the onset of diarrhea.
165,409
  Unfortunately, physical examination data 
were withheld in this study, so further comparisons are not possible.  
 Increased peripheral leukocyte IL-1β, IL-6, and IL-8 expression is consistent with 
changes described in the laminitic hoof,
429-431,493
 and these cytokines predict organ failure and 
correlate negatively with outcome in septic humans.
28,512-514
  In the study reported here, IL-10 
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expression increased in the blood, which contrasts with previous reports of normal or decreased 
expression of this cytokine in laminar tissues.
429,493
  Interleukin-10 is an important negative 
regulator of inflammation that prevents excessive tissue damage while also contributing to the 
development of immunosuppression.
24,29,32
  In humans, high  IL-10 concentrations are  a 
negative prognostic indicator for sepsis,
30,515
 yet inadequate IL-10 responses can also  be 
detrimental.
516
  Compartmentalization of the inflammatory response often occurs during sepsis, 
and inflammatory responses can differ markedly between organs and blood.
517
   Peripheral 
leukocytes may therefore produce IL-10 while laminar tissues do not. 
 Higher plasma TNF-α concentrations have previously been detected following OF 
administration to horses,
409
 but gene expression did not change at comparable time points in our 
samples.  One explanation for this discrepancy is that peripheral leukocytes are not the primary 
source of TNF-α protein, and the liver and lungs produce the majority of circulating 
protein.
427,518,519
  Tumor necrosis factor-α also consistently fails to increase in the laminitic hoof, 
so it may not be important in the pathogenesis of this disease.
429,493
  It is also conceivable that 
compartmentalization of the inflammatory response occurs
517,520
 such that the liver and lungs 
produce TNF-α while hoof tissues do not.  Another explanation for our finding is that TNF-α 
peaked early and expression had decreased below detectable levels by the time that the blood 
sample was collected at 8 hours.  This inflammatory cytokine peaks early in the inflammatory 
cascade and has a half-life of approximately 20 minutes in humans.
18
   
 The commercially available PAXgene
®
 whole blood RNA extraction system was used in 
this study and inflammatory gene expression was successfully quantified. Use of whole blood 
provides an advantage when multiple samples are obtained because samples can be stored and 
processed later.  Leukocyte isolation was considered as an alternative because it eliminates 
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contaminating RNA derived from the erythrocyte and reticulocyte fraction
521-523
 and increases 
the sensitivity of certain gene expression assays.
522
  However loss of leukocyte subsets may 
occur during fractionation and sample handling associated with additional processing steps may 
induce alterations in the gene expression profile.
524,525
  Gene expression profiles change rapidly 
following blood collection,
526,527
 so fractionation procedures must be performed immediately.  
This approach would not have been feasible in the current study due to logistical considerations.     
 Laminitis was first detected between 12 and 24 hours, which is earlier than the 20 to 36 
hour range previously reported.
165,409,417
  The significance of this finding is unclear, but may 
reflect differences in the processing or purity of OF obtained from various commercial suppliers.  
Response of individual animals to carbohydrate overload is also variable, and laminitis has 
previously been reported to develop in approximately 80 to 100% of horses receiving 10 g/kg 
OF.
165,409,417
  All horses in the currently study developed laminitis and 10 animals were severely 
affected (Obel grade 3).   
 No association was found between peak cytokine expression or AUC and laminitis onset 
or severity.  This may be explained by the compartmentalization of inflammatory responses  
within different tissues,
517
 such that whole blood inflammatory cytokine expression fails to 
parallel expression within laminar tissues.  Alternatively, our results suggest that laminitis 
develops closer to the onset of systemic inflammation, before gene expression peaks.  This 
theory is supported by our finding that 10 horses developed laminitis before mean cytokine 
expression peaked at 16 to 20 hours.   
 Our results indicate that systemic inflammation accompanies the development of 
laminitis, but we do not provide evidence of a direct cause and effect relationship.  It remains 
conceivable that other factors trigger laminitis and systemic inflammation is just a co-morbid 
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condition. The equine gastrointestinal tract contains a diverse population of Gram-negative and 
Gram-positive bacteria,
528
 as well as vasoactive protein metabolites,
375
 that gain access to 
systemic circulation following carbohydrate overload.
295,421
  Vasoactive amines directly affect 
the vasculature of the equine digit due to their structural similarities with the endogenous 
vasoconstrictors, serotonin and norepinephrine.
375
   These vasoactive amines, or other gut-
derived factors, may be the trigger for laminitis, with systemic inflammation contributing to the 
process or merely occurring concurrently.   
 The main weakness of our study was that samples were obtained from a study examining 
the efficacy of three different drugs and these products were not described.  Treatment groups 
cannot be accounted for in our statistical analyses and it is conceivable that one or more of these 
drugs impacted results.  However, with the exception of IL-6 and TNF-α, horses receiving drugs 
did not differ significantly from the control group.  Shortcomings of this study are balanced by 
the advantages of testing hypotheses without duplicating laminitis studies.  This is particularly 
important when the animal welfare concerns of laminitis research are considered.    
 We conclude that systemic inflammation can be detected during the experimental 
induction of laminitis by measuring whole blood inflammatory gene expression and the 





Effects of continuous or intermittent lipopolysaccharide administration for 48 hours on the 
systemic inflammatory response in horses 
 
 
This chapter is a revised version of an article by the same name that has been accepted for 
publication in the American Journal of Veterinary Research by Elizabeth M. Tadros and 
Nicholas Frank. 
 
Reference:  Tadros EM, Frank N.  Effects of continuous or intermittent lipopolysaccharide 
administration for 48 hours on the systemic inflammatory response in horses.  Am J Vet Res.  In 
press. 
 
3.1  Introduction 
 
 Systemic inflammation increases the risk of laminitis in horses.
529
  Endotoxin has been 
detected in the blood of horses with gastrointestinal disease,
530
 and exposure to 
lipopolysaccharide (LPS) likely contributes to the development of inflammation in these cases.  
Although LPS elicits a marked inflammatory response,
13
 the true role of LPS in the 
pathophysiology of laminitis remains unclear.  Recent focus has shifted towards understanding 
laminitis as an inflammatory process with similarities to sepsis-associated organ failure.
373,424
  
Increased laminar expression of pro-inflammatory genes has been demonstrated
400,430,493,494,531
 
and laminar inflammation coincides with systemic inflammatory events.
425,428,532
  Intravenous 
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LPS administration increases gene expression of interleukin (IL)-1α, IL-1β, IL-6, IL-8, and 
tumor necrosis factor-α (TNF-α) in equine peripheral blood leukocytes
533
 and also raises 
circulating IL-6 and TNF-α protein concentrations in treated horses.
410,534
  Endotoxemia is 
therefore expected to contribute to the development of laminitis in horses.  It must be recognized 
however, that endotoxin is just one component of a complex syndrome of sepsis, so it may be 
necessary for several factors to converge before laminitis develops in the horse with systemic 
illness.   
 Despite the theoretical basis for endotoxemia inducing laminitis, this condition has not 
been induced by intravenous infusion of LPS in experimental models.
410,414,415,460,534 
One group 
reported hoof discomfort following a 24-hour LPS infusion, yet gross pathological lesions were 
not identified at necropsy.
460
  This discrepancy may be explained by differences between 
experimental models and clinical endotoxemia.
416
  Lipopolysaccharide has usually been 





  and higher dosing regimens
414,460
 have 
been used.  Lipopolysaccharide infusions have not extended beyond 24 hours in previous studies.  
In contrast, clinical endotoxemia is often present for several days before laminitis develops.  
Anecdotal experience also suggests that horses with gastrointestinal diseases such as bacterial 
colitis can experience intermittent worsening of vital parameters and clinical condition.  These 
episodes may correspond to fluctuating amounts of LPS or other trigger factors translocating 
from the gastrointestinal tract.  Repeated exposure to inflammatory stimuli has been implicated 
in the pathogenesis of organ failure during sepsis,
442,444
 so intermittent exposure to LPS could 
increase the magnitude of systemic inflammation and prove more detrimental to laminar tissue.   
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 Inflammation increases secretion of inflammatory cytokines and hormones that inhibit 
insulin signaling and induce insulin resistance.
91
  Altered glucose and insulin homeostasis 
therefore serves as a marker of systemic inflammation.  A single dose of endotoxin perturbs 
insulin sensitivity and glucose homeostasis in horses for 24 hours,
327
 and decreased insulin 
sensitivity persists for 48 hours following an 8-hour LPS infusion.
164
  Measures of glucose and 
insulin dynamics may therefore reflect the magnitude and persistence of systemic inflammation.  
 This study was undertaken to evaluate two experimental models for endotoxemia in 
horses and determine whether laminitis results from LPS administration over 48 hours. We 
hypothesized that the method of LPS administration (intermittent versus continuous) affects the 
magnitude and duration of the systemic inflammatory response, and that prolonged (48 hours) 
endotoxemia induces laminitis.  
 
3.2  Materials and methods 
 
Animals - Twelve healthy adult mares (10) and geldings (2) from the University of Tennessee 
teaching and research herd were included in the study.  Animals ranged in age from 4 to 17 years 
old and body weight ranged from 364 to 559 kg (mean, 502 kg; median, 513 kg).  Breeds of 
horse included Thoroughbred (5), Quarter horse (4), Paint horse (1), Appaloosa (1), and Arabian 
(1).  Horses with a known history of laminitis or evidence of laminitis on physical examination 
were excluded.  Horses were housed in stalls within the University of Tennessee Veterinary 
Medical Center throughout the testing period.  Grass hay and water were provided ad libitum.  
The study protocol was approved by the University of Tennessee Institutional Animal Care and 
Use Committee.   
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Study design – Horses were evaluated in groups of 3 and each animal was evaluated once.  
Animals were transported to the Veterinary Medical Center and allowed to acclimate to their 
environment for 24 hours before procedures were initiated.  Physical examinations were 
performed and body weight measurements obtained at the time of admission.  A 14-gauge 
intravenous (IV) catheter
a
 was placed in each jugular vein and baseline (–24 hour) intravenous 
glucose tolerance tests (IVGTTs) were performed between 0930 and 1100 the morning after 
arrival.  One IV catheter was used for infusions and the other for blood collection.  
Administration of LPS or saline was initiated the following day between 0900 and 0930 (time = 
0 hours).  Horses were randomly assigned to receive a constant rate infusion (CRI) of LPS 
(LPS-CRI; n = 4) or saline (SAL; n = 4), or 8 bolus infusions of LPS over 48 hours (LPS-BOL; 
n = 4).  A crossover study design could not be employed because horses have been shown to 
develop antibodies to core LPS.
535
  Blood samples were collected immediately prior to LPS or 
saline administration for complete blood count (CBC) analysis, biochemical profile, and 
assessment of whole blood inflammatory cytokine gene expression.  Additional CBCs were 
performed at 3 and 24 hours. Physical examinations were performed every 4 hours, at which 
time horses were also assessed for the development of laminitis using the Obel scoring 
method.
536
  Blood samples were collected every 8 hours, and IVGTTs were performed at 8, 24, 
32, and 48 hours. Intravenous catheters were removed at the end of the study period. 
 
Lipopolysaccharide and saline administration – The LPS-CRI group received commercially 
available Escherichia coli O55:B5 LPS solution.
b
  Lipopolysaccharide used to prepare the 
solution was phenol-extracted, then purified using gel filtration and ion exchange 
                                                 
a
 Abbocath-T 14 G X 140 mm, Abbott Laboratories, North Chicago, IL 
b
 Sigma Aldrich, Inc., St Louis, MO 
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chromatography to yield a product containing < 1% protein and < 1% RNA.  The LPS solution 
was diluted to a final concentration of 0.021 μg/mL infused via the IV catheter at a rate of 80 
mL/hr for 48 hours.  Each LPS bolus contained 10 μg LPS diluted in 60 mL sterile saline and 
was administered IV every 6 hours as a slow bolus over 30 minutes.  Horses in the control group 
received a CRI of sterile saline at a rate of 80 mL/hr for 48 hours.   
 
IVGTT procedure – Baseline plasma and serum samples were collected via the IV catheter into 
sodium fluoride / potassium oxalate and serum tubes.  An IV bolus of 50% dextrose solution
c
 
was then administered at a dosage of 100 mg/kg bwt.  Serum and plasma samples were collected 
at 15, 30, 45, 60, 75, 90, 105, 120, and 150 minutes for measurement of blood glucose and 
insulin concentrations.  Sodium fluoride / potassium oxalate tubes were immediately cooled on 
ice and serum tubes were allowed to clot at room temperature for 1 hour.  Tubes were 
centrifuged at 1,000 × g for 10 minutes and plasma or serum was harvested and stored at –20 ºC 
until analyzed.  
 
Measurement of blood variables – Blood samples for CBC, fibrinogen, and biochemical profile 
analysis were collected into appropriate anticoagulant or serum tubes and analyzed by the 
University of Tennessee Clinical Pathology laboratory.   
 
Whole blood inflammatory cytokine gene expression – Blood samples for quantitation of IL-1β, 
IL-6, IL-8, IL-10, TNF-α, and β-glucuronidase (B-Gus) gene expression were collected into 
whole blood RNA collection tubes
d 
and allowed to incubate at room temperature for 8 hours, 
                                                 
c
 Vedco, Inc., St. Joseph, MO 
d
 PAXgene® blood RNA tubes, Qiagen/PreAnalytiX, Valencia, CA 
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then stored at – 20 °C until analyzed.  Total RNA extraction and real-time polymerase chain 
reaction were performed as previously described (refer to chapter 2).  The comparative CT 
(ΔΔCT) method was used to determine fold changes in inflammatory cytokine gene 
expression.
509
  Cytokine expression was normalized to the housekeeping gene B-Gus and each 
horse’s baseline value was used as the calibrator.  Baseline gene expression was therefore equal 
to a 1-fold change for all cytokines.  
 
Plasma glucose and serum insulin concentrations – Plasma glucose concentrations were 
measured in duplicate using a colorimetric assay
e
 on an automated discrete analyzer.
f
  Serum 
insulin concentrations were measured in duplicate using a radioimmunoassay
g
 that has been 
validated for use with equine plasma in our laboratory and by others.
537
  Intra-assay coefficient 
of variation < 5% was required for acceptance of glucose assay results and <10% was required 
for acceptance of insulin assay results.  Area under the curve for glucose (AUCg) and area under 





Statistical Analysis – Mixed model analysis of variance (ANOVA) for repeated measures was 
performed using computer software
i
 to determine effects of treatment and time on rectal 
temperature, heart rate, and respiratory rate.  The autoregressive correlation parameter was 
excluded from the model for analysis of AUCg, AUCi, total white blood cell count, neutrophil 
count, lymphocyte count, and fold changes in whole blood inflammatory cytokine gene 
                                                 
e
 Glucose, Roche Diagnostic Systems, Inc., Somerville, NJ 
f
 Cobas Mira, Roche Diagnostic Systems, Inc., Somerville, NJ 
g
 Coat-A-Count Insulin, Diagnostic Products Corp., Los Angeles, CA
 
h
 SAS, version 9.2, SAS Institute, Inc., Cary, NC 
i
 PROC MIXED, SAS, version 9.2, SAS Institute, Inc., Cary, NC 
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expression.  Mean separation was performed using Fisher’s protected least significant difference 
and significance was set at P < 0.05.  Gene expression data required logarithmic transformation 
to fit ANOVA normal distribution assumptions and data are reported as geometric means with 
95% CI.  One-sample t-tests with Bonferroni correction for multiple comparisons were used to 
compare mean cytokine expression at each time point to the pre-infusion baseline.  Significance 
was set at P<0.0028 when the Bonferroni correction was applied.  Single degree of freedom 
contrasts were employed to compare mean cytokine expression averaged over all time points on 
the first day of sampling to the second day within each treatment group.  Contrasts were also 
used to compare gene expression at corresponding time points on the first and second day (e.g. 8 
hours to 32 hours) within each treatment group.  Body weight was initially included in the model 
as a covariate term, but was excluded from the statistical model due to lack of significance.  
Exclusion of body weight was further supported by Spearman’s rank correlation coefficients and 
Pearson correlation coefficients, which revealed only weak associations between weight and 
other dependent variables.  Associations between cytokine expression, rectal temperature, heart 
rate, and respiratory rate were assessed using Spearman’s rank correlation coefficients.  
Correlation analysis was performed at the level of the individual animal.  Significance was set at 
P<0.05 for all correlations.  Data from both LPS groups were pooled and compared to the SAL 
group for analysis of AUCg and AUCi.  Values for AUCg and AUCi also required logarithmic 
transformation and are reported as geometric means with 95% CI.  All other data are reported as 






3.3  Results 
 
Clinical signs – Treatment groups did not differ significantly with respect to body weight or age.  
All LPS-treated horses exhibited depression, anorexia, and mild colic signs including pawing, 
yawning, stretching, muscle fasciculations, and lateral recumbency in response to LPS.  Three of 
4 horses in the LPS-BOL group exhibited little or no clinical response to LPS after 24 hours, 
although the attitude of one animal remained depressed until 32 hours.  The fourth horse showed 
mild colic signs after LPS administration for 7 of 8 infusions, but did not respond to the final 
infusion.  Depression, anorexia, and signs of colic abated in all horses in the LPS-CRI group by 
12 hours, with the exception of one horse that had a dull attitude until 32 hours.  Laminitis was 
not detected in any of the horses.   
 All LPS-treated horses developed fever (rectal temperature > 38.5 ºC) and transient fever 
was detected at 40 hours in one SAL group horse that developed cellulitis at the IV catheter site.  
Time (P < 0.001) and treatment × time (P < 0.001) effects were significant (Figure 3.1).  Mean 
rectal temperature was significantly above baseline from 4 to 16 hours in the LPS-CRI group and 
peaked at 8 hours (38.9 ± 0.2 ºC).  In the LPS-BOL group, mean rectal temperature was above 
baseline at 4, 8, and 20 hours, and also peaked at 8 hours (39.0 ± 0.1 ºC).  No increase in rectal 
temperature was observed in the LPS-CRI group after 16 hours or in the LPS-BOL group after 
20 hours. Peak rectal temperature did not differ significantly in magnitude between the two LPS 
treatment groups.  Six of 8 horses that received LPS developed tachycardia (heart rate ≥ 48 
bpm), however neither treatment nor time effects were significant.  No significant differences 





Figure 3.1  Change in mean ± SEM rectal temperature of horses receiving an LPS CRI of 80μg 
total over 48 hours, 8 boluses of 10μg LPS q6h for 48 hours, or a saline CRI at 80 mL/h for 48 
hours.  *LPS-BOL: Significant difference from baseline.  
†
LPS-CRI: Significant difference from 
baseline.  
‡
SAL: Significant difference from baseline.  Significant time (P < 0.001) and treatment 




Hematology – Leukocyte counts were not affected by the method of LPS administration (data not 




 was detected in 1 of 4 horses 
from the LPS-CRI group and 2 of 4 horses in the LPS-BOL group. 
 
Inflammatory cytokine gene expression – Significant time effects were detected for the 
expression of IL-1β (P < 0.001; Figure 3.2A), IL-6 (P < 0.006; Figure 3.2B), IL-8 (P < 0.005; 
Figure 3.2C), and IL-10 (P < 0.009; Figure 3.2D).  Treatment × time effects were detected for 
IL-1β (P < 0.001), IL-8 (P < 0.047), and TNF-α (P < 0.044; Figure 3.2E) expression.  A 
significant treatment effect was also detected for IL-8 (P < 0.029), but no differences were 
detected between LPS groups.  Expression of IL-1β, IL-6, and IL-8 significantly increased in 
both LPS groups at one or more time points relative to pre-infusion baseline when one-sample t-
tests were performed, whereas IL-10 and TNF-α expression did not increase over time in either 
group.  Except for TNF-α in the LPS-CRI group, peak expression of cytokines was detected at 8 
hours in the LPS groups.   
 Comparison of corresponding time points on the first and second days of sampling 
revealed significant differences for IL-1β and IL-10 in both LPS groups and IL-6, IL-8, and 
TNF-α in the LPS-BOL group (Table 3.1).  Differences in IL-10 and TNF-α expression were 
detected between days 1 and 2, although there were no differences from baseline.  When gene 
expression was averaged across all time points for each day, expression of IL-1β in both LPS 
groups, and IL-8 and IL-10 in the LPS-BOL group was significantly higher on day 1 than day 2.  
Expression of IL-1β and TNF-α expression varied significantly in the SAL group, but did not 
increase significantly relative to baseline.      
                                                 
j
 Reference ranges used by the University of Tennessee Clinical Pathology laboratory 
89 
 
Figure 3.2  Change in whole blood gene expression of IL-1β, IL-6, IL-8, IL-10, and TNF-α in 
horses receiving an LPS CRI of 80μg total over 48 hours, 8 boluses of 10μg LPS q6h for 48 
hours, or a saline CRI at 80 mL/h for 48 hours.  Data are expressed as geometric means and 95% 
CI, and are displayed on a logarithmic scale.  Significance was set at P < 0.0028 for one-sample 
t-test comparisons between cytokine expression at each time point, compared to baseline.  
Significance for ANOVA main effects and interactions was defined by P < 0.05.  *LPS-BOL: 
Significant difference from baseline.  
†
LPS-CRI: Significant difference from baseline.  A) Time 
(P < 0.001) and treatment × time (P < 0.001) effects were detected for IL-1β.  B) Time (P = 
0.006) effects were detected for IL-6.  C) Treatment (P = 0.029), time (P = 0.005), and treatment 
× time (P = 0.047) effects were detected for IL-8.  D) Time (P = 0.009) effects were detected for 
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Table 3.1.  Geometric means and 95% CI expression of inflammatory cytokines in horses 
receiving an LPS CRI of 80μg total over 48 hours, 8 boluses of 10μg LPS q6h for 48 hours, or a 
saline CRI at 80 mL/h for 48 hours.  Corresponding time points on days 1 and 2 are compared, as 
well as overall mean values across the two 24-h periods, and P values for treatment × time 
effects obtained by analyzing all data using ANOVA are also displayed.  Significance is defined 
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26 (13 to 50)
a 
18 (5.5 to 62)
a 
1.1 (0.62 to 2.0)
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1.9 (1.3 to 2.7)
b 
2.9 (2.0 to 4.3)
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5.3 (2.8 to 10)
a 
4.2 (1.2 to 15)
a 
1.8 (1.1 to 2.9)
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0.83 (0.34 to 2.0)
b 
1.6 (1.1 to 2.3)
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69 (21 to 232)
a 
14 (7.0 to 30)
a 
1.1 (0.28 to 4.7)
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10 (1.9 to 56)
b 
6.6 (3.2 to 14)
a 















6.3 (0.95 to 42)
a 
4.9 (1.1 to 21)
a 
1.1 (0.61 to 2.1)
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0.37 (0.10 to 1.3)
b 
1.2 (0.43 to 3.1)
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2.5 (0.83 to 7.5)
a 
0.67 (0.34 to 1.3)
a 
2.1 (1.2 to 3.6)
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0.78 (0.50 to 1.2)
b 
1.0 (0.30 to 3.6)
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For each variable, different letters indicate significant (P < 0.05) differences between day 1 




Correlations among gene expression and vital parameters – Interleukin-1β expression was 
positively correlated with rectal temperature (Spearman’s rho = 0.49; P < 0.001), IL-8 
expression (Spearman’s rho = 0.57; P < 0.001), and IL-10 expression (Spearman’s rho = 0.53; P 
< 0.001).  Other correlations with Spearman’s rho coefficients less than ± 0.37 were identified, 
but are not reported.  When only peak cytokine expression values and maximum rectal 
temperature, heart rate, and respiratory rate were included in analyses, peak IL-1β expression 
was positively correlated with peak rectal temperature (Spearman’s rho = 0.69; P < 0.013).   
 
Glucose and insulin dynamics – A significant time effect (P = 0.028) was detected for AUCg 
(Figure 3.3A).  Horses that received LPS did not differ from those that received saline.  Neither 
treatment nor time effects were significant for AUCi (Figure 3.3B).  
 
3.4  Discussion 
 Exposure to LPS induced systemic inflammation, but our hypothesis was not supported 
because the method of LPS administration did not affect the magnitude or duration of the 
inflammatory response or induce laminitis. Clinical responses to LPS abated over time in all 
animals indicating the development of endotoxin tolerance.  Inflammatory cytokine expression 
profiles were comparable between groups, with positive correlations detected between IL-1β 
gene expression and rectal temperature, as well as among IL-1β, IL-8, and IL-10 values.   
 Rectal temperature significantly increased following LPS infusion, which is consistent 
with previous reports.
164,327
  Temperature only increased in response to LPS on the first day, 
indicating that animals became refractory to the effects of LPS over time.  No increase in rectal 
temperature was observed in the LPS-CRI and LPS-BOL groups after 16 hours or 20 hours,   
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Figure 3.3  Area under the glucose and insulin concentration curves in horses receiving an LPS 
CRI of 80μg total over 48 hours, 8 boluses of 10μg LPS q6h for 48 hours, or a saline CRI at 80 
mL/h for 48 hours.  A)  Area under the glucose concentration curve values for horses receiving 
LPS or saline. Data were pooled for horses receiving LPS as a continuous rate infusion to deliver 
80μg total over 48 hours and 8 boluses of 10μg LPS q6h for 48 hours.  The control group 
received saline as a CRI at 80 mL/h for 48 hours.  Data are expressed as geometric means and 
95% CI on a linear scale.  Letters denote significant changes in AUCg over time (P = 0.028), 
although the treatment × time effect was not significant.  B)  Area under the insulin 
concentration curve values for the same horses expressed as geometric means and 95% CI.  Time 
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respectively.  When a cut-off value of 38.5°C was used to define a clinically significant fever, 
this response was only detected in the LPS-BOL group at 4 and 8 hours, and in the LPS-CRI 
group from 4 to 12 hours.  Fever was not detected in the SAL group, and the increases in rectal 
temperature observed at 16 and 40 hours likely represent diurnal variation.
538
  A transient fever 
was detected at 40 hours in one SAL group horse and this affected mean temperature for this 
group.   
 Subjective observations also supported the development of endotoxin tolerance in horses 
of both LPS groups.  Attitudes of most animals returned to normal by 12 and 24 hours in the 
LPS-CRI and LPS-BOL groups, respectively.  One horse in the LPS-BOL group continued to 
exhibit mild colic signs and depression following LPS administration for 7 of 8 infusions, but 
reactions became milder over time and eventually ceased in this animal.  Endotoxin tolerance has 
been observed in horses,
460,461
 and refers to a decrease in the ability of LPS to elicit certain 
clinical and biochemical responses following repeated exposures.   
 Inflammatory mediators examined in this study included the pro-inflammatory cytokines 
IL-1β, IL-6, IL-8, and TNF-α, as well as the anti-inflammatory cytokine IL-10, which has 
received much attention for its role in sepsis.
32
  Interleukin-1β, IL-6, IL-8, and TNF-α are major 
regulators of innate immunity,
18,19
 and altered expression of these cytokines as well as cytokines 
of the adaptive immune response occurs in the lamina, lungs, and livers of laminitic horses.
531,532
  
In the current study, peripheral leukocyte responses to LPS infusion were assessed by extracting 
RNA from whole blood samples.  This method was chosen because whole blood RNA collection 
systems have been shown to minimize RNA degradation and alterations in the gene expression 
profile during sample collection and storage.
507
  One finding of this study is that LPS increased 
IL-1β, IL-6, and IL-8 expression.  Surprisingly, IL-10 and TNF-α expression did not increase 
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significantly compared to pre-infusion baseline values in either LPS group.  This may reflect, in 
part, the conservative nature of the Bonferroni correction used in the statistical analysis.
539
  
Alternatively, TNF-α expression may have peaked and declined prior to collection of the first 
blood sample.  This cytokine can peak early in the inflammatory response and decline rapidly 
after 1 to 2 hours, even with continuous infusion of LPS and persistent fever.
410
   
 Two potential weaknesses of our study design were identified.  First, all horses received 
the same total dose of LPS instead of doses calculated by body weight.  This approach was 
deliberately selected to expose all horses to the same challenge because endotoxin load 
associated with clinical disease does not vary according to body weight.  A dose of 10μg per 
bolus infusion was chosen because it approximates a commonly used LPS dose of 20 ng/kg bwt 
for an average 500 kg horse.
327
  The total dose received by each horse in the LPS-BOL group 
was therefore 80 µg, and the same total dose was administered to horses in the LPS-CRI group.  
The impact of this selecting this approach was determined by including body weight as a 
covariate in all analyses. No significant effects were detected.  Second, blood samples were 
collected 2, 4, or 6 hours following LPS administration in the LPS-BOL group.  Decreasing 
cytokine expression across each day might therefore reflect widening intervals between LPS 
administration and blood sample collection.   However, comparisons between the first and 
second day remain meaningful because collection schedules were the same for both days.  For 
example, expression was significantly higher for all cytokines at 8 hours on day 1 in the LPS-
BOL group compared to the corresponding time point relative to LPS administration on day 2 
(time = 32 hours).  Direct comparisons between the two LPS groups were also made at 24 and 48 
hours when horses had received the same cumulative dose of endotoxin.  Cytokine expression 
was also averaged across all time points for each day and compared within groups.  Markedly 
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decreased or absent inflammatory cytokine responses on day 2 compared to day 1 in both LPS 
groups support the conclusion that horses developed endotoxin tolerance. 
 Early-phase endotoxin tolerance occurs within hours to days and results, in part, from 
down-regulation of Toll-like receptor 4 signaling cascades.
76,448
  Tolerance reprograms the cell 
so that secretion of pro-inflammatory cytokines decreases while anti-inflammatory mediator 
secretion and certain antimicrobial functions remain largely unchanged.  This is a protective 
mechanism by which cells minimize damage from rampant inflammation.  It should be 
recognized that this study focused on blood inflammatory cytokine expression, so tissues were 
not evaluated.  Systemic inflammation could still contribute to the development of laminitis, if 
tissues fail to develop tolerance.  Fulminant inflammation can persist in organs even as tolerance 
develops in circulating leukocytes,
469,517
 and sequential exposure of leukocytes to inflammatory 
stimuli aggravates inflammation and worsens organ damage.
440
  Macrophage exposure to 




 during the initial inflammatory event may 
enhance the strength of signaling through Toll-like receptor 4 upon subsequent stimulation.
442
  
Additionally, some tolerized cells may retain the ability to produce pro-inflammatory mediators.  
For example, tolerized neutrophils can continue to produce IL-8 in response to LPS 
stimulation.
477
  Interleukin-8 is a potent neutrophil chemoattractant, so this finding has relevance 
to neutrophil emigration during laminitis.
428
  Further studies are needed to determine whether 
laminar tissues respond to multiple inflammatory events by entering a refractory state, or if 
multiple insults enhance inflammation and increase tissue damage.    
 Laminitis did not develop in any of the horses that received LPS and this finding is 
consistent with results of previous studies.
327,411-413
  Direct evidence linking endotoxemia with 
laminitis remains elusive.  Differences between experimental models and clinical disease include 
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the greater magnitude and duration of clinical endotoxemia and presence of other toxins 
originating from the gastrointestinal tract.  The equine gastrointestinal tract contains a diverse 
population of Gram-negative bacteria, as well as multiple Gram-positive species,
528
 so the LPS 
derived from a single bacterial strain used in most experimental studies is only one component of 
this complex mixture.   Factors other than endotoxins and exotoxins might also play a role.  
Vasoactive protein metabolites are present in the equine hindgut,
375
 and increase in response to 
excess dietary carbohydrate intake.
295
  It is therefore likely that combinations of toxins are 
responsible for triggering laminitis, and LPS is only one contributing factor.  
Lipopolysaccharide-induced platelet activation
409
 and altered vascular reactivity
403,406
 might 
increase the susceptibility of laminar tissue to damage from other factors.  Tissue samples were 
not assessed in this study, so it remains conceivable that LPS induces mild inflammatory changes 
within the hoof that increase susceptibility to damage from other factors if true clinical sepsis 
were to develop.  Lipopolysaccharide did not induce leukocyte emigration or activate matrix 
metalloproteases in laminar tissue collected 12 hours after infusion in a recent study, but vascular 
function and endothelial activation were not assessed directly.
426  
Laminar biopsies should be 
collected in future studies to examine markers of endothelial cell dysfunction in hoof tissues 
following LPS infusion.
542
   
 Lipopolysaccharide administration did not induce significant alterations in glucose and 
insulin dynamics, and this differs from results of our previous studies
164,327
  This discrepancy 
may be explained by the repeated administration of LPS over 48 hours instead of a single bolus 
infusion
327
 or the small group sizes.  Although not significantly lower than baseline, AUCg was 
lowest at 8 hours compared with subsequent time points in all treatment groups, indicating that 
glycemic control decreased over time.  Lower insulin sensitivity has been detected in healthy 
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horses after prolonged stall confinement and this finding is attributed to stress.
354
  Horses in the 
current study were confined to stalls and subjected to testing procedures that could have induced 
stress and affected glucose homeostasis. 
 We conclude that endotoxin tolerance develops in horses continuously or intermittently 
exposed to LPS via intravenous administration.  Inflammatory cytokine expression was only 
examined in peripheral leukocytes, so further studies are required to determine whether the same 
process occurs in tissues.  Results do not support a direct causal role for endotoxin in the 
pathogenesis of laminitis, but LPS induces systemic inflammation and may therefore act in 
synergy with other factors to cause disease.  Future studies should therefore focus on whether 
endotoxemia predisposes laminar tissue to damage from other triggering factors, potentially 








4.1  Introduction 
 
 Equine metabolic syndrome (EMS) is characterized by 3 key abnormalities: generalized 
or regional adiposity, insulin resistance (IR), and laminitis.
4
  While most affected animals exhibit 
all three problems, a lean phenotype also exists.  Although EMS shares some characteristics with 
the metabolic syndrome in humans,
248
 laminitis rather than cardiovascular disease is of primary 
importance in the horse.  It has been established in humans that obesity causes increased 
secretion of inflammatory cytokines and adipokines from adipose tissue and this leads to 
IR
105,106,543
 and vascular endothelial dysfunction.
199,305,307
  Obese horses, like obese humans, 
appear to be in a low-grade systemic inflammatory state.
544
  Increased interleukin (IL)-1 and 
tumor necrosis factor-α (TNF-α) expression has been detected in the blood of obese horses,
104
 
and serum TNF-α protein concentrations are higher obese, laminitis-prone ponies.
255
  The extent 
to which equine adipose tissue contributes to systemic inflammation during obesity has only 
recently been examined.  Studies to date have demonstrated that cytokine expression is highest in 
nuchal fat,
253
 but omental fat is also a site of inflammatory mediator production in horses.
545
   
 Anecdotal reports suggest that horses with EMS are more prone to developing laminitis 
when affected by systemic illness such as bacterial enterocolitis.  In human medicine, obesity is 
associated with a poorer outcome in septic patients.
325,326
  Because endothelial cells are already 
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compromised in obese individuals, they appear to be less capable of withstanding damage 
associated with pathological conditions such as sepsis or ischemia-reperfusion injury.
307
  Obesity 
may render certain vascular beds more vulnerable than others to damage, exacerbating 
microvascular dysfunction and increased susceptibility to organ damage at these sites.
307,546,547
  
The inflammatory and vascular events that occur during laminitis bear many similarities to 
sepsis-associated organ failure.
303,373
  It is therefore conceivable that the laminar vasculature may 
be particularly sensitive to damage from inflammation in obese horses.
298
  Evidence also 
suggests that inflammatory responses may be exaggerated in obese individuals, further 
increasing their risk of organ failure.
325,548
   
 Hepatic lipidosis is manifestation of the metabolic syndrome in humans,
273,274
 and the 
steatotic liver contributes to systemic inflammation and IR.
107,109,114
  Hepatic involvement may 
also occur in EMS because postmortem hepatic lipid accumulation and increased plasma γ-
glutamyl transferase and aspartate aminotransferase activities have been detected in some 
affected horses.
4,549
  The liver is a major site of toxin clearance from the body, so compromised 
liver function might contribute to increased inflammation in obese animals.
279
  A recent study 
showed that hepatic toll-like receptor (TLR) signaling is upregulated in horses with 
endocrinopathic laminitis and this further supports a role for hepatic dysfunction in the 
pathogenesis of this disease.
550
 
 The current study was performed to determine whether horses with EMS respond 
differently than normal animals to systemic inflammation.  We hypothesized that EMS would 
affect the systemic inflammatory response and expression of inflammatory cytokines in 




4.2  Materials and methods 
 
Animals – Six healthy adult mares and 6 horses previously diagnosed with EMS (3 mares and 3 
geldings) from the University of Tennessee teaching and research herd were included in the 
study.  Control animals had no history of laminitis and fasting serum insulin concentrations 
below 20 µU/mL.  Horses with EMS had a history of chronic obesity or abnormal regional 
adiposity, and previously documented resting hyperinsulinemia or IR confirmed by combined 
glucose-insulin or insulin-modified frequently-sampled intravenous glucose tolerance testing.  
Abnormal hoof morphology and radiographic evidence of chronic laminitis were present in 5 of 
6 animals, and divergent hoof growth rings were noted upon physical examination in 1 horse.  
Normal horses ranged in age from 10 to 18 years (mean 12.8 years; median 12 years) and 
weighed 427 to509 kg (mean 473.5 kg; median 480.5 kg).  Breeds included Quarter horse (3), 
Quarter horse cross (1), Appaloosa (1), and Standardbred cross (1).  Horses with EMS were 8 to 
22 years old (mean 15.7 years; median 16 years) and weighed 394 to 525 kg (mean 441.8 kg; 
median 425 kg).  Breeds included Paso Fino (2), Morgan (1), Arabian (1), Tennessee Walking 
Horse (1), and Azteca (1).  Body condition score was assessed by two observes on a scale of 1 to 
9 as described by Henneke, et al.
249
 and mean scores were calculated.  Mean body condition 
scores ranged from 5 to 7.25 (mean 6; median 5.9) for normal horses and from 4 to 9 (mean 6.3; 
median 6.4) for horses with EMS.   
 Animals were paired (1 normal and 1 EMS) and housed together in 15 m × 55 m dirt 
paddocks with run-in sheds at the University of Tennessee Cherokee Farm research facility for a 
minimum of 2 weeks prior to the start of the study.  Grass hay and water were provided ad 
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libitum.  The study protocol was approved by the University of Tennessee Institutional Animal 
Care and Use Committee. 
 
Study Design – Testing was performed between February and April 2010.  A completely 
randomized design with split plot and crossover in the sub plot was employed and horses were 
evaluated in pairs over 2 consecutive weeks.  Three pairs were randomly assigned to receive an 
intravenous (IV) infusion of lipopolysaccharide (LPS) the first week and an IV infusion of 
sterile saline the second week.  Treatment order was reversed for the remaining 3 pairs of horses.  
Animals were transported to the Veterinary Teaching Hospital and housed in 3.7 m × 3.7 m box 
stalls at the start of each testing week.  Body weight measurements and physical examinations 
were performed at the time of arrival.  Horses were allowed to acclimate to the hospital 
environment for a minimum of 24 hours prior to testing.   
 A 14-g polypropylene IV catheter
a
 was aseptically placed in one jugular vein and blood 
was submitted for complete blood count (CBC) analysis and biochemical profile at 0830 on day 
1 (time = -27 hours).  Baseline physical examination parameters and blood samples were 
obtained at 1100 on day 2 (time = -30 minutes), followed immediately by IV infusion of LPS or 
saline as a slow bolus over 30 minutes.  Conclusion of the IV infusion was designated as time = 
0 minutes.  Whole blood was collected for inflammatory cytokine gene expression analysis at 30, 
60, 90, 120, 180, and 240 minutes.  An additional CBC was submitted at 180 minutes.   
 Liver biopsies were performed under standing sedation between 240 and 360 min.  
Physical examinations were performed hourly for 9 hours following LPS or saline 
administration, and at 15 and 21 hours.  Insulin-modified frequently-sampled intravenous 
glucose tolerance tests were performed at -27 hours, 30 minutes, and 21 hours as part of a 
                                                 
a
 Abbocath-T 14 G X 140 mm, Abbott Laboratories, North Chicago, IL 
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concurrent study to assess glucose and insulin dynamics (refer to chapter 5).  Animals had access 
to grass hay and water at all times.  Intravenous catheters were removed at the end of the study 
period and horses were returned to the research farm.  Procedures were repeated the following 
week and the opposite treatment (LPS or saline) was administered to each animal.   
 
Lipopolysaccharide and saline administration – Commercially available Escherichia coli O55:B5 
LPS
b
 (20 ng/kg) was diluted in 60 mL sterile saline and administered IV over 30 minutes.  
Horses receiving the control treatment were administered 60 mL of sterile saline IV over 30 
minutes. 
 
Measurement of blood variables – Blood samples for CBC, fibrinogen, and biochemical profile 
analysis were collected into appropriate anticoagulant or serum tubes and analyzed by the 
University of Tennessee Clinical Pathology laboratory.   
 
Whole blood inflammatory cytokine gene expression – Blood samples for quantitation of IL-1β, 
IL-6, IL-8, IL-10, TNF-α, and β-glucuronidase (B-Gus) gene expression were collected into 
whole blood RNA collection tubes
c 
and allowed to incubate at room temperature for 8 hours, 
then stored at – 20 °C until analyzed.  Total RNA extraction and real-time polymerase chain 
reaction were performed as previously described (refer to chapter 2).  The comparative CT 
(ΔΔCT) method was used to determine fold changes in inflammatory cytokine gene 
expression.
509
  Cytokine expression was normalized to the housekeeping gene B-Gus and each 
                                                 
b
 Sigma Aldrich, Inc., St Louis, MO 
c
 PAXgene® blood RNA tubes, Qiagen/PreAnalytiX, Valencia, CA 
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horse’s baseline value was used as the calibrator.  Baseline gene expression was therefore equal 
to a 1-fold change for all cytokines.  
 





 intercostal spaces was clipped and prepped using povidone-iodine surgical 
scrub.  The biopsy site was infiltrated with 12 mL of 2% mepivacaine hydrochloride and an 
ultrasound-guided needle biopsy was performed using a 14-guage spring-action needle biopsy 
device.
d
  Two 1.5-cm biopsy cores were collected from each animal.  One core was immediately 
fixed in 10% neutral buffered formalin and the other was snap frozen on dry ice and stored at -80 
°C until gene expression analysis.  The skin was sutured and animals were monitored for 
complications following the procedure.    
 
Liver Histopathology – Routing hematoxylin and eosin and periodic acid-Schiff staining was 
performed on formalin-fixed biopsy samples.  Tissue sections (5 µm thickness) were evaluated 
using light microscopy by a single board-certified veterinary pathologist who remained blinded 
to treatment group allocations.  Inflammation, lipid content, and glycogen content were graded 
subjectively on a scale of 0 (absent) to 3 (marked). 
 
Inflammatory cytokine gene expression in liver – Total RNA was extracted from frozen tissue 
samples using a commercially available guanidine-thiocyanate-based extraction kit
e
 accordingly 
to the manufacturer’s instructions.  Concentration and purity of RNA in each sample was 
                                                 
d
 Temno Evolution® biopsy needle, CareFusion Corp., Waukegan, IL 
e





  Reverse transcription was performed using a kit
g
 and 1 μg of 
RNA was loaded into each reaction.  Complementary DNA was then diluted 1:10 with 180 µL of 
nuclease-free water.   
 Real time PCR was performed for IL-1β, IL-6, IL-8, IL-10, TNF-α, and β2 microglobulin 
(B2M) as described for whole blood.  β2 microglobulin was selected as the housekeeping gene 
because B2M expression in liver tissue was more stable than expression of B-Gus in preliminary 
tests.  Cytokine expression in each sample was normalized to B2M and the calibrator used for 
comparative CT (ΔΔCT) calculation was each horse’s ΔCt value after saline infusion.  
Lipopolysaccharide-induced gene expression is therefore expressed relative to the saline 
treatment. 
 
Statistical Analysis – Mixed model analysis of variance (ANOVA) was performed using 
computer software
h
 to determine effects of group (EMS vs. normal), treatment (LPS vs. saline), 
time, and main effect interactions.  Area under the curve (AUC) values for whole blood 
inflammatory cytokine gene expression were calculated using the trapezoidal method and 
computer software.
i
  Blood and hepatic gene expression data, AUC for blood gene expression, 
heart rate, and respiratory rate required logarithmic transformation to fit ANOVA normal 
distribution assumptions.  Transformed data are reported as geometric means with 95% CI.  All 
other data are reported as least squares means ± SEM.  The autoregressive correlation parameter 
was included in the final model for analysis of rectal temperature and heart rate only.  Mean 
                                                 
f
 NanoDrop ND-1000, Thermo Fisher Scientific, Wilmington, DE 
g
 High Capacity cDNA Reverse Transcription Kit with RNase Inhibitor, Applied Biosystems, Foster City, CA 
h
 PROC MIXED, SAS, version 9.2, SAS Institute, Inc., Cary, NC 
i
 SAS, version 9.2, SAS Institute, Inc., Cary, NC 
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separation was performed using Fisher’s protected least significant difference and significance 
was set at P < 0.05.   
 Mean cytokine expression at each time point was also compared to the pre-infusion 
baseline using one-sample t-tests with Bonferroni correction for multiple comparisons.  
Significance was set at P < 0.0021 because the Bonferroni correction was applied.   Hepatic gene 
expression following LPS administration was compared to saline infusion using the same 
method.   
 Baseline blood (time = -30 minutes) and hepatic (following saline administration) gene 
expression was compared between groups by recalculating ΔΔCT using a pooled calibrator value 
for each cytokine generated by averaging all baseline ΔCt values for that gene.  Mean cytokine 
expression was then compared between groups using independent sample t-tests.   
 Associations among blood and hepatic cytokine expression and vital parameters were 
assessed using Spearman’s rank correlation coefficients.  Correlation analysis was performed at 
the level of the individual animal.  Significance was set at P < 0.05 for all correlations.   
 
4.3  Results 
 
Group comparisons – No differences were detected between EMS and control groups with 
respect to mean age, weight, or body condition score.  Two animals in the EMS group exhibited 
generalized obesity with prominent nuchal crest adipose accumulation (body condition score > 
7/9), 2/6 were of normal body condition but showed regional adiposity of the neck and tail head, 
and 2/6 displayed a lean phenotype.  In contrast, only one horse in the control group was obese 
and none of the horses exhibited regional adiposity. 
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Clinical signs – Ten of 12 animals demonstrated transient depression, anorexia, pawing, 
yawning, head shaking, stretching, or muscle fasciculations following LPS infusion.  Two horses 
(1 normal and 1 EMS from the same pair) showed no clinical response to LPS.  Physical 
examination parameters did not change and leukopenia was not detected, so all data from these 
animals collected after LPS infusion were excluded from further analyses.    
 With the exception of the two non-responders, all horses developed fever (rectal 
temperature > 38.5 ºC) following LPS infusion.  Lipopolysaccharide administration significantly 
increased mean rectal temperature (treatment × time; P < 0.001), but no differences were 
detected between groups (Figure 4.1A).  Mean heart rate increased significantly following LPS 
infusion (treatment × time; P < 0.001; Figure 4.1B).  A group effect was detected for this 
variable (P = 0.048), with higher heart rates detected in EMS horses. Mean respiratory rate 
significantly increased following LPS administration (treatment × time; P < 0.001), with higher 
rates detected in the EMS group (P = 0.017; Figure 4.1C).  Group × treatment × time effects 
were not significant for any of the physical examination variables recorded. 
 




 was detected on 1 or more CBCs in 5/6 (83%) EMS horses and 2/6 (33%) normal 
horses.  Concurrently decreased hematocrit values (< 28%)
j
 and hemoglobin concentrations (< 
10.2 g/dL)
j
 were detected in 5/7 (71%) animals.  Mean hematocrit was significantly lower (P < 
0.01) in horses with EMS (32.3 ± 1.0 %) than in normal horses (36.6 ± 0.7 %).  Mean 
hemoglobin concentration was also lower (P < 0.009) in the EMS group (10.9 ± 0.3 g/dL) than 
the normal group (12.32 ± 0.2 g/dL).    
                                                 
j




Figure 4.1  Changes in physical examination parameters of normal and EMS horses following 
IV bolus administration of LPS at 20 ng/kg or saline infusion.  Data for rectal temperature are 
expressed as means ± SEM, while data for heart rate and respiratory rate are expressed as 
geometric means and 95% CI on a linear scale.  *Asterisks refer to treatment × time effects and 
denote significant differences from baseline following LPS infusion.  A) Treatment × time (P < 
0.001) effects were detected for rectal temperature.  B) Treatment × time (P < 0.001) and group 
(P = 0.048) effects were detected for heart rate.  C)  Treatment × time (P < 0.001) and group (P 
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 was detected 180 minutes 









 were detected in 7/9 (78%) and 8/9 
(89%) of these animals, respectively. 
 
Whole blood cytokine gene expression – Treatment × time effects were significant for IL-1β (P < 
0.001; Figure 4.2A) and TNF-α (P < 0.001; Figure 4.2B), and significant treatment effects were 
detected for IL-6 (P < 0.001; Figure 4.2C), IL-8 (P < 0.001; Figure 4.2D), and IL-10 (P < 
0.001; Figure 4.2E). 
 Group × treatment × time effects did not reach statistical significance for any of the 
inflammatory cytokines examined, but group × time effects were significant for IL-1β (P = 
0.027) and group effects were significant for TNF-α (P = 0.040). 
 Results of one-sample t-tests demonstrated that cytokine expression remained 
significantly elevated above baseline for longer in horses with EMS following LPS 
administration (P < 0.0021). Expression of IL-6 and IL-8 increased relative to baseline in EMS 
but not normal horses at 1 and 3 time points, respectively.  Interleukin-10 expression did not 
differ statistically from baseline at any time point in the normal group, but was increased at 30, 
180, and 240 minutes in the EMS group.  Tumor necrosis factor-α expression increased relative 
to baseline at all time points in horses with EMS, but was only increased at 60 minutes in normal 
animals.  Baseline (-30 minute) gene expression did not differ between normal horses and 
animals with EMS. 
 Lipopolysaccharide administration significantly increased AUC for IL-1β, IL-6, IL-8, IL-
10, and TNF-α expression (treatment, P < 0.001), but differences between EMS and normal   
                                                 
k
 Reference ranges used by the University of Tennessee Clinical Pathology laboratory 
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Figure 4.2  Change in whole blood gene expression of IL-1β, TNF-α, IL-6, IL-8, and IL-10 in 
normal and EMS horses following IV bolus administration of LPS at 20 ng/kg or saline infusion.  
Data are expressed as geometric means and 95% CI, and are displayed on a logarithmic scale.  
Significance was set at P < 0.0021 for one-sample t-test comparisons between cytokine 
expression at each time point, compared to baseline.  Significance for ANOVA main effects and 
interactions was defined by P < 0.05.  *Significant difference from baseline following LPS 
infusion in EMS group only.  
†
Significant difference from baseline following LPS infusion in 
both normal and EMS groups.  A) Treatment × time (P < 0.001) and group × time (P = 0.027) 
effects were detected for IL-1β.  B) Treatment × time (P < 0.001) and group (P = 0.040) effects 
were detected for TNF-α.  C) Treatment (P < 0.001) effects were detected for IL-6.  D) 
Treatment (P < 0.001) effects were detected for IL-8.  E) Treatment (P < 0.001) effects were 


























Figure 4.2, continued.  
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horses were not detected by ANOVA (Table 4.1).  Area under the curve for IL-10 was 
significantly increased in horses with EMS compared to normal animals (group, P = 0.046). 
 
Liver cytokine gene expression – Expression of IL-6 increased following LPS infusion in normal 
horses, and IL-8 expression increased in both normal and EMS animals (P < 0.0025; Figure 
4.3).  Expression did not differ in magnitude between the EMS and normal groups.  Baseline 
gene expression was assessed after saline infusion, and did not differ significantly between 
horses with EMS and normal animals. 
 
Liver histopathology – Twenty-three biopsy specimens of diagnostic quality were obtained.  One 
unusable sample from an EMS horse receiving LPS was excluded from analysis.  Differences 
were not apparent between normal and EMS horses or between animals that received LPS or 
saline.  Moderate (grade 2) to abundant (grade 3) intracellular glycogen was detected in all 
samples.  Mild intracellular lipid accumulation (grade 1) was observed in 1 normal horse and 1 
horse with EMS following saline infusion.  Lipid was not identified in the second biopsy sample 
from either horse.  Mild to moderate mixed portal inflammation (grade 1 - 2) was identified in 
both biopsy specimens from 1 EMS horse, and in the post-LPS samples from 2 normal and 2 
EMS horses.  Two animals with portal inflammation also had ductal hyperplasia and edema (1 
normal and 1 EMS) and moderate portal fibrosis was identified in 1 horse with EMS.  Mild 
sinusoidal accumulation of non-degenerate neutrophils (grade 1) was identified in 2 normal and 
2 EMS horses following LPS administration, including the 2 animals that were considered non-
responders to LPS infusion.    
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Table 4.1  Geometric means and 95% CI of AUC values for whole blood inflammatory cytokine 
expression in normal and EMS horses following IV bolus administration of LPS at 20 ng/kg or 






Cytokine Group Treatment  
AUC ([fold change  


























175.7 (107.6 to 286.8) 
2.37 (1.66 to 3.39) 
 
133.7 (70.8 to 252.4) 
2.07 (1.56 to 2.73)
 















80.8 (44.1 to 148.0) 
3.37 (2.10 to 5.40) 
 
49.6 (21.6 to 113.7) 
4.07 (3.04 to 5.43) 















97.6 (74.3 to 128.1) 
3.04 (1.14 to 8.14) 
 
67.4 (17.4 to 261.4) 
2.19 (1.23 to 3.93)
 















44.7 (24.7 to 81.0)
 
4.40 (2.67 to 7.25) 
 
10.4 (3.40 to 31.8) 
2.87 (1.40 to 5.88)
 















31.3 (13.7 to 71.7) 
4.57 (2.47 to 8.43) 
 
12.6 (6.45 to 24.7) 
2.86 (1.74 to 4.71)
 
 
0.077 0.001 0.493 
*Where significant, AUC increased in the EMS group relative to the normal group. 
†







Figure 4.3  Hepatic gene expression of IL-1β, IL-6, IL-8, IL-10, and TNF-α in normal and EMS 
horses after receiving a 20 ng/kg IV bolus of LPS.  Data are expressed as geometric means and 
95% CI, and are displayed on a logarithmic scale.  *Significantly higher expression following 




Correlations – Analysis was performed using data from all time points when both physical 
examination parameters and whole blood inflammatory gene expression were measured.  
Cytokine gene expression was positively correlated with rectal temperature, heart rate, and 
respiratory rate (Table 4.2).  Positive correlations were also identified among inflammatory 
cytokines (data not shown).   
 
4.4  Discussion 
 
 Systemic inflammation developed in both normal and EMS horses following an 
endotoxin challenge, and whole blood inflammatory cytokine gene expression increased in both 
groups.  Although the magnitude of the increase in expression did not differ between groups, 
increased cytokine expression persisted for longer in horses with EMS.  Endotoxin infusion also 
increased hepatic cytokine gene expression, but differences were not detected between normal 
and EMS horses.  Results therefore support our hypothesis that EMS affects inflammatory 
responses to endotoxin, but further studies are required to confirm these findings.   
 Lipopolysaccharide infusion increased rectal temperature, heart rate, and respiratory rate 
in a manner consistent with previous studies,
164,354
 but responses did not differ significantly 
between normal and EMS horses.  These alterations in physical examination parameters are 
expected, considering the known effects of inflammatory mediators such as IL-1β on body 
temperature regulation and metabolic rate.
551
 Interestingly, horses with EMS demonstrated 
higher overall heart rates and respiratory rates than normal animals following both LPS and 
saline administration.  Cardiopulmonary abnormalities relating to fat mass are well described in 
obese humans,
552
 and  these findings suggest that similar abnormalities occur in obese horses.    
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Table 4.2  Spearman’s rank correlation coefficients for associations among whole blood gene 
expression values and physical examination parameters in normal and EMS horses after 
receiving a 20 ng/kg IV bolus of LPS.  Significance was set at P < 0.05 and P values are 
displayed in parentheses. 
 























































 Inflammatory cytokine expression increased in both blood and hepatic tissues following 
LPS infusion.  Lipopolysaccharide is recognized by the cell-surface pattern recognition receptor 
TLR4,
13
 and many cells, especially those with immunologic functions, express this receptor and 
respond to LPS stimulation.
11,553
   Activation of TLR4 signalling culminates in the secretion of 
inflammatory mediators that orchestrate the innate and adaptive immune responses.
7,11
  The pro-
inflammatory cytokines IL-1β, IL-6, IL-8 and TNF-α measured in this study are major regulators 
of innate immunity,
18,19
 and are known to increase in response to LPS administration in 
horses.
269,410,506,534
  Interleukin-1β, IL-6, and IL-8 are used as prognostic indicators in septic 
humans, with increased cytokine expression predicting organ failure and mortality.
28,512-514
   
Laminar tissue expression of these mediators increases during the onset of laminitis,
429-431,493
 and 
increased expression of IL-1β, IL-6, IL-8, and TNF-α occurs in the liver and lungs of laminitic 
horses.
427
  Interleukin-10 is an anti-inflammatory mediator that is responsible for limiting 
inflammation and reducing tissue damage during sepsis.
24,32,516
  When produced in excess, 
however, IL-10 contributes to the development of immunosuppression,
24,29,32
 and high IL-10 





 Lipopolysaccharide administration increased the expression of all cytokines in whole 
blood samples, with TNF-α peaking at 60 and 90 minutes in normal and EMS horses, 
respectively, and IL-1β, IL-6, IL-8, and IL-10 peaking between 120 and 240 minutes in all 
horses. Our findings are consistent with those of a recent report in which administration of a 30 
ng/kg IV bolus of LPS increased inflammatory cytokine gene expression in the blood of healthy 
horses.
506
  Although we report longer times to peak cytokine expression, LPS was administered 
at a lower dose in the current study, which could account for this discrepancy.  In both studies, 
TNF-α expression returned to baseline by 180 minutes in normal horses, although our results 
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indicate that elevated TNF-α expression persisted in horses with EMS.  Interleukin-8 expression 
returned to baseline in the previous study, but remained elevated in normal and EMS horses in 
this study.   
 Although the magnitude of cytokine responses did not differ significantly between 
normal and EMS horses, inflammatory gene expression remained elevated longer in horses with 
EMS.  Most notably, TNF-α expression only increased relative to baseline at 1 time point in 
normal horses, whereas expression was consistently increased in horses with EMS.  Disparity 
between groups was also seen in IL-8 and IL-10 expression.  These differences between normal 
and EMS horses are not directly explained by obesity because only 2 of 6 affected animals were 
obese, while another 2 horses exhibited regional adiposity.  It must therefore be concluded that 
IR or the historical problem of obesity affected the systemic inflammatory response.  It is also 
possible that adipose tissues are abnormal even in lean EMS horses and may contribute to 
differences in the inflammatory response.  
 Baseline blood cytokine expression did not differ between normal and EMS horses in this 
study, but significant group × time and group effects were detected for IL-1β and TNF-α, 
respectively, indicating that cytokine expression was higher overall in horses with EMS during 
the 240 minute periods following LPS and saline infusion.  Area under the curve for IL-10 was 
also higher in EMS horses.  These results further support obesity as a pro-inflammatory state in 
the horse as it is in other species, and are consistent with previous findings in obese horses.
104,255
  
Although increased IL-10 is not consistently associated with obesity, increased IL-10 production 






 The extent to which obesity impacts circulating leukocyte responses to inflammatory 
stimuli is not clear.  Cross-talk between adipose tissue macrophages and circulating leukocytes is 
likely to occur because peripheral blood mononuclear cells from obese humans are in a pro-
inflammatory state and demonstrate increased basal cytokine expression when compared to 
normal-weight individuals.
556
  Equine peripheral blood mononuclear cells also show different 
cytokine  responses to in vitro stimulation if harvested from obese versus thin animals.
557
   
 Other potential modulators of cross-talk between adipose depots and circulating 
leukocytes include the adipokines adiponectin and leptin.  Immune functions consume a 
substantial amount of energy, so  adipokines make sure that the immune system remains 
appraised of available energy stores in the body.
154





 exerts direct anti-inflammatory effects on cells of the immune 
system.
317,558
  Leptin secretion increases in direct proportion to fat mass,
336,337
 and also in 
response to inflammation.
322,323
  Leptin promotes pro-inflammatory responses such as cytotoxic 
polarization of lymphocyte differentiation
105
 and increased inflammatory cytokine expression.
343
  
Whether obesity affects in vivo leukocyte responses to endotoxin remains unknown, but results 
of the current study suggest that cytokine production is prolonged in horses with EMS.   
 We did not demonstrate that EMS altered the magnitude of blood inflammatory cytokine 
responses in horses, but it is possible that exaggerated inflammatory responses originate from 
tissues rather than circulating leukocytes.  Adipocytes express TLR4 and are capable of 
responding to LPS stimulation by secreting pro-inflammatory cytokines and chemokines such as 
IL-6, TNF-α, and macrophage chemoattractant protein-1.
110,334
  Cultured equine adipocytes and 
preadipocytes produce IL-1β, IL-6, and TNF-α in response to LPS stimulation, and adipose 
tissue biopsies obtained from horses following IV LPS infusion demonstrate increased 
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expression of these cytokines.
269
  Inflammatory reactions may therefore be exaggerated in EMS 
by virtue of increased fat mass or abnormal adipose tissues.
110
  Adipose tissue cytokine 
responses were not assessed in the current study, but warrant further consideration.   
 Lipopolysaccharide administration increased the expression of IL-6 and IL-8 in hepatic 
tissues, but differences were not apparent between normal and EMS horses.  It is possible that 
aspects of the study design limited out ability to detect differences between groups.  Because 
hepatic cytokine responses to an endotoxin challenge have not previously been examined in 
horses, timing of sample collection was based on gene expression studies in rodents
559-561
 and 
approximated  times previously reported for increased serum and plasma cytokine expression in 
horses after  IV LPS administration.
410,534
  Differences might have been detected between normal 
and EMS horses had the timing of sample collection differed or if multiple samples were 
collected.  Obesity promotes hepatic inflammation in other species because intermediates of lipid 
metabolism are toxic to hepatocytes and activate Kupffer cells.
278,279,562
  Lipid accumulation 
within hepatocytes also distorts  sinusoids and decreases blood flow velocity, leading to 
prolonged exposure of Kupffer cells to antigens or leukocytes.
279
  More comprehensive 
examination of hepatic dysfunction in horses with EMS is therefore indicated in future studies. 
 Alterations in liver function may be relevant to the pathophysiology of laminitis in EMS 
horses. It has been hypothesized that EMS horses are more susceptible to laminitis because 
repeated inflammatory insults occur to the laminar vascular endothelium, and these processes 
may be exaggerated in affected animals.
298,307
  Inflammatory insults may arise from minor 
intestinal carbohydrate overload events occurring in horses grazing on pasture.
298
  Because a 
major function of the liver is to remove toxins that escape the gastrointestinal tract before they 
enter systemic circulation, horses with liver dysfunction associated with EMS may experience 
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more frequent and severe inflammatory events that might increase their risk of developing 
laminitis. 
 An important finding of this study is that LPS administration neither induced laminitis in 
normal horses nor exacerbated the condition in horses with EMS.  Although horses with clinical 
signs suggestive of endotoxemia are at an increased risk of developing laminitis
3
 and endotoxin 
has been detected in the blood during carbohydrate overload laminitis induction,
409,423
 
administration of LPS alone has consistently failed to induce the disease.
327,354,410,534
  
Endotoxemia may act synergistically with other factors such as hindgut-derived Gram-positive 
exotoxins or vasoactive amines
375,528
 to induce laminitis, but multiple factor models have not 
been explored to date in horses.    
 One aspect of the current study that may have limited our ability to detect differences 
between normal and EMS horses was that horses with EMS were part of an intensively managed 
research herd and several animals had lost weight prior to enrollment in this study.  It is therefore 
possible that administration of LPS to obese animals in an exacerbated state of inflammation and 
IR would have produced greater disparity in the cytokine responses between groups.  Weight 
loss and normalization of metabolic functions in the EMS group could explain why differences 
were not detected in baseline blood or hepatic gene expression values, and why liver 
histopathology did not differ between normal and EMS horses.   
 Despite losing weight, horses with EMS still responded differently to endotoxin 
challenge than normal animals.  This could reflect underlying physiological defects that are not 
strictly related to adiposity.  Evidence from human studies indicates that not all metabolic 
parameters normalize with weight loss.
563-565
  In the current study, some EMS horses with a lean 
phenotype still retained abnormal characteristics such as regional adiposity.  Additionally, 
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certain phenotypic abnormalities in horses with EMS may only be unmasked in response to a 
challenge.  For example, laminitis-prone obese ponies manifest seasonal hypertension and 
reduced insulin sensitivity in response high dietary carbohydrate intake.
256
  Endotoxin challenge 
may therefore have unmasked inherent defects in the inflammatory responses of horses with 
EMS.  
 An interesting finding in this study was that anemia was detected at least once in 5 of the 
6 horses with EMS, and affected horses had significantly lower hematocrit values and 
hemoglobin concentrations than normal animals.  Horses with EMS may develop anemia of 
chronic disease from obesity-related inflammation.
566
  Iron deficiencies have been described in 
obese humans,
567,568
 and are ascribed to both true iron deficiency and inflammation-related 
functional deficiencies.
569
  Iron status was not assessed in the current study, but measurements of 
serum iron and ferritin and total iron binding capacity should be considered in the future. 
 We conclude that EMS affects systemic inflammatory responses to endotoxin by 
prolonging inflammatory cytokine gene expression in the blood.  However, physical examination 
findings and the magnitude of the inflammatory response did not differ between groups.  
Intravenously administered LPS also induces pro-inflammatory cytokine expression in hepatic 
tissue of both normal and EMS horses.  Notably, endotoxin challenge does not induce laminitis 
or exacerbate the condition in horses with EMS.  Further studies are required to determine the 
role of inflammation in EMS.  Future studies should also include direct assessment of adipose 




Intravenous lipopolysaccharide infusion alters glucose and insulin dynamics in horses with 
Equine Metabolic Syndrome 
 
 
5.1  Introduction 
 
 Obesity and insulin resistance (IR) are established risk factors for laminitis in horses and 
ponies,
182,226,250
 and the term Equine Metabolic Syndrome (EMS) has been adopted to describe 
animals that exhibit generalized or regional adiposity, IR, and laminitis.  In human medicine, 
metabolic syndrome defines a set of risk factors, including obesity and IR that predict the 
development of cardiovascular disease.
248
  In contrast, laminitis is of primary importance in 
horses with EMS.  Insulin resistance  is linked to cardiovascular disease through its effects on the 
vascular endothelium in humans and this mechanism is also being examined in horses.
296
  
Increased expression of microvascular endothelial insulin receptors occurs in the equine hoof 
following high dietary carbohydrate consumption, indicating that insulin affects endothelial 
function in this species.
570
     
 Hyperglycemia is not a component of EMS,
4
 but abnormal glucose homeostasis might 
still play a role in the development of laminitis.  A recent report identified increased 
fructosamine concentrations in laminitic horses, although the study population was not limited to 
animals with EMS.
571
  Hyperglycemia increases the production of reactive oxygen species and 
the formation of advances glycation end products, which damage tissues and are important in the 
pathogenesis of cardiovascular disease in diabetic humans.
190,572
  Interstitial glucose 
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concentrations in obese, insulin-resistant horses are variable throughout the day and sometimes 
exceed reference range.
243
  This may be important because it has been demonstrated in humans 
that mild fasting hyperglycemia increases cardiovascular risk, and postprandial hyperglycemia 
well below the cutoff for diabetes causes endothelial dysfunction if occurring over a prolonged 
period of time.
573-575
  These findings can be related to laminitis because horses with EMS often 
suffer from mild laminitis  that goes unnoticed by owners and develops over time after grazing 
on carbohydrate-rich pasture.
4
   
 Both IR and hyperglycemia develop acutely during systemic inflammation because 
inflammatory cytokines and stress hormones such as glucocorticoids, catecholamines, and 
glucagon inhibit post-receptor insulin signaling pathways and promote hepatic glucose 
output.
91,576
  Horses with EMS often develop laminitis after grazing on carbohydrate-rich pasture 
and it has been suggested that inflammation contributes to the development of disease.
4
  Pasture 
grazing increases the risk of intestinal carbohydrate overload and translocation of gut-derived 
toxins such as lipopolysaccharide (LPS), exotoxins, and vasoactive amines into systemic 
circulation.
298
  Horses could therefore experience mild episodes of systemic inflammation while 
on pasture, and this might have an additional impact on glucose and insulin dynamics. 
Lipopolysaccharide infusion decreases insulin sensitivity in normal horses,
164,269,327,354
 but this 
situation has not been examined in horses with EMS.   It must therefore be determined whether 
pre-existing derangements in glucose and insulin homeostasis are acutely exacerbated by 
inflammation in these animals, which could increase their risk of developing laminitis. 
 Clinical experience suggests that horses with EMS are at greater risk of developing 
laminitis when systemic illnesses such as bacterial enterocolitis develop.  Obesity is associated 
with increased morbidity and mortality in critically ill humans,
325,326
  and obese patients are at 
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increased risk of developing hyperglycemia.
142,144
  Laminitis shares many similarities with 
sepsis-associated organ failure, including microvascular dysfunction,
303,373
 and endothelial 
function is further compromised in obese individuals during sepsis.
307
  It is therefore our overall 
hypothesis that EMS increases the risk of laminitis developing in association with systemic 
inflammation.  The current study was undertaken to determine whether glucose and insulin 
dynamics differ between EMS and normal horses in response to inflammation.  We hypothesized 
that EMS impacts alterations in glucose and insulin homeostasis induced by LPS infusion. 
 
5.2  Materials and methods  
 
Animals – Six healthy adult mares and 6 horses previously diagnosed with EMS (3 mares and 3 
geldings) from the University of Tennessee teaching and research herd were included in the 
study.  Control animals had no history of laminitis and fasting serum insulin concentrations 
below 20 µU/mL.  Horses with EMS had a history of chronic obesity or abnormal regional 
adiposity, IR, and laminitis.  Body condition scores ranged from 5 to 7.25 (mean 6; median 5.9) 
for normal horses and from 4 to 9 (mean 6.3; median 6.4) in horses with EMS on the scale of 1 
to 9 described by Henneke, et al.
249
  The study protocol was approved by the University of 
Tennessee Institutional Animal Care and Use Committee. 
 
Study Design – Glucose and insulin dynamics were assessed concurrently with inflammatory 
responses to LPS infusion, and the complete study design is described in chapter 4.  Baseline 
insulin-modified frequently-sampled intravenous glucose tolerance tests (FSIGTTs) were 
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performed at 0830 on day 1 (time = -27 hours) and then repeated at 0.5 and 21 hours (0830 on 
day 3).    
 
FSIGTT procedure – Testing was performed as described by Hoffman, et al.
232
 and modified by 
Tóth, et al.
577
  Plasma and serum samples were collected into sodium fluoride / potassium 
oxalate and serum tubes via the intravenous (IV) catheter
a
 at -10, -5, and 0 minutes relative to 
dextrose infusion and values were averaged to obtain the baseline.  An IV bolus of 50% dextrose 
solution
b
 was then administered at a dosage of 150 mg/kg bwt.  Plasma and serum samples were 
collected at 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, and 19 minutes for measurement of blood glucose 
and insulin concentrations.  A bolus of regular insulin
c
 (30 mU/kg bwt) was administered IV at 
20 minutes.  Plasma and serum were subsequently collected at 22, 23, 24, 25, 27, 30, 35, 40, 50, 
60, 70, 80, 90, 100, 120, 150, and 180 minutes.  Sodium fluoride / potassium oxalate tubes were 
immediately cooled on ice and serum tubes were allowed to clot at room temperature for 1 hour.  
Tubes were centrifuged at 1,000 × g for 10 minutes and plasma or serum was harvested and 
stored at –20 ºC until analyzed. 
 
Plasma glucose and serum insulin concentrations – Plasma glucose concentrations were 
measured in duplicate using a colorimetric assay
d
 on an automated discrete analyzer.
e
  Serum 
insulin concentrations were measured in duplicate using a radioimmunoassay
f
 that has been 
validated for use with equine plasma in our laboratory and by others.
537
  Intra-assay coefficient 
                                                 
a
 Abbocath-T 14 G X 140 mm, Abbott Laboratories, North Chicago, IL 
b
 Vedco, Inc., St. Joseph, MO 
c
 Humulin R, Eli Lilly and Co., Indianapolis, IN 
d
 Glucose, Roche Diagnostic Systems, Inc., Somerville, NJ 
e
 Cobas Mira, Roche Diagnostic Systems, Inc., Somerville, NJ 
f




of variation < 5% was required for acceptance of glucose assay results and <10% was required 
for acceptance of insulin assay results.   
 
Interpretation of FSIGTT data using the minimal model – Minimal model
578
 parameters for 
insulin sensitivity (SI), glucose effectiveness (Sg), acute insulin response to glucose (AIRg), and 
disposition index (DI) were calculated as previously described
232,579
 using computer software.
g,h
  
Disposition index was calculated by multiplying AIRg × SI.   
 
Statistical Analysis – Mixed model analysis of variance (ANOVA) was performed using 
computer software
i
 to determine effects of group (EMS vs. normal), treatment (LPS vs. saline), 
time, and main effect interactions.  Area under the curve values for glucose and insulin were 
calculated using the trapezoidal method and computer software.
j
  Area under the curve for 
insulin and baseline insulin values required logarithmic transformation to fit ANOVA normal 
distribution assumptions.  Minimal model parameters required square root transformation.  
Transformed data are reported as geometric means with 95% CI.  All other data are reported as 
least squares means ± SEM.  The autoregressive correlation parameter was excluded from the 
final model for all analyses.  Mean separation was performed using Fisher’s protected least 
significant difference and significance was set at P < 0.05.   
 Associations among peak blood cytokine expression values (refer to chapter 4) and 
indices of glucose and insulin homeostasis were assessed using Spearman’s rank correlation 
                                                 
g
 MinMod Millennium, version 6.10, Raymond Boston, University of Pennsylvania, Kennet Square, PA 
h
 Stata 9.2, Stata Corp., College Station, TX 
i
 PROC MIXED, SAS, version 9.2, SAS Institute, Inc., Cary, NC
 
j
 SAS, version 9.2, SAS Institute, Inc., Cary, NC 
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coefficients.  Correlation analysis was performed at the level of the individual animal.  
Significance was set at P < 0.05 for all correlations.   
 
5.3  Results 
 
Group comparisons – Mean body condition score did not differ between the EMS and control 
group, however 2 animals in the EMS group exhibited generalized obesity with prominent 
nuchal crest adipose accumulation (body condition score > 7/9), 2/6 were of normal body 
condition but showed regional adiposity of the neck and tail head, and 2/6 displayed a lean 
phenotype.  In contrast, only one horse in the control group was obese and none of the horses 
exhibited regional adiposity. 
 
Clinical signs – As reported in chapter 4, 10 of 12 animals demonstrated transient depression, 
anorexia, pawing, yawning, head shaking, stretching, or muscle fasciculations following LPS 
infusion.  Two horses (1 normal and 1 EMS from the same pair) showed no clinical response to 
LPS.  Vital parameters did not change and leukopenia was not detected, so all data collected after 
LPS infusion was excluded from further analyses.   
 
Baseline glucose and insulin values – Baseline plasma glucose and serum insulin concentrations 
from each FSIGTT are summarized in Table 5.1.  Values represent resting glucose and insulin 
concentrations.  Lipopolysaccharide significantly increased baseline insulin (P < 0.001) and 
glucose (P < 0.001) concentrations at 21 hours, but differences were not detected between EMS 
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Table 5.1  Baseline plasma glucose and serum insulin concentrations from each FSIGTT in normal and EMS horses following IV 
bolus administration of LPS at 20 ng/kg or saline infusion.  Baseline insulin values are reported as geometric means and 95% CI and 
baseline glucose values are reported as means ± SEM.  Significance was set at P < 0.05.  
 
*Insulin concentrations were higher overall in horses with EMS than in normal animals 
†
For each variable, values increased significantly at 21 hours in the LPS groups, but differences between EMS and normal horses were 
not detected.  Changes were not significant in horses that received Saline infusions.  
 
 
   FSIGTT 
 
P value 




















13.7 (9.8 to 19.2) 
13.9 (8.0 to 23.9) 
 
7.1 (4.1 to 12.3) 
5.4 (3.8 to 7.7) 
8.0 (6.9 to 9.3) 
25.8 (12.1 to 55.1) 
 
6.1 (2.9 to 12.9) 
6.0 (3.2 to 11.4) 
31.4 (19.4 to 51.0) 
24.1 (11.9 to 49.2) 
 
11.5 (5.9 to 22.6)  


















































and normal horses.  Horses with EMS has higher baseline insulin concentrations overall (P < 
0.007).   
 Resting hyperinsulinemia (> 20 µU/mL)
a
 was detected in 2/6 horses with EMS and 1/6 
normal horses prior to the testing period (at -27 hours) during one or both weeks of the study.  
Lipopolysaccharide infusion induced hyperinsulinemia in 5/5 (100%) EMS horses and 1/6 (17%) 
normal horses at 21 hours.  This normal horse was not the same one in which hyperinsulinemia 
was detected at -27 hours.  Saline infusion induced hyperinsulinemia 4/6 (67%) and 3/6 (50%) 
EMS horses at 0.5 and 21 hours, respectively.  Resting hyperinsulinemia was not detected in 
normal horses when they received saline.   
 Resting hyperglycemia (>110 mg/dL)
b
 was not detected in any horse at -27 or 0.5 hours, 
but LPS infusion induced hyperglycemia in 4/5 (80%) EMS horses and 1/6 (17%) normal horses 
at 21 hours.  One of 6 (17%) horses with EMS became hyperglycemic 21 hours after saline 
infusion.   
 
Area under the curve for glucose and insulin – Area under the curve values for glucose and 
insulin are summarized in Table 5.2.  Significant group × treatment × time interactions were 
detected for area under the curve for glucose (AUCg) from 0 to 180 min (P = 0.039) and area 
under the curve for insulin (AUCi) during the first 19 minutes, before IV dextrose administration 
(P = 0.016).  Treatment × time interactions were significant for AUCi from 0 to 180 min (P = 
0.014; Figure 5.1) and AUCg for the first 19 minutes (P < 0.001; Figure 5.2).   When group and 
group x time effects were examined, AUCi (group; P = 0.005) and AUCg (group; P = 0.030, 
group × time; P = 0.011) from 0 to 180 min were higher in horses with EMS.  
                                                 
a
 Reference range for the Coat-A-Count insulin radioimmunoassay  
b
 Reference range used by the University of Tennessee Clinical Pathology laboratory 
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Table 5.2  Area under the curve values for glucose and insulin in normal and EMS horses following IV bolus administration of LPS at 
20 ng/kg or saline infusion.  Values for AUCi (0 to 180 minutes) are reported as geometric means and 95% CI and all other data are 
reported as means ± SEM.  Significance was set at P < 0.05. 
a-f
Within each variable, superscript letters indicate significant (P < 0.05) differences between means.  
   FSIGTT 
 
P value 
 Group Treatment  -27 Hours 0.5 Hours 21 Hours 
Group 
× treatment 
 × time 





















8.6 (7.1 to 10.3) 
10.8 (8.4 to 14.0) 
 
5.4 (4.5 to 6.4) 
6.0 (4.7 to 7.5) 
 
12.3 (6.9 to 22.1) 
15.4 (9.4 to 25.2) 
 
6.8 (5.6 to 8.2) 
4.8 (3.7 to 6.3) 
 
20.1 (12.9 to 31.3) 
13.2 (7.4 to 23.6) 
 
8.5 (6.4 to 11.2) 



























































































































3.6 ± 0.1 
3.8 ± 0.1 
 
3.7 ± 0.1 
3.7 ± 0.1 
 
3.7 ± 0.2 
3.9 ± 0.1 
 
3.8 ± 0.1 
3.8 ± 0.1 
 
4.4 ± 0.1 
3.9 ± 0.1 
 
4.1 ± 0.1 








Figure 5.1  Treatment × time interactions (P = 0.014) for AUCi from 0 to 180 minutes following 
IV bolus administration of LPS at 20 ng/kg or saline infusion in normal and EMS horses.  Data 
are expressed as geometric means and 95% CI, and are displayed on a linear scale.  Letters 






Figure 5.2  Treatment × time interactions (P < 0.001) for AUCg from 0 to 19 minutes following 
IV bolus administration of LPS at 20 ng/kg or saline infusion in normal and EMS horses.  Data 
are expressed as means ± SEM, and are displayed on a linear scale.  Letters denote significant 




Minimal Model Analysis – Minimal model results are summarized in Table 5.3.  Insulin 
sensitivity decreased in response to LPS infusion (treatment × time, P < 0.001; Figure 5.3A) and 
significant group × time interactions were also detected (P = 0.016; Figure 5.3B).  Baseline 
mean SI values did not differ between normal and EMS horses, but SI was lower overall in EMS 
horses (group; P < 0.001) across the study.  Glucose effectiveness decreased in the EMS group 
over time (group × time; P = 0.002; Figure 5.4), while treatment × time effects were significant 
for AIRg (P < 0.001; Figure 5.5).  Disposition index decreased in response to LPS infusion 
(treatment × time; P < 0.001; Figure 5.6A) and in EMS horses over time (group × time, P = 
0.044; Figure 5.6B).   
 
Correlations – Peak cytokine gene expression (refer to chapter 4)  in the blood was negatively 
correlated with minimal model parameters at 0.5 and 21 hours, and positively correlated with 
AUCi at 21 hours (Table 5.4).  
 
5.4  Discussion 
 
 Lipopolysaccharide lowered insulin sensitivity in normal and EMS horses, but did not 
induce laminitis.  Horses with EMS exhibited a transient decrease in pancreatic insulin secretion 
and greater loss of glycemic control following LPS administration.   Our hypothesis that EMS 
impacts alterations in glucose and insulin dynamics induced by LPS administration was therefore 
supported. 
 Two methods were used to assess glucose and insulin dynamics from FSIGTT data.  Area 
under the curve values for glucose and insulin were calculated for each full FSIGTT procedure 
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Table 5.3  Minimal model results for normal and EMS horses following IV bolus administration of LPS at 20 ng/kg or saline infusion.  
Data are reported as geometric means and 95% CI.  Significance was set at P < 0.05. 
 
 





























2.28 (1.24 to3.64) 
1.03 (0.59 to 1.59) 
 
3.25 (2.24 to 4.45) 
1.81 (0.86 to 3.11) 
 
0.93 (0.34 to 1.82) 
0.86 (0.48 to 1.35) 
 
3.40 (1.90 to 5.33) 
3.99 (2.39 to 6.01) 
 
0.22 (0.11 to 0.38) 
0.70 (0.33 to 1.20) 
 
0.98 (0.15 to 2.55) 
























2.64 (1.44 to 4.19) 
2.58 (1.89 to 3.38) 
 
2.66 (2.10 to 3.29) 
2.01 (1.53 to 2.56) 
 
3.25 (1.92 to 4.94) 
2.15 (1.68 to 2.69) 
 
3.10 (1.74 to 4.84) 
2.61 (1.81 to 3.54) 
 
0.64 (0.22 to 1.27) 
1.42 (0.65 to 2.48) 
 
2.74 (1.41 to 4.52) 





















660 (357 to 1055) 
533 (309 to 820) 
 
255 (143 to 400) 
212 (87 to 394) 
 
309 (10 to 1021) 
883 (518 to 1345) 
 
108 (22 to 258) 
260 (128 to 439) 
 
423 (206 to 719) 
821 (458 to 1291) 
 
333 (206 to 493) 



















1479 (603 to 2743) 
622 (182 to 1327) 
 
770 (423 to 1220) 
372 (108 to 796) 
 
250 (0.34 to 1037) 
819 (285 to 1628) 
 
379 (45 to 1039) 
923 (521 to 1439) 
 
61 (25 to 116) 
522 (286 to 829) 
 
339 (22 to 1035) 






Figure 5.3  Insulin sensitivity in normal and EMS horses following IV bolus administration of 
LPS at 20 ng/kg or saline infusion.  Data are expressed as geometric means and 95% CI, and are 
displayed on a linear scale.  A) Treatment × time (P < 0.001) and B) group × time (P = 0.016) 











Figure 5.4  Group × time interactions (P = 0.002) for Sg in normal and EMS horses following 
IV bolus administration of LPS at 20 ng/kg or saline infusion.  Data are expressed as geometric 







Figure 5.5  Treatment × time interactions (P < 0.001) for AIRg following IV bolus 
administration of LPS at 20 ng/kg or saline infusion in normal and EMS horses.  Data are 
expressed as geometric means and 95% CI, and are displayed on a linear scale.  Letters denote 




Figure 5.6  Disposition index in normal and EMS horses following IV bolus administration of 
LPS at 20 ng/kg or saline infusion.  Data are expressed as geometric means and 95% CI, and are 
displayed on a linear scale.  A) Treatment × time (P < 0.001) and B) group × time (P = 0.044) 






Figure 5.6, continued.  
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Table 5.4  Spearman’s rank correlation coefficients for associations among peak blood cytokine 
gene expression values and minimal model parameters in normal and EMS horses after receiving 

































































and for the first 19 minutes of each curve.  Area under the curve values provide an estimation of 
insulin sensitivity, and have been shown to increase in insulin-resistant horses.
254
  Examination 
of insulin responses during the first 19 minutes of the FSIGTT procedure (before administration 
of exogenous insulin) provides information on the pancreatic response to a glucose challenge, 
and increased insulin secretion suggests pancreatic compensation for peripheral IR.   
 Minimal model analysis was the other method used in this study.  This is a 
compartmental model of glucose and insulin dynamics that partitions glucose disposal into 
glucose-dependent and insulin-dependent components.
221,232,233
  The SI parameter is an index of 
peripheral insulin sensitivity and describes the ability of insulin to mediate glucose disposal.  
Glucose effectiveness describes the ability of glucose to stimulate its own disposal through mass 
effect, and becomes increasingly important to glucose homeostasis when insulin-dependent 
glucose disposal is impaired.
234,235
  The AIRg parameter assesses the pancreatic response to a 
glucose challenge, and is calculated from values obtained in the first 10 min, prior to 
administration of exogenous insulin.  Disposition index is an assessment of whether pancreatic 
insulin secretion is adequately compensating for alterations in peripheral insulin sensitivity and is 
calculated by multiplying SI with AIRg.
580
   
 Mean baseline SI values for normal horses in this study compared favorably to previously 
reported values in lean light-breed horses.
225,232,327,354,577,581
  Baseline SI values for horses with 







previously reported for a cohort of Arabian and Arabian-cross 
geldings in which obesity was induced through dietary manipulation.
581
  Values were also higher 


















   
 One reason for this discrepancy is that horses with EMS were part of an intensively 
managed research herd and several animals had lost weight prior to enrollment in this study.  
Weight loss has previously been shown to improve insulin sensitivity in horses and ponies.
582-584
  
Although a cut-off value for determining IR in horses has not been established, SI values less 






 correspond to the lowest quintile reported in a group of 46 
healthy horses and can be used as a guideline for interpreting results.
225
  Variability in baseline 
SI was seen in both normal and EMS horses between the first and second weeks of the study.  
This could represent inherent variability in glucose and insulin homeostasis due to factors such 
as stress.  Although mean baseline SI values did not differ between normal and EMS horses, a 
significant group effect was detected, indicating that SI was lower overall in horses with EMS as 
treatments were administered and procedures performed.  
 Area under the insulin curve (0 to 180 min) increased and SI values decreased in both 
normal and EMS horses 21 hours after LPS infusion.  These findings indicate that IR developed 
in response to endotoxin infusion and are consistent with previous reports by our research group 
demonstrating IR in normal horses 20 to 24 hours after LPS administration at the same 
dose.
327,354













 were reported at 20 and 24 hours, respectively. In another report, Vick, et al.
269
 detected IR 
in normal mares 24 hours after endotoxin infusion using a hyperinsulinemic-euglycemic clamp 
procedure, and inflammatory cytokine expression also increased in blood and adipose tissue.  
Blood cytokine gene expression was also measured for 4 hours following LPS administration in 
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this study (refer to chapter 4), and negative correlations were detected between peak cytokine 
expression and indices of glucose and insulin homeostasis at 24 hours.   
 Development of IR following LPS administration can be explained by the cross-talk that 
occurs between inflammatory cytokine and  insulin signaling pathways, such that  insulin 
sensitivity decreases during systemic inflammation.
91
  Serine kinases such as protein kinase C, c-
Jun NH2-terminal kinase, and inhibitor of κB kinase are integral to inflammatory signaling, and 
also phosphorylate key components of the insulin signaling pathway on serine residues, which 
induces IR.
88,114
  Although systemic inflammation might be expected to affect insulin sensitivity 
to a greater extent in horses with EMS, differences in SI did not reach statistical significance.  
However, resting hyperinsulinemia was detected in all EMS horses following LPS infusion, 
whereas only one normal horse became hyperinsulinemic, and AUCg (0 to 180 min) was 
significantly higher 21 hours after LPS in affected horses.   
 Insulin sensitivity decreased over time in horses with EMS independent of treatment.  
Stress from hospitalization and testing procedures could have contributed to IR in these animals 
because decreased insulin sensitivity has been attributed to stress in horses during prolonged stall 
confinement.
354
  Stress hormones including glucocorticoids and epinephrine decrease insulin 
sensitivity through mechanisms that include down-regulation of proteins in the insulin signaling 
cascade and inhibition of glucose uptake and storage.
100-103,585-588
  In contrast, insulin sensitivity 
increased transiently in normal horses at 0.5 hours.  Transient increases in insulin sensitivity and 




 following LPS 
administration, but increase in horses receiving saline is difficult to explain.  Insulin sensitivity 
varied markedly in EMS horses throughout the study and this suggests that stress, diet, housing, 
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or other factors influenced this variable.   Horses with EMS may therefore be less able to adapt 
to situations such as hospitalization, and IR may be exacerbated under these conditions. 
 Insulin resistance was measured in this study because microvascular dysfunction caused 
by IR plays an important role in the pathogenesis of cardiovascular disease in humans,
296
 and 
could also contribute to development of laminitis in horses with EMS.  Insulin has 
vasoregulatory functions in addition to its effects on cellular glucose uptake, and exerts mainly 
vasodilatory effects in normal individuals.
198,199
  Binding of insulin to its receptor activates 
multiple intracellular signaling pathway, with phosphoinositide 3-kinase and mitogen activated 
protein kinase most important to vasoregulation.
198,199
  Insulin resistance selectively inhibits the 
phosphoinositide 3-kinase pathway of insulin signaling, which is responsible for both insulin-
mediated glucose uptake and production of the vasodilator nitric oxide by endothelial cells.
198,199
  
Insulin signaling through the mitogen activated protein kinase pathway remains active even in 
the insulin-resistant state and leads to endothelial cell production of the potent vasoconstrictor 
endothelin-1.
198,199
  The balance therefore shifts to favor vasoconstriction during IR,  an effect 
that has been reproduced in vitro in equine digital vessels.
591
  Compensatory hyperinsulinemia 
that develops in response to IR may further exacerbate vasoconstriction.
199
  Increased 
endothelin-1 production occurs in the hoof during the development of acute laminitis,
486
 so 
horses with IR may be at increased risk of developing the disease because their vessels are 
already prone to vasoconstriction. 
 Both AUCi (0 to 19 min) and AIRg assess the pancreatic responses to a glucose 
challenge.  Increased pancreatic insulin secretion indicates compensation for peripheral IR.
327
  In 
this study, AUCi (0 to 19 min) did not change over time in normal animals with either treatment, 
but transiently decreased in EMS horses that received LPS.  This finding suggests that  
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pancreatic insulin output is acutely inhibited, and has been documented 12 hours after LPS 
administration in rats.
592
   Horses with EMS horses are more susceptible to suppression of 
pancreatic insulin output caused by inflammation.     
 Values for AIRg in normal horses in this study fell within ranges previously reported for 
lean light-breed horses, although considerable variability exists among reports.
225,232,327,354,577,581
  
In previous studies, AIRg in normal horses ranged from a mean value of 206 mU × min × L
-1 
reported by Carter et al.
581 
to 520 mU × min × L
-1 
reported by our research group in a cohort of 
16 healthy horses.
327
  These values overlap with AIRg reported in obese thoroughbred geldings 




 and the upper limit of the range is consistent with baseline 
values obtained for EMS horses in the current study.  Direct comparisons among studies may be 
hampered by variability in study populations or in methodology.  Although not statistically 
significant, AIRg was approximately 2- to 3-fold higher in EMS than normal horses, suggesting 
a degree of compensated IR.
183,226,581
  In this study, only values for EMS horses 0.5 and 21 hours 
after saline infusion were comparable to those previously reported in obese light-breed horses 




 and this provides further evidence that horses with 
EMS are susceptible to IR caused by stress.  Of note, AIRg did not increase at 21 hours after 
LPS in either normal or EMS horses, which contrasts with the finding from a  previous report 
that pancreatic compensation occurs 24 hours after  LPS administration.
327
   
 Glucose effectiveness has been identified as an important determinant of glucose 
tolerance in obese horses,
232
 but baseline values did not differ between groups in this study.  A 
decrease in Sg was detected at 21 hours in horses with EMS independent of treatment.  This 





  Reductions in Sg are reported in response to epinephrine infusion in dogs,
593,594
 
which supports the hypothesis that horses with EMS are more affected by physiological stress. 
 Although insulin secretion increased as a result of IR in both normal and EMS horses, 
glucose homeostasis was not maintained as effectively in horses with EMS when LPS was 
administered.  Higher AUCg (0 to 180 min) values were detected  in both groups at 21 hours 
post-LPS administration, but the magnitude of this increase was greater in EMS horses; 
suggesting greater loss of glycemic control.  Resting hyperglycemia was also detected in 80% of 
EMS horses compared to 17% of normal animals following LPS administration.  Changes in DI 
also support inadequate pancreatic compensation and loss of glycemic control.  Hyperglycemia 
can be explained by reduced tissue insulin sensitivity or inadequate pancreatic insulin secretion.  
It can also result from increased hepatic glucose production because the major source of glucose 
during sepsis is hepatic gluconeogenesis.
91,144,292
  Insulin normally inhibits hepatic glucose 
output, but sepsis hinders this control mechanism by inducing hepatic IR.
144,595
A recent study by 
our research group demonstrated reduced hepatic insulin clearance in horses with EMS, and this 
may be a manifestation of hepatic IR.
596
  Horses with EMS might therefore be more susceptible 
to hyperglycemia during systemic illness and this could contribute to the development of 
laminitis. 
 Mild hyperglycemia can cause endothelial damage,
573-575
  so this may explain why horses 
with EMS are at greater  risk of  developing laminitis during  systemic inflammation .
307
  
Hyperglycemia causes mitochondrial overproduction of reactive oxygen species in endothelial 
cells, leading directly to endothelial dysfunction.
572
  Reactive oxygen species incite inflammation 
and the production of inflammatory cytokines.
91,572
  They also promote vasoconstriction by 
reacting with and depleting nitric oxide
302,572





Hyperglycemia augments the production of inflammatory cytokines in septic human patients,
597
 
and has been shown to increase matrix metalloproteinase 1, 2 and 9 expression in cultured 
endothelial cells and macrophages.
401
  Inflammation, vascular dysfunction, and increased matrix 
metalloproteinase activity are key features of acute laminitis,
303,373,598
 and might therefore be 
exacerbated by hyperglycemia. 
 Hyperglycemia is also associated with increased mortality in horses with colic
288,291,599
 
and in critically ill neonatal foals.
289
  In one study, over 50% of horses with acute abdominal 
disease were reported to be hyperglycemic at presentation, and higher blood glucose 
concentrations were negatively associated with short and long-term survival.
288
  A well-known 
series of studies by Van den Berghe and colleagues
331-333
   demonstrated that maintaining tight 
glycemic control, defined as blood glucose concentrations between 80 and 110 mg/dL, 
significantly reduced morbidity and mortality in critically ill humans. Optimal blood glucose 
target ranges, however, remain an area of ongoing debate.
600-605
   
 Resting hyperinsulinemia was detected in all EMS horses and 1 normal horse after LPS 
infusion.  Recent studies have demonstrated that hyperinsulinemia per se is detrimental to 
laminar tissues independently of IR.
384,385
  In these studies, maintaining insulin at 
supraphysiologic concentrations for approximately 2 days induced laminitis in normal horses and 
ponies.  The mechanisms responsible for laminitis development are incompletely understood, but 
may include increased glucose delivery to the hoof and localized glucotoxicity as a result of 
insulin-induced vasodilation and capillary recruitment.
296,299
  Mitogenic stimulation by insulin 
and abnormal laminar tissue proliferation has also been suggested.
387,388
  Mean serum insulin 
concentrations used to induce laminitis under experimental conditions exceed 1000 µU/mL and 
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are not commonly encountered in clinical cases.   However, it is possible that moderate 
elevations in insulin adversely affect the laminae with prolonged exposure. 
 One limitation of this study was that horses in the EMS and normal groups did not differ 
with respect to body condition score or baseline insulin sensitivity, although some EMS horses 
retained abnormal characteristics such as generalized or regional adiposity.  It is possible that 
greater differences would have been detected between groups if horses had been in an 
exacerbated state of IR or obesity.  Small group sizes also limited the power of the study.   
 Despite these limitations, differences were detected between normal and EMS horses, 
particularly with regard to glycemic control and responses to stress.  Equine Metabolic 
Syndrome is thought to have an underlying genetic basis
226,246
  and manifestation of the 
syndrome may rely upon interactions between individual horses and their environment.  For 
example, exaggerated insulin responses and decreased insulin sensitivity occur in response to 
high dietary carbohydrate intake in laminitis-prone ponies.
256,257
  In humans, hyperglycemia 
during sepsis is sometime the first indication of occult diabetes mellitus.
144
  Endotoxin challenge 
may therefore have unmasked inherent defects in insulin and glucose regulation in horses with 
EMS. 
 We conclude that EMS modulates glucose and insulin responses and adversely impacts 
glycemic control following exposure to LPS.  Horses with EMS may also be more susceptible to 
derangements in glucose and insulin homeostasis as a result of stress, which could increase the 
risk of laminitis in stressful situations such as hospitalization.  Further studies are required to 




Endotoxemia as a predisposing factor for laminitis in horses 
 
 
6.1  Introduction 
 
 An ongoing challenge of laminitis research is to untangle the relationships among 
inflammation, endotoxemia, and insulin resistance (IR).  Insulin resistance
182,226,250
 and systemic 
inflammation
3
 are independent risk factor for laminitis; reportedly increasing the odds of 
laminitis 10- and 5-fold, respectively.
3,226
  The role of endotoxin is controversial, because 
endotoxin administration alone consistently fails to induce laminitis in the horse.
327,354,410,534
  
That said, laminitis is a common complication of diseases in which endotoxemia occurs, 
including gastrointestinal disease, metritis, pneumonia, and Gram-negative septicemia.
13,606,607
  
Endotoxin has also been detected in the blood of horses following experimental laminitis 
induction by carbohydrate overload,
409,423





  A theoretical basis therefore exists for its role in laminitis, possibly as 
a predisposing factor. 
 Laminitis is frequently observed in insulin-resistant horses after grazing on abundant 
pasture with high carbohydrate content, and this is referred to as pasture-associated laminitis.
298
  
Clinical experience suggests that affected horses only develop laminitis after several days of 
consuming excessive amounts of grass, which suggests a cumulative process.  Most of our 
understanding of pasture-associated laminitis comes from carbohydrate overload models.
298
  In 
these models, starch is administered in amounts that exceed small intestinal digestive capacity or 
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horses receive oligofructose (OF), which is minimally hydrolyzed within the mammalian 
foregut.
165,418,499
  Rapid fermentation of carbohydrates by lactate-producing Gram-positive 
streptococcal species in the hindgut causes a precipitous drop in cecal pH, an increase in mucosal 
permeability, and increased cecal endotoxin concentrations.
165,420,422,500-505
  Gut-derived 
endotoxins, exotoxins, and vasoactive amines translocating from the gastrointestinal tract may 
directly trigger laminitis or indirectly induce the disease by inciting systemic inflammation.
375
  
Acute laminitis shares many characteristics with sepsis-associated organ failure, and might be a 
manifestation of end-organ damage in the horse.
373
 
 Although these carbohydrate overload models are an imperfect method of studying 
pasture-associated laminitis because carbohydrate is administered as a single large bolus, grazing 
horses can theoretically consume a comparable amount of carbohydrate in one day under certain 
pasture conditions.
499
  It is also conceivable that minor intestinal carbohydrate overload events 
occur in grazing horses and trigger laminitis in susceptible animals.
298
  Systemic inflammation 
lowers insulin sensitivity,
91
 and IR is a known risk factor for laminitis, so these factors may 
combine to induce the disease.  Our research group previously examined this situation by 
administering lipopolysaccharide (LPS) and OF to horses.
164 
 Lipopolysaccharide lowers insulin 
sensitivity in horses
269,327,354
 and OF administration also affects glucose dynamics,
608
 so it was 
postulated that a combination of these treatments would alter glucose and insulin dynamics to a 
greater extent than each factor alone and cause laminitis.  Horses received LPS or saline and then 
OF, and the incidence and severity of laminitis tended to increase in horses that received  both 
treatments .
164
  Both LPS and OF administration lowered insulin sensitivity, but an additive 
effect was not documented.   An alternative hypothesis is therefore that initial inflammatory 
164 
 
events induced by LPS prime the immune system and this results in a more severe inflammatory 
reaction following carbohydrate overload. 
 In what has been termed the “two-hit hypothesis” of organ damage, sequential exposure 
to inflammatory stimuli can exacerbate inflammatory responses and increase mortality during 
sepsis.
440
  The initial inflammatory response primes the immune system and causes an 
exaggerated response to a second, sometimes innocuous, stimulus.
437-439
  Animal models have 
been developed to examine this phenomenon using combinations of fecal peritonitis, gut 
ischemia-reperfusion injury, hemorrhagic shock, burn injury, and LPS administration.
442-445
  
Increased infiltration of the liver and lungs with neutrophils, higher pro-inflammatory cytokine 
and chemokine expression, and a greater incidence of acute lung injury have been demonstrated 
in animals that receive multiple treatments.
442-445
  In humans, neutrophils from trauma patients 
are primed in vivo by inflammatory mediators and release more superoxide anion than those 
from healthy individuals when harvested and stimulated in vitro.
446
  Trauma patients may 
therefore be at increased risk of multiple organ failure in the face of a second inflammatory event 
such as hemorrhage or infection.
446,609,610
    In LPS models, the initially inflammatory event is 
thought to enhance Toll-like receptor 4 reactivity and augment pro-inflammatory signaling 
pathways, while also disrupting negative regulatory mechanisms.
442
  Extrapolation of the two-hit 
hypothesis to the horse might explain why sequential administration of LPS and OF increased 
the severity of laminitis as reported by Tóth, et al.,
164
 and provides a theory linking multiple 
carbohydrate overload events to the pathogenesis of pasture-associated laminitis. 
 The current study was performed to provide evidence for the two-hit hypothesis in 
horses.  We hypothesized that that the systemic inflammation induced by intestinal carbohydrate 
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overload would be more pronounced in horses that were pre-treated with LPS and horses 
receiving both treatments would have a greater incidence and severity of laminitis. 
 
6.2  Materials and methods 
 
Animals – All horses used in this study had chronic diseases or behavioral abnormalities that 
warranted euthanasia.  Animals were either donated to the University of Tennessee for 
euthanasia by their owners or were purchased for the study.  Adult light breed geldings and 
nonpregnant mares were accepted, and animals with active laminitis or other lameness severe 
enough to interfere with laminitis assessments during the study were excluded. 
 Twenty-four mares (10) and geldings (14) met the inclusion criteria.  Horses ranged in 
age from 3 to 25 years (mean 13.3 year; median 13.5 years), weighed between 334 and 555 kg 
(mean 402.8 kg; median 385), and had body condition scores of 2 to 8.5 (mean 4.5; median 4) on 
the scale of 1 to 9 developed by Henneke, et al.
249
  Breeds included Tennessee Walking Horses 
and Tennessee Walking Horse crosses (8), Quarter Horses (5), Paint Horses (3), American 
Saddlebreds and Saddlebred crosses (3), Appaloosas and Appaloosa crosses (2), an Arabian (1), 
Morgan cross (1), and Haflinger cross (1).  Horses were to be euthanized for the following 
reasons:  musculoskeletal disease (10), behavioral abnormalities (5), blindness (4), recurrent 
uveitis (3), neurological abnormalities (3), unexplained weight loss (2), cardiac disease (1), and 
squamous cell carcinoma (1).  Multiple problems were present in some animals.  The study 





Study Design – Horses were housed in 3.7 m × 3.7 m box stalls in the Veterinary Teaching 
Hospital for the duration of the study.  Body weight measurements and physical examinations 
were performed at the time of arrival.  Grass hay and water were provided ad libitum at all times.  
Beginning 2 days before testing, all animals received OF (1 g/kg daily) added to the basal ration 
and physical examination monitoring was initiated.  Baseline blood samples were collected for 
analysis of whole blood inflammatory cytokine gene expression and measurement of plasma 
glucose and serum insulin concentrations at 0800 on the first day of testing (designated as time = 
-24 hours).  Baseline blood samples were also submitted for complete blood count (CBC) 
analysis.  Horses were then randomly assigned to receive an 8-hour continuous rate infusion 
(CRI) of either LPS (LPS-OF group, n = 12) or saline (SAL-OF group, n = 12).  At 0800 the 
next morning (time = 0 hours), OF was administered to all horses via nasogastric tube at a 
dosage of 5 g/kg.  Animals were monitored for the developments of laminitis over the next 48 
hours using the Obel grading scale.
508
  Horses were euthanized by intravenous barbiturate 
overdose
a
 and tissues were harvested within 4 hours of the onset of Obel grade 2 laminitis or at 
48 hours if Obel grade 2 laminitis did not develop.  Liver biopsies were performed under 
standing sedation 24 hours after OF administration in horses that had not developed laminitis by 
this time.  Physical examinations and lameness evaluations were performed hourly during LPS or 
saline infusion, and every 4 hours thereafter.  Blood samples were collected for measurement of 
inflammatory cytokine gene expression at -24, -20, -16, and -12 hours, then every 4 hours from 0 
to 48 hours.  Plasma and serum were collected for glucose and insulin measurements every 4 
hours from time = -24 to 0 hours, then every 2 hours from 0 to 48 hours.  An additional CBC was 
submitted at -20 hours.   
 
                                                 
a
 Beuthanasia D, Schering-Plough Animal Health Corp, Union, NJ 
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Lipopolysaccharide and saline administration – A 14-g polypropylene IV catheter
b
 was 
aseptically placed in the jugular vein 12 hours prior to LPS or saline administration.  Horses in 
the LPS-OF group received commercially available Escherichia coli O55:B5 LPS solution
c 
infused via the IV catheter at a dose of 5 ng/kg/hr for 8 hours.  Lipopolysaccharide was diluted in 
sterile saline so that an infusion rate of 100 mL/hr provided the appropriate LPS dose for each 
animal.  Horses in the SAL-OF group received a CRI of sterile saline at a rate of 100 mL/hr for 8 
hours.   
 
Oligofructose administration – Horses received 1 g/kg OF
d 
divided into two daily feedings and 
mixed with 0.5 kg of oats for 3 days prior to laminitis induction to adapt the hindgut flora to this 
carbohydrate.  A laminitis induction dose of 5 g/kg OF was dissolved in 4 L of warm water and 
administered via nasogastric intubation at time = 0 hours.  
 
Measurement of blood variables – Blood samples for CBC analysis were collected into 
ethylenediaminetetraacetic acid anticoagulant tubes and analyzed by the University of Tennessee 
Clinical Pathology laboratory.   
 
Whole blood inflammatory cytokine gene expression – Blood samples for quantitation of 
interleukin (IL)-1β, IL-6, IL-8, IL-10, TNF-α, and β-glucuronidase (B-Gus) gene expression 
were collected into whole blood RNA collection tubes
e 
and allowed to incubate at room 
temperature for 8 hours, then stored at – 20 °C until analyzed.  Total RNA extraction and real-
                                                 
b
 Abbocath-T 14 G X 140 mm, Abbott Laboratories, North Chicago, IL 
c




 P95, formerly marketed as Beneo
®








time polymerase chain reaction were performed as previously described (refer to chapter 2).  The 
comparative CT (ΔΔCT) method was used to determine fold changes in inflammatory cytokine 
gene expression.
509
  Cytokine expression was normalized to the housekeeping gene B-Gus and 
each horse’s baseline value was used as the calibrator.  Baseline gene expression was therefore 
equal to a 1-fold change for all cytokines. 
 
Plasma glucose and serum insulin concentrations – Plasma and serum samples were collected 
into appropriate anticoagulant or serum tubes.  Tubes were centrifuged at 1,000 × g for 10 
minutes and plasma or serum was harvested and stored at –20 ºC until analyzed.  Plasma glucose 
and serum insulin concentrations were measured as previously described (refer to chapter 3). 
 
Liver Biopsies – Samples were collected for gene expression analysis and histopathology as 
previously described (refer to chapter 4).    
 
Postmortem tissue collection – Approximately 20 g of both liver and lung tissues were harvested 
immediately after euthanasia and trimmed into 2 cm × 2 cm × 2 cm blocks.  Limbs were 
disarticulated at the metacarpophalangeal and metatarsophalangeal joints and laminar tissue 
obtained from all four hooves by sectioning with a bandsaw, as previously described.
361
  Mid-
dorsal laminar sections were trimmed into 2 cm × 1 cm × 0.5 cm strips using a scalpel.  Two 
blocks of each tissue were fixed in 10% neutral buffered formalin, and the rest of the tissue was 
immediately placed on dry ice and transported to a -80°C freezer for storage.  Cecal and right 




Histopathology – Routing hematoxylin and eosin staining was performed on all formalin-fixed 
tissue samples, and tissue sections (5 µm thickness) were evaluated using light microscopy by 
one of two board-certified veterinary pathologists who remained blinded to treatment group 
allocations.    Periodic acid-Schiff staining was performed on laminar sections, and laminitis was 
graded using a previously described histological scoring system on a scale of 0 (no lesions) to 3 
(severe lesions).
361
   
 
Inflammatory cytokine gene expression in liver, lung, and laminar tissues – Total RNA was 
obtained from frozen postmortem liver, lung, and laminar tissue samples using guanidinium 
thiocyanate-phenol-chloroform extraction.
611,612
  Tissue samples (200 mg for laminar tissue and 
liver; 500 mg for lung) were disrupted in guanidine thiocyanate-phenol solution
f
 (1 mL per 100 
mg tissue) while still frozen using a rotor-stator homogenizer.
g
  Samples were incubated at room 
temperature for 5 minutes.  Chloroform
h 
(0.5 ml per 100 mg tissue) was added to each sample, 
followed by a 5 minute incubation at room temperature and centrifugation (2,770 × g for 20 
minutes at 4°C).  The aqueous phase was collected and transferred to a clean tube, and RNA was 
precipitated by adding 100% isopropyl alcohol
h 
(0.5 mL per 100 mg tissue).  Samples were 
incubated at room temperature for 20 minutes, then centrifuged (2,770 × g for 20 minutes at 
4°C).  The RNA pellet was then resuspended and washed with 70% ethanol
h 
(1 mL per 100 mg 
tissue), centrifuged (2,770 × g for 20 minutes at 4°C), and air-dried for 10 minutes at room 
temperature.  The RNA pellet was resuspended in 100 µL of nuclease-free water and purified 
using a commercially available kit
i 
accordingly to the manufacturer’s instructions.   








 700, Fisher Scientific, Pittsburgh, PA 
h




 Mini Kit, Qiagen, Valencia, CA 
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 A commercially available kit
j
 was used to perform column-based total RNA extraction 
from frozen liver biopsy samples accordingly to the protocol provided by the manufacturer.  This 
method was chosen because it achieved the greatest RNA yield from small samples in 
preliminary tests.   
 Concentration and purity of RNA in each sample was measured via spectrophotometry.
k
  
Reverse transcription was performed using a kit
l
 and 1 μg of RNA was loaded into each reaction.  
Complementary DNA was then diluted 1:10 with 180 µL of nuclease-free water.   
 Real time PCR was performed for IL-1β, IL-6, IL-8, IL-10, TNF-α, and β2 microglobulin 
(B2M) as described for whole blood.  β2 microglobulin was selected as the housekeeping gene 
because B2M expression in tissue was more stable than expression of B-Gus in preliminary tests.  
Cytokine expression in each sample was normalized to B2M and ΔΔCT calculations were 
performed using a pooled calibrator value that was generated for each cytokine by averaging all 
ΔCt values for that gene.    
 
Statistical Analysis – Mixed model analysis of variance (ANOVA) for repeated measures was 
performed using computer software
m
 to determine effects of treatment, time, and main effect 
interactions.  Area under the curve (AUC) values for whole blood inflammatory cytokine gene 
expression were calculated using the trapezoidal method and computer software.
n
  Blood gene 
expression data was available for all horses until 24 hours, after which point some animals were 
removed from the study.  To maintain consistency among animals, calculations for AUC values 
included only points up to 24 hours.  Blood gene expression data, plasma glucose, serum insulin, 




 Mini Kit, Qiagen, Valencia, CA 
k
 NanoDrop ND-1000, Thermo Fisher Scientific, Wilmington, DE 
l
 High Capacity cDNA Reverse Transcription Kit with RNase Inhibitor, Applied Biosystems, Foster City, CA 
m
 PROC MIXED, SAS, version 9.2, SAS Institute, Inc., Cary, NC 
n
 SAS, version 9.2, SAS Institute, Inc., Cary, NC 
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and selected tissue gene expression and AUC variables required log transformation to fit 
ANOVA normal distribution assumptions.  Transformed data are reported as geometric means 
with 95% CI.  All other data are reported as least squares means ± SEM.  The autoregressive 
correlation parameter was excluded from the final model for analysis of IL-6 and TNF-α 
expression in blood.  Mean separation was performed using Fisher’s protected least significant 
difference and significance was set at P < 0.05.   
 Mean blood cytokine expression at each time point was compared to the pre-infusion 
baseline using one-sample t-tests with Bonferroni correction for multiple comparisons.  
Significance was set at P < 0.0016 after the Bonferroni correction was applied.  For all horses 
that had liver biopsies performed at 24 hours, gene expression was compared between liver 
biopsy and liver necropsy samples using paired t-tests.  Two-tailed Fisher’s exact tests were used 
to compare the incidence of laminitis and histologic findings between treatment groups.  Blood 
cytokine AUC values and tissue gene expression results were correlated with time to onset of 
Obel grade 1 and 2 laminitis in responders using Spearman’s rank correlation coefficients.  
Associations between blood cytokine expression and vital parameters were also assessed using 
Spearman’s rank correlation coefficients.  Correlation analyses were performed at the level of the 
individual animal.  Significance was set at P < 0.05 for all correlations. 
 Treatment was not statistically significant in any analyses, so horses were reclassified as 
responder and non-responders based upon the development of clinically detectable laminitis.  
Treatment was eliminated from the model and all analyses were repeated.  Because responders 





6.3  Results 
 
Clinical signs – Treatment groups did not differ significantly with respect to age, body weight or 
body condition score.  All horses that received LPS exhibited transient depression, anorexia, 
muscle fasciculations, or mild colic signs such as pawing, stretching, or sternal recumbency 
during the infusion.  Profound depression, anorexia, and/or abdominal discomfort developed in 
15/24 horses following OF administration, mild responses were noted in 8/24 horses, and 1 horse 
showed no change in demeanor following OF administration.  Diarrhea was observed in 21/24 
horses between 8 and 32 hours following OF administration and continued in 3 horses until 44 or 
48 hours.  Cardiovascular compromise developed in 3 animals following the onset of diarrhea, 
and each received 10 to 20 L of crystalloids to maintain hemodynamic stability. 
 Treatment (LPS versus saline) × time effects were significant for mean rectal temperature 
(P < 0.001; Figure 6.1A), heart rate (P = 0.003; Figure 6.1B), and respiratory rate (P < 0.001; 
Figure 6.1C).  Biphasic responses corresponding to LPS infusion and OF administration were 
detected for these variables in the LPS-OF group, while single peaks following OF 
administration occurred in the SAL-OF group.  During LPS infusion, mean rectal temperature 
and heart rate peaked from -22 to -16 hours. In contrast, there was an initial decrease in 
respiratory rate, followed by an increase during the same time period.  Mean rectal temperature 
and heart rate increased in both groups approximately 12 to 24 hours after OF administration, 
and respiratory rate increased at 8 hours in the SAL-OF group and from 20 to 24 hours in both 
groups.  Peaks following OF administration did not differ in magnitude between groups.   
 When horses were reclassified as responders and non-responders on the basis of whether 




Figure 6.1  Changes in physical examination parameters of horses receiving either an 8-hour 
LPS CRI (5 ng/kg/hr) or saline CRI, followed by administration of OF (5 g/kg).  Data are 
expressed as means ± SEM.  *LPS-OF:  Significant difference from baseline.  
†
SAL-OF:  
Significant difference from baseline.  Treatment (LPS versus saline) × time effects were 
significant for A) mean rectal temperature (P < 0.001), B) mean heart rate (P = 0.003), and C) 
mean respiratory rate (P < 0.001).  The vertical dotted line denotes the time of OF 










Figure 6.1, continued.  
176 
 
P = 0.008), corresponding to the onset of laminitis (data not shown).  Mean rectal temperature 
and respiratory rate did not differ between responders and non-responders.  All responders 
showed clinical signs of systemic inflammation following OF administration, and 13/15 (87%) 
had diarrhea.  All of the non-responders (n = 9) showed transient clinical signs of systemic 
inflammation (n = 8) or diarrhea (n = 8) after OF was administered.  One non-responder (from 
the SAL-OF group) became acutely recumbent and developed severe metabolic acidosis at 32 
hours, and was euthanized early. 
 
Laminitis – Laminitis developed in 8/12 (67%) of horses in the LPS-OF group compared to 7/12 
(58%) horses in the SAL-OF group, and this was not significant when analyzed using the 
Fisher’s exact test.  The overall laminitis induction rate was therefore 63%.  In the 15 responders, 
Obel grade 2 laminitis developed at 20 hours (3 horses), 24 hours (8 horses), and 28 hours (4 
horses), and 4 horses continued to deteriorate rapidly before euthanasia was performed.  No more 
than 12 hours elapsed from the time laminitis was first detected to the onset of Obel grade 2 in 
any animal.  Neither time to onset of laminitis nor time to onset of Obel grade 2 laminitis 
differed between treatment groups.   
 
Hematology – Leukocyte counts were not significantly affected by LPS administration (data not 




 was detected in 3/12 (25%) 
horses when measured 4 hours after starting the LPS infusion, but not in  horses that received  
saline. 
 
                                                 
o
 Reference ranges used by the University of Tennessee Clinical Pathology laboratory 
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Whole blood cytokine gene expression – Treatment (LPS versus saline) × time effects were 
significant for interleukin (IL)-1β (P < 0.001; Figure 6.2A), IL-6 (P = 0.040; Figure 6.2B), and 
tumor necrosis factor-α (TNF-α; P = 0.016; Figure 6.2C).  Significant treatment effects were 
detected for IL-8 (P = 0.002; Figure 6.2D), and time effects were significant for IL-10 (P < 
0.001; Figure 6.2E).  During LPS or saline infusion, IL-1β and IL-6 expression differed between 
treatment groups from -20 to -12 hours and TNF-α expression differed from -16 to -12 hours.   
 Differences in inflammatory cytokine expression were detected between treatment groups 
on occasion after OF administration, but did not follow a recognizable pattern.  Interleukin-1β 
expression increased relative to baseline during LPS infusion in the LPS-OF group, and 
following OF administration in both groups.  Increases in IL-6 and IL-8 expression were also 
detected in the LPS-OF group during LPS infusion and after OF administration, while a decrease 
in IL-8 expression relative to baseline was noted at -16 hours in the SAL-OF group.  Expression 
of IL-10 and TNF-α did not differ significantly from baseline in either group, but IL-10 
expression increased approximately 16 to 28 hours after OF administration in both treatment 
groups. 
 Area under the curve values for IL-1β (P < 0.001), IL-6 (P < 0.001), and IL-8 (P = 0.002) 
expression were higher in the LPS-OF group compared to the SAL-OF group during the time 
period from -24 to 0 hours when infusions were performed (Table 6.1).  Area under the curve for 
IL-8 was also higher in the LPS-OF group after OF administration (P = 0.014). 
 When responders and non-responders were compared, IL-1β expression remained 
elevated for longer relative to baseline in responders after OF administration, but there were no 
differences in the magnitude of responses (Figure 6.3).  Area under the curve for IL-1β was   
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Figure 6.2  Change in whole blood gene expression of IL-1β, IL-6, TNF-α, IL-8, and IL-10 in 
horses receiving either an 8-hour LPS CRI (5 ng/kg/hr) or saline CRI, followed by 
administration of OF (5 g/kg).  Data are expressed as geometric means and 95% CI, and are 
displayed on a logarithmic scale.  Significance was set at P < 0.0016 for one-sample t-test 
comparisons between cytokine expression at each time point, compared to baseline.  Significance 
for ANOVA main effects and interactions was defined by P < 0.05.  *LPS-OF:  Significant 
difference from baseline.  
†
SAL-OF:  Significant difference from baseline.  Treatment (LPS 
versus saline) × time effects were significant for A) IL-1β (P < 0.001), B) IL-6 (P = 0.040), and 
C) TNF-α (P = 0.016).  D) Treatment effects were significant for IL-8 (P = 0.002).  E) Time 



























Figure 6.2, continued.  
184 
 
Table 6.1  Area under the curve values for whole blood inflammatory cytokine expression in 
horses receiving either an 8-hour LPS CRI (5 ng/kg/hr) or saline CRI, followed by 
administration of OF (5 g/kg).  Area under the curve values were also compared between 
laminitis responders and non-responders.  Comparisons were made during the time period from  
-24 to 0 hours when infusions were performed and from 0 to 24 hours after OF administration.  
Values for IL-8 and TNF-α (0 to 24 hours) in comparisons of LPS-OF and SAL-OF groups and 
TNF-α (0 to 24 hours) in comparisons of responders and non-responders are expressed as means 





Table 6.1, continued. 
a,b
For each variable, letters indicate significant differences between LPS-OF and SAL-OF groups during 
LPS or Saline infusion 
c,d
Letters indicate significant differences between LPS-OF and SAL-OF groups after OF administration 
e,f
Letters indicate significant differences between Responders and Non-responders after OF administration  





(-24 to 0 hours) 
P value  
After OF 
administration 
(0 to 24 hours) 
P value 














75.5 (48.7 to 117.1) 









70.3 (47.7 to 103.6)
a 




66.0 (42.8 to 101.7) 









127.4 (63.1 to 257.4)
a 

















29.8 (16.7 to 53.2) 
31.0 (21.1 to 45.5) 
0.909  
 
44.3 (22.4 to 87.6) 









40.3 (27.2 to 59.7) 
23.6 (15.5 to 35.8) 
0.075  
 
36.7 ± 5.4 
27.8 ± 5.9 
0.275 








48.4 (26.6 to 88.0) 
41.6 (23.7 to73.0) 
0.738  
 
100.4 (67.0 to 150.4)
e 










37.2 (25.2 to 54.9) 
49.2 (25.4 to 95.2) 
0.442  
 
59.2 (39.8 to 88.0) 









50.4 (22.9 to 110.6) 
64.0 (24.7 to 165.9) 
0.703  
 
114.5 (45.7 to 286.7) 









30.6 (19.8 to 47.3) 
30.0 (16.8 to 53.7) 
0.958  
 
61.9 (39.0 to 98.3) 









31.0 (20.4 to 47.0) 
30.6 (19.7 to 47.5) 
0.968  
 
32.9 ± 5.1 






Figure 6.3  Whole blood IL-1β expression in laminitis responders and non-responders.  Data are 
expressed as geometric means and 95% CI, and are displayed on a logarithmic scale.  
Significance was set at P < 0.0023 for one-sample t-test comparisons between cytokine 
expression at each time point, compared to baseline.  Significant ANOVA main effects were not 
detected (P > 0.05).  
§
Responders:  Significant difference from baseline.  
‡
Non-responders:  





significantly higher in responders than non-responders for the period of time following OF 
administration (P = 0.010).  
 
Liver, lung, and laminar tissue cytokine gene expression – Results are summarized in Table 6.2.  
No differences were detected between LPS-OF and SAL-OF groups, but significant differences 
were detected for all tissues between responders and non-responders.  When liver biopsy and 
post mortem liver samples were compared in non-responders (n = 9), mean IL-8 expression was 
significantly higher (approximately 2.5-fold difference) in post mortem samples.  
 
Histopathology – All liver biopsy specimens obtained at 24 hours from non-responders were of 
diagnostic quality.  Mild portal inflammation and/or sinusoidal neutrophil infiltration was 
identified in 7/9 (78%) non-responders.   
 Mild portal inflammation was identified in liver samples from 22/24 (92%) horses at 
necropsy.  The 2 horses without evidence of portal inflammation were both non-responders.  
Nascent microthrombi and/or hemorrhage were noted in medium to large pulmonary arteries in 
11/24 (46%) horses, including 5/12 (42%) horses in the LPS-OF group and 6/12 (50%) horse in 
the SAL-OF group.  When classified as responders and non-responders, lung lesions were 
identified in 8/15 (53%) responders and 3/9 (33%) non-responders.  These differences were not 
significant when analyzed using the Fisher’s exact test.  Significant lesions were not identified in 
the colon or cecum.  
 Gross evidence of mild chronic laminitis (e.g. rotation or remodeling of the distal 
phalanx) was seen in 3 horses at necropsy.  Laminar histologic scores (calculated as the sum of 
the grades for each hoof) did not correspond to Obel scores at the time of euthanasia 
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Table 6.2  Tissue gene expression of inflammatory cytokines in laminitis responders and non-responders.  Gene expression in post 
mortem samples was compared for all tissue types.  Post mortem liver samples in responders (obtained at approximately 24 hours) 
were also compared to 24-hour liver biopsy samples in non-responders.  Values for IL-10 and TNF-α in liver biopsy comparisons and 
IL-1β in post mortem liver and lung comparisons are expressed as means ± SEM.  All other data are expressed as geometric means 
and 95% CI.  Significance was set at P < 0.05. 
 
  Relative gene expression 








1.4 (1.0 to 2.0)
a 





                     
0.7 ± 0.2
b
    
 
1.5 ± 0.2   
1.0 ± 0.3                     
 
1.3 (0.8 to 2.1)
 
0.6 (0.4 to 1.1)
 
 
1.5 (1.1 to 2.2)
a 









1.4 (0.7 to 2.6)
a 
0.5 (0.2 to 1.0)
b 
 
1.4 (0.7 to 2.6)
 
0.6 (0.4 to 1.0)
 
 
1.3 (0.7 to 2.5) 
0.6 (0.3 to 1.2) 
 
1.8 (0.8 to 3.7)
a 
0.1 (0.1 to 0.3)
b 
 
2.0 (1.0 to 3.9)
a 









1.5 (0.9 to 2.3)
a 
0.2 (0.1 to 0.5)
b 
 
1.5 (0.9 to 2.3)
a 
0.5 (0.2 to 1.2)
b 
 
1.5 (1.0 to 2.2)
a 
0.5 (0.3 to 0.8)
b 
 
1.3 (0.9 to 1.9)
a 
0.6 (0.4 to 1.1)
b 
 
1.6 (1.0 to 2.7)
a 









2.6 ± 0.5 
1.9 ± 0.6     
 
1.8 (1.0 to 3.1)
a 
0.4 (0.4 to 1.0)
b 
 
1.5 (1.0 to 2.1)
a 
0.5 (0.3 to 0.9)
b 
 
0.8 (0.4 to 1.7) 
1.3 (0.5 to 3.0) 
 
1.0 (0.5 to 2.1) 










                    
0.5 ± 0.1
b
    
 
1.2 (0.9 to 1.6)
 
0.7 (0.5 to 1.2)
 
 
0.8 (0.6 to 1.1)
 
1.4 (0.8 to 2.2)
 
 
1.3 (0.8 to 2.2)
 
0.6 (0.3 to 1.1)
 
 
1.4 (0.8 to 2.4) 
0.6 (0.2 to 1.4) 
a,b




(Spearman’s rho = 0.133; P = 0.536).  Changes consistent with laminitis were identified in at 
least one hoof from all horses, including non-responders.  In individual samples with histologic 
laminitis grades of 1 and 2, typically less than 25% of the secondary epidermal laminae were 
affected.  Grade 3 lesions involved global changes to the laminae in most specimens.  A 
histologic grade of 3 was assigned to at least one hoof from 3 horses.  Of these, one had laminitis 
that had progressed beyond Obel grade 2 in the short time interval between detection and 
euthanasia and 2 were non-responders (including an animal with evidence of mild chronic 
laminitis).   
 
Glucose and insulin dynamics – Time effects were detected for plasma glucose (P < 0.001; 
Figure 6.4A) and serum insulin (P < 0.001; Figure 6.4B).  Time effects remained significant 
when horses were grouped as responders and non-responders, and a group effect was detected, 
which indicates that glucose concentrations were higher overall in responders (P = 0.012).   
 
Correlations – Cytokine gene expression was positively correlated with rectal temperature, heart 
rate, and respiratory rate (Table 6.3).  Positive correlations were also identified among 
inflammatory cytokines (data not shown).   
 Within the responder group, there were no biologically significant correlations detected 









Figure 6.4  Plasma glucose and serum insulin concentrations of horses receiving either an 8-hour 
LPS CRI (5 ng/kg/hr) or saline CRI, followed by administration of OF (5 g/kg).  Data are 
expressed as geometric means and 95% CI, and are displayed on a logarithmic scale.  
¶
Refers to 
time effects and denotes points that are significantly different from baseline.  Time effects were 
detected for A) plasma glucose (P < 0.001) and B) serum insulin (P < 0.001).  The vertical 
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Table 6.3  Spearman’s rank correlation coefficients for associations among whole blood gene 
expression values and physical examination parameters in horses receiving either an 8-hour LPS 
CRI (5 ng/kg/hr) or saline CRI, followed by administration of OF (5 g/kg).  Significance was set 
at P < 0.05 and P values are displayed in parentheses. 
 
























































6.4  Discussion 
 
 Systemic inflammation developed in response to LPS infusion and alimentary 
carbohydrate overload in this study.  The magnitude of the systemic inflammatory response to 
carbohydrate overload and the incidence of laminitis were not affected by endotoxin 
pretreatment, so our hypothesis was not supported.  We have, however, provided evidence that 
inflammatory responses in tissues such as the liver and lungs may be more severe in horses that 
develop carbohydrate overload laminitis when compared to non-responders.  Further studies are 
needed to confirm these findings and determine the role of specific organs and inflammatory 
mediators in carbohydrate overload laminitis. 
 Increases in rectal temperature, heart rate, and respiratory rate observed during LPS 
infusion are consistent with previous studies in which LPS was administered to horses as a CRI 
or single bolus, including the studies described in chapters 3 and 4.
164,327
  When LPS was infused 
for 8 hours in a previous study,  changes in physical examination variables persisted the duration 
of the CRI.
164
  These variables were also affected by OF administration in the study reported 
here, which indicates that systemic inflammation developed in response to intestinal 
carbohydrate overload.  Oligofructose administration at high doses has also been associated with 
clinical signs of systemic inflammation.
165,409
  It has previously been reported that clinical signs 
of systemic inflammation develop approximately 24 hours after OF administration when the 
lower 5 g/kg dose is used.
164,608
  Diarrhea also develops after OF administration, and the timing 
and duration observed in this study were consistent with previous reports.
164,608
  In all studies 
performed to date, including this one, laminitis develops approximately 20 to 36 hours after OF 





 Lipopolysaccharide infusion increased the expression of IL-1β, IL-6, and IL-8 in whole 
blood.  Although LPS administration altered the expression of TNF-α over time, and IL-10 
changed over time in both groups, expression of these cytokines did not differ significantly from 
baseline values in either treatment group or when responders and non-responders were 
compared.  Lipopolysaccharide is recognized by many cell types through the cell-surface pattern 
recognition receptor Toll-like receptor 4,
13
 and stimulates the production of inflammatory 
mediators that regulate both the innate and adaptive immune responses.
7,11
  The pro-
inflammatory cytokines IL-1β, IL-6, IL-8 and TNF-α have been shown to increase in response to 
LPS administration in horses.
269,410,506,534
  It is not clear why TNF-α did not increase following 
LPS infusion in this study, but the timing of measurements serves as one explanation.  Tumor 
necrosis factor-α peaks early in the inflammatory response and can decline rapidly within 1-2 
hours, even during continuous LPS infusion.
18,410,511
  The method of LPS administration in this 
study may also limit direct comparisons to studies in which LPS was administered as a bolus.  
For instance, Nieto, et al.
506
 described robust increases in inflammatory cytokine gene expression 
that declined substantially 3 hours after LPS was administered intravenously as a 30 ng/kg bolus.  
A comparable cumulative LPS dose was delivered over 6 hours in the current study, so the lower 
cytokine responses observed here reflect the slower rate of administration.   Similarly, in the 
study performed by Vick, et al.,
269
 a higher dosage of 45 ng/kg was used.   
 Inflammatory gene expression results show that both LPS and intestinal carbohydrate 
overload induce systemic inflammation, but there was little evidence that pretreatment with LPS 
enhances the inflammatory response to carbohydrate overload.    Only AUC for IL-8 was higher 
following OF administration when horses were pretreated with LPS, indicating that endotoxin 
had a priming effect on the release of this cytokine.  Interleukin-8 was the only cytokine that 
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showed this response, so results must be interpreted with caution.  However, earlier and more 
pronounced expression of cytokine-induced neutrophil chemoattractant, the rat ortholog of IL-8, 
has been described in primed alveolar macrophages in a rodent two-hit model.
443
   
 Consistent with other reports, peak expression of IL-1β and IL-6 occurred 20 hours 
following the administration of OF, while 2 peaks in IL-8 expression were detected at 20 and 44 
hours.  In a previous study, TNF-α protein plasma concentrations increased12 to 24 hours after 
OF was administered at a dosage of 10 g/kg.
409
  In addition, results reported in chapter 2 show 
that IL-1β, IL-6, IL-8, and IL-10 expression increased over the 24 hours that followed OF 
administration at the higher dosage.   
 Blood cytokine responses did not appear to differ markedly when LPS and OF 
administration were compared in this study. It has been suggested that the duration of 
inflammation is longer with intestinal carbohydrate overload than experimental endotoxemia 
because this model is closer to cecal ligation and puncture models in rodents.
613
 Accordingly, 
this might explain why carbohydrate overload induces laminitis whereas short-lived 
inflammatory reactions to LPS do not.  Lipopolysaccharide  induced similar blood cytokine 
expression to carbohydrate overload in this study, but laminitis did not develop before OF was 
administered.
164
  One explanation for this finding is that factors other than inflammation are 
important to the pathogenesis of laminitis, including the release of vasoactive amines from the 
hindgut.
375,421
  Alternatively, cytokine production in circulating leukocytes may contribute less to 
systemic inflammation in this model than cytokine production within tissues such as the liver and 
lung.
517,519,614
  Serial tissue sampling would have been required to assess the duration of 
inflammation in tissues, and should be considering in future studies.  Early removal of 
responders could conceivably have hindered detection of prolonged cytokine expression in the 
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blood following OF administration, but it is unlikely because IL-1β expression declined by 20 
hours in this group and other cytokines were not significantly different from non-responders. 
 Endotoxin tolerance often occurs in circulating leukocytes after repeated LPS 
exposures,
76,448,517
 and we documented this finding in the study described in chapter 3.  Previous 
studies have also detected endotoxin tolerance in horses.
460,461
  In this study, cytokine production 
increased following carbohydrate overload even though LPS was administered 24 hours 
beforehand.  This suggests that endotoxin tolerance did not develop in the horses studied here or 
that other agents stimulated the immune system during intestinal carbohydrate overload.  Both 
LPS and Gram-positive bacterial products are expected to escape from the gut following OF 
administration.  Heterotolerance between different Toll-like receptor agonists occurs,
450,615
 but 
the variety and number of toxins escaping the intestine may stimulate multiple signalling 
pathways.   
 Tumor necrosis factor-α gene expression did not increase in blood following 
carbohydrate overload in this study despite the fact that OF administration has previously been 
associated with higher TNF-α protein concentrations.
409
  This is consistent with our previous 
findings that TNF-α gene expression failed to increase in blood following 10 g/kg OF 
administration (refer to chapter 2).  It is possible that organs such as the liver and lungs, rather 
than circulating leukocytes, are the primary source of circulating TNF-α protein following 
carbohydrate overload.  These organs are thought to be major contributors to systemic 
inflammation through their release of inflammatory mediators.
517,519,614
  Some studies even 
suggest that leukocytes are not the primary source of cytokines such as IL-6 during sepsis, and 
organs are responsible for the majority of detectable protein in circulation.
517
  In the current 
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study, expression of TNF-α was increased in 24-hour liver biopsy samples from responders, 
supporting the theory that organs are the primary source of this mediator.  
 One important finding from this study is that responders demonstrated prolonged IL-1β 
expression in the blood and increased AUC values when compared to non-responders.  
Interluekin-1β is a major regulator of the innate immune response, with multiple functions 
including stimulation of other cytokines and activation of neutrophils and macrophages.
18,19,511
  
Sepsis-associated organ failure in humans is the result of an overwhelming inflammatory 
response and the excessive release of cytokines that result in endothelial injury, infiltration of 
leukocytes into tissues, and ultimately parenchymal damage.
21,511,616
  The release of 
inflammatory cytokines from distant locations is responsible for initiating this cascade, while 
local mediator production plays a significant role in the later phases of organ damage.
616
  
Increased circulating IL-1β concentrations correlate with the severity of sepsis in humans, 
although IL-1β does not appear to be a reliable predictor of mortality.
511
  In contrast,  increased 
plasma IL-1β concentrations predict mortality in humans with acute respiratory distress 
syndrome,
28
 and show promise as a prognostic indicator for septic cats.
617
  The utility of IL-1β as 
a prognostic indicator for laminitis in horses therefore warrants further consideration. 
 Perhaps the most important finding from this study is that inflammatory cytokine gene 
expression increased in the liver and lungs of responders when compared to non-responders.  
The liver and lungs are actively participants in the inflammatory response.
517,519,614
  Increased IL-
6, IL-8, and TNF-α expression has been detected in both liver and lung of horses during the 
developmental stage of black-walnut extract-induced laminitis.
427
  However, the question 
remains as to whether systemic inflammation is simply a comorbid condition, or directly causes 
laminitis.  In this study, 4 of the 5 cytokines measured were higher in liver samples from 
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responders 24 hours after OF administration.  This evidence of inflammation was also found in 
liver samples taken at necropsy.  
 In the current study, cytokine expression in liver tissue was compared at 24 hours in both 
groups, and both liver and lung samples were compared at the time of necropsy.  Most horses in 
the responder group were euthanized at approximately 24 hours, while non-responders were 
euthanized at 48 hours. It is possible that differences in liver and lung gene expression between 
groups at necropsy were a result of the 24-hour intervening period in non-responders.  However 
gene expression was compared between liver biopsy and necropsy samples from non-responders 
and, with the exception of IL-8, did not change over time.  Inflammatory cytokine expression 
was also higher in lung tissues from responders.  Although, lung biopsies at the 24-hour time 
point were not performed in non-responders for logistical reasons, it is unlikely that 
inflammation would have subsided by the time of necropsy, and results suggest that pulmonary 
inflammation plays a role in laminitis induced by carbohydrate overload.  Furthermore, in a 
species such as the horse that possesses pulmonary intravascular macrophages, the lungs might 
be expected to play a sizable role in the systemic inflammatory response.
519
  Euthanizing all 
horses 24 hours following OF administration was considered, but it was decided that non-
responders should be monitored for 48 hours to ensure that laminitis did not develop at a later 
time in these animals. 
 Histological examination of liver and lung samples supports a role for these organs in the 
inflammatory response.  Although findings did not differ between groups, approximately 50% of 
all horses had pulmonary microthrombi.  These lesions are characteristic of acute lung injury,
618
 
although other findings consistent with this problem, including neutrophilic infiltration were not 
observed.  Portal inflammation was also identified in most horses following the administration of 
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OF.  Mixed and lymphohistiocytic portal inflammation, as well as lobular inflammation, have 
been described in human patients with fatal sepsis,
619
 however a certain amount of inflammation 
might be expected in normal horses given the role of the liver in removing gut-derived toxins 
from the portal circulation.  Because samples were not obtained prior to the administration of 
OF, it is not possible to determine whether inflammation was already present or occurred in 
response to carbohydrate overload.  
 Results of this study suggest that production of inflammatory mediators in tissues such as 
the liver and lung may be more important to the pathogenesis of laminitis than release of 
cytokines from circulating leukocytes.  Compartmentalization of inflammatory response is a 
common feature in sepsis.
517
  Opposite inflammatory responses can even be detected in different 
organs within the same animal.
520,620,621
  Factors including local tissue microenvironment and 
inherent differences in mononuclear phagocyte and endothelial cell populations contribute to 
compartmentalization, and the largest discrepancies are often seen between tissues and blood.
517
  
Leukocytes from various tissues and blood can show different responses to sepsis and two-hit 




 Expression of IL-1β, IL-6, and IL-8 was higher in laminar tissues from responders in this 
study.  These cytokines have previously been shown to increase in both black walnut extract and 
carbohydrate overload models of laminitis, 
429-431,493,622
 and our results provide further support 
for these mediators playing a role in the pathogenesis of laminitis.  Laminar expression of IL-10 
and TNF-α did not differ between responders and non-responders in this study and these 
cytokines consistently remain unaffected in the laminitic hoof, suggesting that local production 
of these cytokines is not important in the pathogenesis of this disease.
429,430,493
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 Laminar histologic scores did not agree with severity of laminitis based on clinical 
assessments, and the reason for this finding is unclear.  Although the exclusion criteria used in 
this study only applied to horses with active laminitis or morphological evidence of past 
episodes, it is unlikely that residual damage from chronic laminitis affected results of lesions 
post mortem because laminar pathology differs markedly in the chronic and acute phases.
623
  
Histological laminitis scores correlated well with clinical severity in the report that established  
this scoring method, but abnormal histologic grades were also assigned to samples from 2/8 
sound horses,
361
 so some lesions may be incidental findings.  Histological scoring results in this 
study suggest that subclinical laminitis developed in all animals, which significantly impacts the 
concept of responders and non-responders.   For the purposes of this study, laminitis was defined 
by clinical signs rather than histologic score.   
 Glucose and insulin responses changed over time in this study, but differences were not 
detected between treatment groups.  Inflammation induces IR through the release of 
inflammatory cytokines and counter-regulatory hormones such as glucocorticoids and 
catecholamines.
91
  Serum insulin concentrations typically increase to compensate for IR in 
horses, but this was not observed in the current study.  Glucose concentrations increased over 
time, however, suggesting some loss of glycemic control.  Glucose concentrations were higher 
overall in responders, and may reflect a difference in the magnitude of systemic inflammation 
compared to non-responders.   
 A certain percentage of horses fail to develop laminitis following carbohydrate overload, 
with laminitis previously reported in approximately 50% of horses that receive OF at the 5 g/kg 
dose.
164,608
  Even at higher doses, the response rate is 80 to 100% with OF administration
165,409,417
 
and approximately 75% in the starch overload model.
493,624
  It is not clear why some horses 
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develop laminitis whereas others do not.  Studies to date suggest that the gut microflora does not 
differ between laminitis-prone and normal ponies,
295
 but this question has not been explored 
during laminitis induction models.  In horses, factors such as polymorphisms in proximal 
components of the LPS signalling cascade have not explained inter-individual variability in the 
response to endotoxin,
625
 but more work is required in this area.  Recently, Leise, et al.
493
 found 
that non-responders in a starch overload model of laminitis failed to develop a febrile response, 
indicating that systemic inflammation was absent in these animals.  In contrast, assessment of 
physical examination parameters and blood cytokine expression in the current study indicates 
that inflammation also developed in non-responders after OF administration.  However, changes 
in demeanor were milder in many of these animals.    It is also conceivable that local protective 
mechanisms in the hoof prevent laminitis from developing in some animals, but these 
mechanisms must still be identified.   
 One drawback of this study is the heterogeneous population of horses studied.  This 
approach was selected for ethical reasons to reduce the number of healthy animals euthanized for 
research purposes.  Although variability among animals may have decreased the power of the 
study, examining a diverse group of animals allows us to extrapolate findings to the general 
horse population. 
 We conclude that repeated inflammatory events over the course of two days do not 
exacerbate the systemic inflammatory responses induced by intestinal carbohydrate overload or 
increase the incidence of laminitis in horses.  Our hypothesis was not supported.  However, we 
have demonstrated that laminitis following intestinal carbohydrate overload is associated with 
the development of systemic inflammation, and results of this study suggest that inflammation in 
tissues such as the liver and lungs may pose a greater risk.  Future studies should assess the 
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contributions of tissue-generated inflammatory mediators to the pathogenesis of laminitis.  The 
use of IL-1β as a prognostic indicator for the development of laminitis also warrants further 





Conclusions and future directions 
 
 
 Studies presented in this dissertation serve to further characterize the role of systemic 
inflammation in the development of equine laminitis.   
 A series of studies were performed to test the overall hypothesis that endotoxin causes 
laminitis if endotoxemia is induced in a manner that approximates naturally occurring disease, or 
if predisposing factors such as obesity and insulin resistance (IR) are present.  Systemic 
inflammation is a known risk factor for laminitis and it is commonly assumed that endotoxemia 
is the cause of inflammation, and therefore laminitis.
3
 This association exists in the veterinary 
literature, despite the lack of evidence linking endotoxemia with laminitis or measuring 
endotoxin concentrations in clinical cases.   
 Laminitis often develops several days after the onset of illness, so our first study 
examined the relationship between systemic inflammation and laminitis.  We used a method of 
quantifying gene expression in whole blood samples developed by Rainen, et al.
507
 to assess 
systemic inflammation.  Peripheral blood is easily accessible and circulating leukocytes 
continuously survey the body for signs of disease, so blood samples provide useful information 
when examining inflammatory conditions.
524
  However, one disadvantage of using blood is that 
only peripheral leukocyte responses are assessed.  Because compartmentalization of the 
inflammatory response occurs, blood may not be representative of inflammation in all tissues.
517
  
The method we used to assess cytokine responses in blood minimizes RNA degradation and 
changes in the gene expression profile associated with sample collection and storage.
507
  An 
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alternative technique would have been to isolate leukocytes from whole blood samples, which 
eliminates contaminating RNA from erythrocytes and reticulocytes and increases the sensitivity 
of some gene expression assays.
522,523
  However, leukocyte isolation must be performed 
immediately after sample collection,
526,527
 which would not have been feasible in our studies, and 
the additional processing steps can induce alterations in the gene expression profile.
525
  Using the 
whole blood RNA isolation technique, we demonstrated that carbohydrate overload increases 
expression of inflammatory cytokines and is associated with systemic inflammation.   
 Our second study determined whether prolonged exposure to lipopolysaccharide (LPS) 
over 48 hours induced laminitis.  Two LPS dosing methods were employed: continuous exposure 
and intermittent bolus administration.  Amounts of LPS or other toxins entering systemic 
circulation may fluctuate during the course of illness, explaining intermittent episodes of 
worsening clinical condition that are sometimes observed in horses with gastrointestinal disease 
or infections such as metritis.  In what has been termed the “two-hit hypothesis” of organ 
damage during sepsis, exposure to an initial inflammatory stimulus can prime the immune 
system and cause exaggerated responses to subsequent, sometimes innocuous, stimuli.
437-439
  
Intermittent LPS exposure might therefore be expected to exacerbate inflammation and increase 
the risk of laminitis.  When this hypothesis was tested, laminitis did not develop, and horses 
became tolerant to endotoxin within approximately 24 hours.  We can conclude from this study 
that exposure to endotoxin alone does not induce laminitis, although it remains conceivable that 
endotoxemia combines with other factors to initiate the events of laminitis. 
 Although endotoxin administered alone did not induce laminitis, it was postulated that 
pre-existing conditions such as Equine Metabolic Syndrome (EMS) affect the systemic 
inflammatory response.  Previous studies had only examined responses to experimental 
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endotoxemia in normal horses,
269,327,410,506,534
 so this was the first time that horses with EMS had 
been evaluated in this way.  Endotoxin still did not induce laminitis in horses with EMS, but our 
study yielded interesting results.  Of note, peripheral leukocyte cytokine expression remained 
increased for longer in horses with EMS.  This is a major finding because exaggerated 
inflammation might explain why horses with EMS are predisposed to laminitis.  Adipose tissue 
participates in  inflammatory responses,
269
 so future studies should also assess the contributions 
of increased fat mass and abnormal adipose tissue to systemic inflammation in horses with EMS.  
This could be accomplished by performing adipose tissue biopsies following the administration 
of LPS in affected animals. 
 We also demonstrated that hepatic inflammation occurs in response to LPS 
administration, although differences were not detected between normal and EMS horses.  Given 
the potentially important role of obesity-related liver dysfunction in systemic inflammation and 
IR,
109,279
 additional studies are needed to characterize liver function in horses with EMS.  Our 
ability to detect differences between EMS and normal horses was limited by the design of the 
study; serial biopsies should be performed in the future to characterize hepatic inflammation in 
obese horses as systemic illness progresses.   
 Examination of glucose and insulin dynamics during systemic inflammation in normal 
and EMS horses revealed two major findings.  Although resting hyperglycemia is not a feature of 
EMS,
4
 greater loss of glycemic control occurred in affected animals after LPS administration.  
Hyperglycemia might increase the risk of laminitis by compromising the vascular 
endothelium.
190,572
 Glucose dysregulation is often detected during the development of 
experimental laminitis and it is possible that this factor contributes to the development of the 
disease.
164,165,608
  Glycemic control in EMS horses is a potential target for therapeutic 
206 
 
intervention during systemic illness, and the role of transient hyperglycemia in pasture-
associated laminitis also warrants further consideration.   
 The second key finding from this study was that insulin sensitivity decreased over time in 
horses with EMS after treatment with LPS or saline, but did not decrease after saline infusion in 
normal animals.  Stress hormones such as glucocorticoids and catecholamines lower insulin 
sensitivity,
626
 and results suggest that horses with EMS are more susceptible to derangements in 
glucose and insulin homeostasis under stressful conditions such as hospitalization.   
 One limitation of the studies involving EMS horses was that animals were part of an 
intensively managed research herd, so weight loss may have normalized metabolic functions.  
While this limited our ability to detect differences between groups, an interested finding 
emerged.  Endotoxin challenge appeared to unmask inherent differences in glucose and insulin 
homeostasis and inflammatory responses among horses.  This supports an underlying genetic 
basis for EMS,
226,246
 and suggests that horses with the condition remain at risk of developing 
laminitis, even after weight loss. 
 Our finding that systemic inflammation is accompanied by loss of glycemic control in 
horses with EMS highlights the importance of focusing on microvascular function in the future.  
Obesity and IR adversely affect the vascular endothelium, and endothelial dysfunction might be 
greatly exacerbated during systemic illness because affected animal are prone to exaggerated 
inflammatory responses and hyperglycemia.  Studies should be undertaken to assess endothelial 
dysfunction in horses with EMS that are experiencing systemic inflammation.  These studies 
should include investigations of naturally occurring EMS and experimentally induced obesity.   
 Lipopolysaccharide administration was not sufficient to trigger laminitis in healthy horses 
or those with EMS and results of our final study make us question whether endotoxemia should 
207 
 
even be considered as predisposing factor.  Our research group previously reported that the 
incidence and severity of laminitis tended to increase in horses pretreated with LPS prior to 
oligofructose administration.
164
  This study was therefore repeated with the aims of examining 
more horses and characterizing the systemic inflammatory response.   Our results reveal that 
endotoxin pretreatment had little effect on the systemic inflammatory response induced by 
intestinal carbohydrate overload.  Furthermore, pretreatment with LPS failed to increase the 
incidence of laminitis.  These results call into question the role of endotoxemia in the 
pathogenesis of laminitis.  Although endotoxin undoubtedly contributes to systemic 
inflammation in a number of common equine diseases, it neither causes laminitis when 
administered alone nor predisposes horses to the disease. 
 Results of two of our studies confirm that systemic inflammation occurs during the 
development of carbohydrate overload laminitis, as measured by blood inflammatory cytokine 
expression.  However, this alone does not prove that inflammation directly causes laminitis.  It 
was also an important finding that expression of inflammatory cytokines was higher in liver and 
lung tissues from horses that developed laminitis when compared to non-responders.  These 
results suggest that tissues, rather than blood leukocytes, are the major source of circulating 
protein because the magnitude of peripheral leukocyte responses did not show the same 
association with laminitis.  In addition, tumor necrosis factor-α gene expression did not increased 
in peripheral leukocytes following oligofructose administration, while increases were detected in 
liver tissues of responders. These tissues may therefore represent the source of circulating protein 
previously reported in horses subjected to this model.
409
  Future studies should therefore focus on 
characterizing the roles of specific organs and inflammatory mediators in carbohydrate overload 
laminitis.   
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 Only one inflammatory cytokine, interleukin-1β, exhibited higher expression in 
peripheral leukocytes of laminitis responders compared to non-responders, and its utility as a 
prognostic indicator for laminitis should be evaluated. 
 In conclusion, we have provided evidence that systemic inflammation accompanies the 
development of laminitis in horses, and that EMS exacerbates inflammatory responses.  
Additionally, horses with EMS may experience greater alterations in glucose and insulin 
homeostasis during systemic illness, which would be expected to increase the risk of laminitis.  
Our results do not support a role for LPS as the causal agent of laminitis or for endotoxemia as a 
predisposing factor for the disease.  Results also suggest that tissue-generated inflammatory 
mediators may be of greatest importance to the development of laminitis.  These findings are 
important because they provide potential targets for therapeutic intervention in animals at risk of 
developing laminitis. 
 To further investigate these questions, a number of studies should be performed.  The 
first study would be designed to assess inflammatory responses to carbohydrate overload in 
horses with EMS.  Results to date suggest that LPS-induced inflammation is prolonged in 
affected animals, and it is also possible that hepatic and adipose tissue inflammation contribute 
significantly to the risk of laminitis in obese horses following intestinal carbohydrate overload.  
A study should therefore be conducted in which blood and tissue inflammatory responses are 
measured following carbohydrate overload in horses with EMS. 
 A series of studies could be performed to test the hypothesis that EMS is associated with 
microvascular dysfunction, and that endothelial function is further compromised during systemic 
inflammation.  Techniques including in vitro evaluation of endothelium-dependent vasodilation, 
assessment of microvascular blood flow, and gene expression and immunohistochemistry studies 
209 
 
of adhesion molecule expression by endothelial cells could be employed to evaluated 
microvascular function in digital and laminar vessels.  Endothelial function should first be 
assessed in horses with naturally occurring EMS and compared to normal animals following 
experimental induction of obesity.  Subsequently, systemic inflammation should be induced in 
obese animals using LPS infusion or carbohydrate overload to evaluate the combined effects of 
obesity and inflammation on the endothelium.   
 Finally, additional studies are indicated to elucidate the role of inflammation in organs 
such as the liver and lung during laminitis.  Production of inflammatory mediators in these 
tissues should be evaluated at multiple time points during the onset of experimental laminitis, 
and a broader panel of mediators must be examined.  Although studies of naturally occurring 
laminitis are logistically more difficult to perform, inflammation in organs also warrants 
consideration in these cases.  Additionally, the role of hepatic dysfunction in horses with EMS 
requires further study.  The prevalence of hepatic lipidosis in this population could be 
determined through post mortem evaluation of naturally occurring cases, and abnormal hepatic 
lipid metabolism might be detected using gene expression techniques.  Studies could also be 
undertaken to evaluate Kupffer cell functions in horses with EMS because abnormalities such as 
decreased phagocytic activity or exaggerated production of inflammatory cytokines could 
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